
<html lang="en"     class="pb-page"  data-request-id="43e00536-7850-4682-af70-73e00b284724"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2012.55.issue-8;article:article:10.1021/jm2010964;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans" /></meta><meta name="dc.Creator" content="P. Douglas  Boatman" /></meta><meta name="dc.Creator" content="Brett  Lauring" /></meta><meta name="dc.Creator" content="Thomas O.  Schrader" /></meta><meta name="dc.Creator" content="Michelle  Kasem" /></meta><meta name="dc.Creator" content="Benjamin R.  Johnson" /></meta><meta name="dc.Creator" content="Philip  Skinner" /></meta><meta name="dc.Creator" content="Jae-Kyu  Jung" /></meta><meta name="dc.Creator" content="Jerry  Xu" /></meta><meta name="dc.Creator" content="Martin C.  Cherrier" /></meta><meta name="dc.Creator" content="Peter J.  Webb" /></meta><meta name="dc.Creator" content="Graeme  Semple" /></meta><meta name="dc.Creator" content="Carleton R.  Sage" /></meta><meta name="dc.Creator" content="Jens  Knudsen" /></meta><meta name="dc.Creator" content="Ruoping  Chen" /></meta><meta name="dc.Creator" content="Wen-Lin  Luo" /></meta><meta name="dc.Creator" content="Luzelena  Caro" /></meta><meta name="dc.Creator" content="Josee  Cote" /></meta><meta name="dc.Creator" content="Eseng  Lai" /></meta><meta name="dc.Creator" content="John  Wagner" /></meta><meta name="dc.Creator" content="Andrew K.  Taggart" /></meta><meta name="dc.Creator" content="Ester  Carballo-Jane" /></meta><meta name="dc.Creator" content="Milton  Hammond" /></meta><meta name="dc.Creator" content="Steven L.  Colletti" /></meta><meta name="dc.Creator" content="James R.  Tata" /></meta><meta name="dc.Creator" content="Daniel T.  Connolly" /></meta><meta name="dc.Creator" content="M. Gerard  Waters" /></meta><meta name="dc.Creator" content="Jeremy G.  Richman" /></meta><meta name="dc.Description" content="G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment of d..." /></meta><meta name="Description" content="G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment of d..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 9, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm2010964" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm2010964" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm2010964" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm2010964" /></link>
        
    
    

<title>(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm2010964" /></meta><meta property="og:title" content="(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0007.jpeg" /></meta><meta property="og:description" content="G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment of dyslipidemia due to its capacity to positively affect serum lipids to a greater extent than other currently marketed drugs. We report a series of tricyclic pyrazole carboxylic acids that are potent and selective agonists of GPR109a. Compound R,R-19a (MK-1903) was advanced through preclinical studies, was well tolerated, and presented no apparent safety concerns. Compound R,R-19a was advanced into a phase 1 clinical trial and produced a robust decrease in plasma free fatty acids. On the basis of these results, R,R-19a was evaluated in a phase 2 study in humans. Because R,R-19a produced only a weak effect on serum lipids as compared with niacin, we conclude that the beneficial effects of niacin are most likely the result of an undefined GPR109a independent pathway." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm2010964"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm2010964">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm2010964&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm2010964&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm2010964&amp;href=/doi/10.1021/jm2010964" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3644-3666</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201271b" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm201548z" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">(1a<i>R</i>,5a<i>R</i>)1a,3,5,5a-Tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=P.+Douglas++Boatman">P. Douglas Boatman</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brett++Lauring">Brett Lauring</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+O.++Schrader">Thomas O. Schrader</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Kasem">Michelle Kasem</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin+R.++Johnson">Benjamin R. Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Skinner">Philip Skinner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jae-Kyu++Jung">Jae-Kyu Jung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jerry++Xu">Jerry Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+C.++Cherrier">Martin C. Cherrier</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+J.++Webb">Peter J. Webb</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Graeme++Semple">Graeme Semple</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carleton+R.++Sage">Carleton R. Sage</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jens++Knudsen">Jens Knudsen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ruoping++Chen">Ruoping Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wen-Lin++Luo">Wen-Lin Luo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luzelena++Caro">Luzelena Caro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Josee++Cote">Josee Cote</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eseng++Lai">Eseng Lai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Wagner">John Wagner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+K.++Taggart">Andrew K. Taggart</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ester++Carballo-Jane">Ester Carballo-Jane</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Milton++Hammond">Milton Hammond</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven+L.++Colletti">Steven L. Colletti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Tata">James R. Tata</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+T.++Connolly">Daniel T. Connolly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M.+Gerard++Waters">M. Gerard Waters</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeremy+G.++Richman">Jeremy G. Richman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Departments of Medicinal Chemistry and <sup>‡</sup>Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, California 92121, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Merck Research Laboratories, Rahway, New Jersey, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 858-6920529. E-mail: <a href="/cdn-cgi/l/email-protection#e29286808d83968f838ca29b838a8d8dcc818d8f"><span class="__cf_email__" data-cfemail="f38397919c92879e929db38a929b9c9cdd909c9e">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm2010964&amp;href=/doi/10.1021%2Fjm2010964" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3644–3666</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 21, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 August 2011</li><li><span class="item_label"><b>Published</b> online</span>9 April 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 April 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm2010964" title="DOI URL">https://doi.org/10.1021/jm2010964</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3644%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DP.%2BDouglas%2BBoatman%252C%2BBrett%2BLauring%252C%2BThomas%2BO.%2BSchrader%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D8%26contentID%3Djm2010964%26title%3D%25281aR%252C5aR%25291a%252C3%252C5%252C5a-Tetrahydro-1H-2%252C3-diaza-cyclopropa%255Ba%255Dpentalene-4-carboxylic%2BAcid%2B%2528MK-1903%2529%253A%2BA%2BPotent%2BGPR109a%2BAgonist%2Bthat%2BLowers%2BFree%2BFatty%2BAcids%2Bin%2BHumans%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3666%26publicationDate%3DApril%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm2010964"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2697</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm2010964" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;P.&quot;,&quot;last_name&quot;:&quot;Douglas Boatman&quot;},{&quot;first_name&quot;:&quot;Brett&quot;,&quot;last_name&quot;:&quot;Lauring&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;O. Schrader&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Kasem&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;R. Johnson&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Skinner&quot;},{&quot;first_name&quot;:&quot;Jae-Kyu&quot;,&quot;last_name&quot;:&quot;Jung&quot;},{&quot;first_name&quot;:&quot;Jerry&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;C. Cherrier&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;J. Webb&quot;},{&quot;first_name&quot;:&quot;Graeme&quot;,&quot;last_name&quot;:&quot;Semple&quot;},{&quot;first_name&quot;:&quot;Carleton&quot;,&quot;last_name&quot;:&quot;R. Sage&quot;},{&quot;first_name&quot;:&quot;Jens&quot;,&quot;last_name&quot;:&quot;Knudsen&quot;},{&quot;first_name&quot;:&quot;Ruoping&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Wen-Lin&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Luzelena&quot;,&quot;last_name&quot;:&quot;Caro&quot;},{&quot;first_name&quot;:&quot;Josee&quot;,&quot;last_name&quot;:&quot;Cote&quot;},{&quot;first_name&quot;:&quot;Eseng&quot;,&quot;last_name&quot;:&quot;Lai&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Wagner&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;K. Taggart&quot;},{&quot;first_name&quot;:&quot;Ester&quot;,&quot;last_name&quot;:&quot;Carballo-Jane&quot;},{&quot;first_name&quot;:&quot;Milton&quot;,&quot;last_name&quot;:&quot;Hammond&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;L. Colletti&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Tata&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;T. Connolly&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Gerard Waters&quot;},{&quot;first_name&quot;:&quot;Jeremy&quot;,&quot;last_name&quot;:&quot;G. Richman&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;3644-3666&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm2010964&quot;},&quot;abstract&quot;:&quot;G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment of dyslipidemia due to its capacity to positively affect serum lipids to a greater extent than other currently marketed drugs. We report a series of tricyclic pyrazole carboxylic acids that are potent and selective agonists of GPR109a. Compound R,R-19a (MK-1903) was advanced through preclinical studies, was well tolerated, and presented no apparent safety concerns. Compound R,R-19a was advanced into a phase 1 clinical trial and produced a robust decrease in plasma free fatty acids. On the basis of these results, R,R-19a was evaluated in a phase 2 study in humans. Because R,R-19a produced only a weak effect on serum lipids as compared with niacin, we conclude that the beneficial effects of niacin are most likely the result of an undefined GPR109a independent pathway.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2010964&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2010964" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2010964&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2010964" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2010964&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2010964" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm2010964&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2010964&amp;href=/doi/10.1021/jm2010964" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm2010964" /></input><a href="/doi/pdf/10.1021/jm2010964" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm2010964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm2010964%26sid%3Dliteratum%253Aachs%26pmid%3D22435740%26genre%3Darticle%26aulast%3DBoatman%26date%3D2012%26atitle%3D%25281aR%252C5aR%25291a%252C3%252C5%252C5a-Tetrahydro-1H-2%252C3-diaza-cyclopropa%255Ba%255Dpentalene-4-carboxylic%2BAcid%2B%2528MK-1903%2529%253A%2BA%2BPotent%2BGPR109a%2BAgonist%2Bthat%2BLowers%2BFree%2BFatty%2BAcids%2Bin%2BHumans%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D8%26spage%3D3644%26epage%3D3666%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291456" title="Hydrocarbons">Hydrocarbons</a>,</li><li><a href="/action/doSearch?ConceptID=291137" title="Lipids">Lipids</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jmcmar.2012.55.issue-8/production/jmcmar.2012.55.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment of dyslipidemia due to its capacity to positively affect serum lipids to a greater extent than other currently marketed drugs. We report a series of tricyclic pyrazole carboxylic acids that are potent and selective agonists of GPR109a. Compound <i>R</i>,<i>R</i>-<b>19a</b> (MK-1903) was advanced through preclinical studies, was well tolerated, and presented no apparent safety concerns. Compound <i>R</i>,<i>R</i>-<b>19a</b> was advanced into a phase 1 clinical trial and produced a robust decrease in plasma free fatty acids. On the basis of these results, <i>R</i>,<i>R</i>-<b>19a</b> was evaluated in a phase 2 study in humans. Because <i>R</i>,<i>R</i>-<b>19a</b> produced only a weak effect on serum lipids as compared with niacin, we conclude that the beneficial effects of niacin are most likely the result of an undefined GPR109a independent pathway.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Worldwide, coronary heart disease and stroke remain the leading causes of death and disability. A recent case-control study in 52 countries, INTERHEART, identified that high ratios of apolipoprotein B to apolipoprotein A, the major lipoproteins of low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c), respectively, accounted for more than half of the population-attributable risk for a first myocardial infarction.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The management of associated risk factors and the widespread use of statins to lower plasma LDL-c levels, thereby improving the LDL-c/HDL-c ratio, have contributed to an overall decrease in morbidity and mortality in many developed countries.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Niacin (niacin) has been used for over 50 years for the treatment of dyslipidemia due to its capacity to lower very-low-density lipoprotein cholesterol (VLDL-c), LDL-c, and lipoprotein (a) (Lp(a)) and, most importantly, to increase HDL-c to a greater extent than other currently marketed drugs. A recent meta-analysis of clinical use of niacin alone or in combination with statins concluded that the use of niacin decreased major coronary events by 25%, stroke by 26%, and all cardiovascular events by 27%.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Despite the therapeutic advantages of niacin treatment, its use is less widespread than statins for the treatment lipid disorders mainly due to limited patient compliance because of adverse side effects that are associated with its use, most notably an uncomfortable cutaneous flushing effect.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Although the mechanism by which niacin raises HDL-c is not clear, niacin has been shown to cause a rapid, robust decrease in plasma free fatty acids (FFA). It has been hypothesized that this decrease in the concentration of free fatty acids available to the liver attenuates triglyceride synthesis and VLDL-c production. The reduced synthesis of triglyceride-rich VLDL-c particles in the liver leads to a decreased rate of HDL-c metabolism by limiting the cholesterol ester transfer protein (CETP)-mediated exchange of cholesterol from HDL-c to VLDL-c and triglyceride from VLDL-c to HDL-c.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Since the identification of the G-protein coupled receptor (GPCR) GPR109a as a molecular target for niacin (niacin), interest in developing new therapeutic agents with the lipid modulating properties of niacin but with a reduced flushing effect has intensified.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> GPR109a is expressed in adipocytes, spleen, and immune cells, including macrophage and Langerhans cells, and shares 95% identity with GPR109b and 52% identity with GPR81, two GPCRs which are also found in adipose and have been identified as hydroxycarboxylic acid receptors.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The flush side effect of niacin has been attributed to a GPR109a-dependent vasodilation resulting from a combination of effects on both Langerhans cells and keratinocytes.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Various strategies have been employed to separate the beneficial effects on lipids from flush induced by niacin such as sustained release formulations and combinations of niacin with aspirin or prostaglandin D<sub>2</sub> receptor antagonists to suppress the contribution of vasodilation following prostaglandin release from Langerhans cells.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The discovery of ligand biased signaling mediated via GPR109a, whereby agonists differentially activate downstream signaling pathways, led to the development of <b>1 (</b>MK-0354).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Compound <b>1</b> is a GPR109a agonist that activates the antilipolytic pathways in adipose cells but does not signal via the ERK 1/2 pathway that leads to prostaglandin production and vasodilation.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Thus, <b>1</b> produced a decrease in plasma free fatty acids in mice but did not induce the vasodilation associated with flushing. In humans, <b>1</b> behaved similarly, reducing plasma FFAs acutely without a significant associated flushing response but did not have a statistically significant effect on HDL, LDL, or triglycerides after 28-days dosing.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The failure of <b>1</b> to increase HDL cholesterol in the clinic led us to three alternative hypotheses. The first of these was that more potent analogues with a similar biased signaling profile to <b>1</b> would result in beneficial effects on serum lipids and triglycerides as relatively high doses of <b>1</b> were required to see any effect on FFA in humans. The second hypothesis was that the separation of signaling pathways that inhibit cAMP production from those that activate MAP kinase influences both the effects on lipids and the flushing side effect. The third is that the therapeutic effects of niacin are not entirely mediated via GPR109a.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0009.gif" alt="" id="fx1" /></img><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Time course of the effect of <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> on plasma FFA in male Sprague–Dawley rats after oral administration. <i>N</i> (animal number) is indicated in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A number of more potent analogues of <b>1</b> were synthesized and evaluated. From these, compound <b>2</b> was identified as a potent agonist of GPR109a which lowered free fatty acids in mice and did not induce flush.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, to evaluate the second hypothesis, compounds with profiles more like niacin, i.e., compounds that activate both antilipolytic and vasodilation pathways, were required. During the studies that led to the discovery of <b>2</b>, it was observed that the tricyclic pyrazole system generally provided potent GPR109a agonists. Importantly, it was also determined that in contrast to the tetrazole analogues, carboxylic acids based on this scaffold retained efficacy equal to that of niacin and were shown to activate both the antilipolytic and vasodilation pathways. These agonists appeared ideal for examination of the first two hypotheses: that increased agonist potency and that both antilipolytic and vasodilation effects are required to affect serum HDL-c levels. The synthesis and evaluation of these GPR109a full agonists is described here.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">A straightforward route to the key bicyclo[3.1.0]hexan-2-one intermediates involved the preparation of a number of 1,2-epoxy-5-alkenes (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Cross metathesis of 2-(but-3-enyl) oxirane (<b>3</b>) with various alkenes promoted by second-generation Grubbs’ catalyst or Zhan catalyst gave epoxyolefins <b>5</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), generally as mixtures of <i>E</i>/<i>Z</i> isomers. Alternatively, addition of in situ generated (bromomethyl)lithium to commercially available <i>cis</i>- and <i>trans</i>-4-decenal to gave the epoxyolefins <b>5f</b> as individual isomers. Because of the lack of a readily available aldehyde or olefin precursor to prepare epoxy olefin <b>5n</b>, an alternate route was developed. Alkynylation of cyclopropylmethyl bromide with alkyne <b>7</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> followed by hydrogenation of the resulting alkyne with Lindlar catalyst and subsequent hydrolysis of the acetonide, produced diol <b>8</b>. Closure to the oxirane was accomplished using triisopropylsulfonylimidazole (TrisIm) to give alkene <b>5n</b>. Stereospecific intramolecular carbenoid ring closure of the epoxyalkenes,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> followed by oxidation of the resultant alcohols, provided bicyclo[3.1.0]hexan-2-one intermediates <b>9</b>. In cases where mixtures of <i>E</i>/<i>Z</i> isomers were used, the resultant mixture of R<sup>1</sup> (<i>exo</i>)- and R<sup>2</sup> (<i>endo</i>)-substituted bicyclo[3.1.0]hexan-2-one diastereomers were carried through the synthesis and separated via chromatography after conversion to the tricyclic pyrazoles.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Zhan catalyst or second-generation Grubbs’ catalyst; (b) <i>n</i>-BuLi, CH<sub>2</sub>Br<sub>2</sub>, THF; (c) <i>n</i>-BuLi, DMPU, THF, (CH<sub>2</sub>)<sub>2</sub>CHCH<sub>2</sub>Br; (d) Pd/BaSO<sub>4</sub>, quinoline, H<sub>2</sub>; (e) AcOH, H<sub>2</sub>O; (f) TrisIm, NaH; (g) LiTMP, MTBE; (h) cat. TPAP, NMO, 4 Å MS, DCM.</p></p></figure><div class="NLM_p">A more versatile cyclopropyl ketone intermediate was obtained from reaction of dichlorocarbene with commercially available 2-cyclopenten-1-one ethylene ketal <b>11</b> to give 6,6-dichlorospiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane (<b>12</b>) (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Stereoselective introduction of the <i>exo</i>-methyl group in <b>13</b> was accomplished by lithium halogen exchange with <i>t</i>-butyllithium followed by quenching with methyl iodide. A second lithium halogen exchange using lithium 4,4′-di-<i>tert</i>-butyl-biphenyl (LiDBB) and quenching of the anion with ethanol gave <i>exo</i>-<b>6b</b> with >95% d.e. Alternatively, reduction of <b>12</b> with zinc dust gave the monochlorocyclopropyl derivative <b>14</b> as a separable mixture of diastereomers. Lithium halogen exchange of either diastereomer, or as a mixture, and quenching with an alkyl halide (CH<sub>3</sub>I or CH<sub>3</sub>CH<sub>2</sub>I), yielded only substitution on the <i>endo</i>-face. This remarkable stereoselectivity may be attributed to chelation of lithium by the ketal oxygen on the endoface. Finally, hydrolysis of the ketal gave the requisite ketones <i>endo</i>-<b>6b</b> and <i>endo</i>-<b>6c</b>, which were then elaborated to the final pyrazoles.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 50% NaOH, CHCl<sub>3</sub>, DCM, cat. triethylbenzylammonium chloride, 45 °C; (b) (1) <i>t</i>-BuLi, THF, −100 °C, (2) MeI, −100 °C to rt; (c) (1) LiDBB, THF, −78 °C, (2) EtOH; (d) cat. TsOH, acetone, H<sub>2</sub>O, rt; (e) Zn dust, KOH, EtOH, 80 °C; (f) (1) LiDBB, THF, −78 °C, (2) R<sup>2</sup>I, rt.</p></p></figure><div class="NLM_p">Multiple functionalities were introduced on the apex of the cyclopropane using chlorocyclopropane intermediate <b>14</b> as a precursor (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Generation of the lithium anion with LiDBB and reaction with dimethylformamide gave aldehyde <b>15</b> as a separable mixture of diastereomers (<i>exo</i>:<i>endo</i> = 7:1) after aqueous workup. The lack of stereocontrol in this addition is likely due to epimerization of the chiral center adjacent to the aldehyde. Vinyl analogues <i>endo</i>-<b>10k</b> and <i>exo</i>-<b>10k</b> were prepared by Wittig olefination of the aldehyde followed by removal of the acetonide. A cyclopropanation of the vinyl group using palladium acetate and diazomethane was used to prepare <i>endo</i>-<b>10 m</b>. Reduction of the <i>endo</i>-aldehyde <b>15</b> with sodium borohydride gave the alcohol <b>16</b>, which was alkylated with methyl iodide to produce the methyl ether <i>endo</i>-<b>10o</b>. The endothiomethyl ether <b>10p</b> was also prepared from alcohol <b>16</b> by mesylation and displacement with sodium thiomethoxide. Phenyl ether <b>10o</b> was also prepared from alcohol <b>16</b> using Mitsonobu conditions.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0012.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) LiDBB, THF, −78 °C, (2) DMF, rt; (b) [(Ph<sub>3</sub>)PCH<sub>3</sub>]<sup>+</sup>Br<sup>–</sup>, <i>n</i>-BuLi, THF, rt; (c) cat. TsOH, acetone, H<sub>2</sub>O, rt; (d) Pd(OAc)<sub>2</sub>, CH<sub>2</sub>N<sub>2</sub>, Et<sub>2</sub>O, rt; (e) NaBH<sub>4</sub>, EtOH, rt; (f) NaH, MeI, THF, 0 °C to rt; (g) MsCl, Et<sub>3</sub>N, DCM, 0 °C to rt; (h) NaSMe, DMF; (i) PhOH, D<i>t</i>-BAD, PyPh<sub>2</sub>P, THF.</p></p></figure><div class="NLM_p">The spirocyclic cyclohexyl- and cyclopentycyclopropanes were synthesized via the olefin cross metathesis route, however, no appropriate starting material was available to synthesize a spiro cyclobutyl cyclopropane in this manner. In an attempt to prepare a spiro-fused cyclobutyl cyclopropane, cyclobutyldiphenylsulfonium trifluoromethanesulfonate (<b>17</b>) was reacted with <i>t</i>-BuLi followed by cyclopentenone (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). The only product isolated from the reaction mixture, however, was the allyl substituted cyclopropane <b>10l</b> resulting from ring-opening of the cyclobutyl ring. This mixture of ketone diastereomers was used to prepare the allyl substituted analogues.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0013.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (CH<sub>3</sub>)<sub>3</sub>S(O)I, NaH, THF; (b) <i>t</i>-BuLi, THF.</p></p></figure><div class="NLM_p">Ketones <b>10</b> were converted to the tricyclic pyrazole esters <b>18</b> by Claisen condensation of the ketones with diethyl oxalate followed by condensation of the resulting diketones with hydrazine (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). Hydrolysis of the esters <b>18</b> gave the corresponding carboxylic acids, <b>19</b>. In cases where diastereomeric mixtures were present, separation of the isomers was accomplished by HPLC at either the ester or acid stage. The cyclopropane regioisomer <b>22</b> was prepared in analogous fashion from the symmetrical bicyclo[3.1.0]hexan-3-one <b>20</b>. To synthesize the <i>exo</i>-methyl ester of <b>19o</b> (R1 = CH<sub>2</sub>OMe, R2 = H), the pyrazole of intermediate <b>17</b> (R1 = CH<sub>2</sub>OH, R2 = H) was selectively benzylated and the free hydroxyl was alkylated by deprotonation with sodium hydride and followed by addition of methyl iodide. Debenzylation and ester hydrolysis were both accomplished by treatment with potassium <i>tert</i>-butoxide and dimethyl sulfoxide in the presence of air to give <i>endo</i>-<b>18x</b>. To probe substitutions at the ring fused positions of the cyclopropane, ketones <b>25</b> and <b>26</b> were prepared by direct cyclopropanation of cyclopentenones <b>23</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and <b>24</b>, respectively, with the sulfonium ylide derived from trimethylsulfoxonium iodide deprotonated by sodium hydride (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0014.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) KO<i>t</i>-Bu, EtOH, (EtO<sub>2</sub>C)<sub>2</sub>, 0 °C to rt, (2) hydrazine monohydrochloride, H<sub>2</sub>O, rt; (b) LiOH, dioxane, H<sub>2</sub>O; (c) benzyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF; (d) NaI, MeI, THF; (e) KO<i>t</i>-Bu, DMSO, air; (f) (CH<sub>3</sub>)<sub>3</sub>SOI, NaH.</p></p></figure><div class="NLM_p">To determine if any stereochemical bias for activation of GPR109a by the pyrazole acids existed, all four stereoisomers of compound <b>19b</b> were synthesized by the route shown in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. Starting from enantiopure lactols <i>R</i>-<b>29</b> and <i>S</i>-<b>29</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Wittig reaction with ethyltriphenylphosphonium bromide and lithium hexamethyldisilazide proceeded with concomitant epoxide ring closure to give both enantiomers of epoxide <i>R</i>-<b>5b</b> and <i>S</i>-<b>5b</b> as mixtures of olefin isomers (<i>E</i>:<i>Z</i> = 2.3:1). Intramolecular carbenoid cyclization and oxidation provided (1<i>R</i>,5<i>S</i>)-6-methylbicyclo[3.1.0]hexan-2-one (<i>R</i>,<i>S</i>-<b>10b</b>) and (1<i>S</i>,5<i>R</i>)-6-methylbicyclo[3.1.0]hexan-2-one (<i>S</i>,<i>R</i>-<b>10b</b>) as mixtures of <i>endo</i>- and <i>exo</i>-isomers. These mixtures were converted to the tricyclic pyrazole esters as described above, and the diastereomers were separated by HPLC. Ester hydrolysis of the individual enantiomers provided all four pyrazole acid stereoisomers.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0015.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) [(Ph<sub>3</sub>)PCH<sub>2</sub>CH<sub>3</sub>]<sup>+</sup>Br<sup>–</sup>, LiHMDS, THF, 0 °C to rt; (b) LiTMP, MTBE; (c) cat. TPAP, NMO, 4 Å MS, DCM; (d) (1) KO<i>t</i>-Bu, EtOH, (EtO<sub>2</sub>C)<sub>2</sub>, 0 °C to rt, (2) hydrazine monohydrochloride, H<sub>2</sub>O, rt, (3) HPLC separation; (e) LiOH, dioxane, H<sub>2</sub>O.</p></p></figure><div class="NLM_p">The examples above established that the 1a<i>R</i>,5a<i>S</i> stereoisomers provided the greatest GPR109a agonist potency (see below). To confirm this observation, other examples with the same stereochemical orientation were synthesized (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>). Synthesis of the ethyl substituted <i>R</i>,<i>S</i>-<i>endo</i>-<b>19c</b> and <i>R</i>,<i>S</i>-<i>exo</i>-<b>19c</b> isomers started via addition of butynyllithium to the readily available optically pure iodide <b>30</b> to give alkyne <i>R</i>-<b>9c</b> following hydrolysis of the acetal. Conversion of diol <b>30</b> to the epoxide by treatment with TrisIm and sodium hydride was accompanied by some loss of optical purity (86% e.e.) due to lack of selectivity for activation of the primary alcohol. Therefore, the epoxide was resolved using a hydrolytic kinetic resolution described by Jacobsen<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> to regain optical purity. Hydrogenation of the alkyne catalyzed by palladium on barium sulfate in the presence of quinoline gave epoxide <i>R</i>-<b>5c</b> as a mixture of olefin isomers (<i>E</i>:<i>Z</i> = 11.5:1).</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0016.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-butyne, <i>n</i>-BuLi, THF, DMPU, −78 °C to rt; (b) AcOH, H<sub>2</sub>O; (c) TrisIm, NaH; (d) Pd/BaSO<sub>4</sub>, quinoline, H<sub>2</sub>; (e) Jacobsen HKR; (f) LiTMP, MTBE; (g) cat. TPAP, NMO, 4 Å MS, DCM; (h) (1) KO<i>t</i>-Bu, EtOH, (EtO<sub>2</sub>C)<sub>2</sub>, 0 °C to rt, (2) hydrazine monohydrochloride, H<sub>2</sub>O, rt; (i) LiOH, dioxane, H<sub>2</sub>O, rt.</p></p></figure><div class="NLM_p last">The unsubstituted analogue <b>18a</b> and the cyclopropylmethyl analogue <i>endo</i>-<b>18n</b> were synthesized as single enantiomers employing Jacobsen’s hydrolytic kinetic resolutions (HKR) of epoxyolefins <b>3</b> and <b>5n</b>. The chiral epoxides were used in the synthesis described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> to produce chiral ketones that were elaborated to the final products <i>R</i>,<i>R</i>-<b>18a</b>, <i>R</i>,<i>S</i>-<i>endo</i>-<b>5n</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>5c</b> with the stereochemical orientations shown in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> In Vitro Studies</h3><div class="NLM_p">All compounds were assayed for GPR109a agonist activity using a homogeneous time-resolved fluorescence (HTRF) cAMP assay in cells stably transfected with GPR109a. The cells were stimulated to produce cAMP by treatment with 5 μM forskolin, and a dose response of the capacity of each compound to decrease cAMP production was generated. The tricyclic pyrazole acid <b>22</b> and the tricyclic acids <b>27</b> and <b>28</b> with substitution at the bridgehead positions produced no response in this assay. The results of the HTRF-cAMP assays for the remaining compounds are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Agonist Activity of Tricyclic Pyrazolecarboxylic Acids in the Whole Cell HTRF Assay at the hGPR109a Receptor</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0001.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center"><i>endo</i> EC<sub>50</sub><br /></br>(nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">efficacy<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>exo</i> EC<sub>50</sub><br /></br>(nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">efficacy<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">niacin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">51</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">286</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center">27.5</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="left">methyl</td><td class="colsep0 rowsep0" align="center">37</td><td class="colsep0 rowsep0" align="center">94</td><td class="colsep0 rowsep0" align="center">573</td><td class="colsep0 rowsep0" align="center">104</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="center">43.4</td><td class="colsep0 rowsep0" align="center">98.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19d</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-propyl</td><td class="colsep0 rowsep0" align="center">1770</td><td class="colsep0 rowsep0" align="center">89</td><td class="colsep0 rowsep0" align="center">1630</td><td class="colsep0 rowsep0" align="center">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19e</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-butyl</td><td class="colsep0 rowsep0" align="center">225</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">5450</td><td class="colsep0 rowsep0" align="center">88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19f</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-pentyl</td><td class="colsep0 rowsep0" align="center">1120</td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19g</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-propyl</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19h</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-butyl</td><td class="colsep0 rowsep0" align="center">81</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">5330</td><td class="colsep0 rowsep0" align="center">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19i</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-pentyl</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19j</b></td><td class="colsep0 rowsep0" align="left">dimethyl</td><td class="colsep0 rowsep0" align="center">1024</td><td class="colsep0 rowsep0" align="center">91</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19k</b></td><td class="colsep0 rowsep0" align="left">vinyl</td><td class="colsep0 rowsep0" align="center">1290</td><td class="colsep0 rowsep0" align="center">94</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19l</b></td><td class="colsep0 rowsep0" align="left">allyl</td><td class="colsep0 rowsep0" align="center">28</td><td class="colsep0 rowsep0" align="center">98</td><td class="colsep0 rowsep0" align="center">227</td><td class="colsep0 rowsep0" align="center">96.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19m</b></td><td class="colsep0 rowsep0" align="left">cyclopropyl</td><td class="colsep0 rowsep0" align="center">1980</td><td class="colsep0 rowsep0" align="center">90</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19n</b></td><td class="colsep0 rowsep0" align="left">cyclopropylmethyl</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">93</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19o</b></td><td class="colsep0 rowsep0" align="left">methoxymethyl</td><td class="colsep0 rowsep0" align="center">141</td><td class="colsep0 rowsep0" align="center">97</td><td class="colsep0 rowsep0" align="center">2470</td><td class="colsep0 rowsep0" align="center">91.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19p</b></td><td class="colsep0 rowsep0" align="left">methylthiomethyl</td><td class="colsep0 rowsep0" align="center">83</td><td class="colsep0 rowsep0" align="center">97</td><td class="colsep0 rowsep0" align="center">857</td><td class="colsep0 rowsep0" align="center">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19q</b></td><td class="colsep0 rowsep0" align="left">ethoxymethyl</td><td class="colsep0 rowsep0" align="center">192</td><td class="colsep0 rowsep0" align="center">92</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">112</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19r</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OPh</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">76.4</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19s</b></td><td class="colsep0 rowsep0" align="left">spiro cyclopentyl</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">101</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19t</b></td><td class="colsep0 rowsep0" align="left">spiro cyclohexyl</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19u</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19v</b></td><td class="colsep0 rowsep0" align="left">benzyl<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">93</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">EC<sub>50</sub> values are the average of three determinations.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Efficacy is expressed as a % of the signal produced by 100 μM niacin as positive control. NA; not applicable, only one isomer is possible. ND; not determined, only one of the two possible isomers was isolated.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Tested as a mixture of isomers (5:1, <i>exo</i>:<i>endo</i>).</p></div></div></div><div class="NLM_p">The tricyclic pyrazole acids were generally potent full agonists of GPR109a. The cyclopropyl ring imparts additional agonistpotency over the unsubstituted bicyclic pyrazolecarboxylic acid (EC<sub>50</sub> = 0.86 μM in a Flashplate cAMP assay).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a>As with the tetrazole series, agonist potency is very sensitive to substitution on the cyclopropane ring. The unsubstituted derivative <b>19a</b> is slightly more potent than niacin and was equally as effective at decreasing cAMP production (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). That compounds <b>27</b> and <b>28</b>, with substituents at the ring junctions, were completely inactive in this assay demonstrated that substitution around the cyclopropane was only tolerated at the apex of the ring.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Agonist Activity of Enantiopure Tricyclic Pyrazolecarboxylic Acids in the Whole Cell HTRF-cAMP Assay at the hGPR109a Receptor</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub>(nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">efficacy<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b></td><td class="colsep0 rowsep0" align="center">16.4</td><td class="colsep0 rowsep0" align="center">111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>,<i>S</i>-<i>exo</i>-<b>19b</b></td><td class="colsep0 rowsep0" align="center">311</td><td class="colsep0 rowsep0" align="center">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S</i>,<i>R</i>-<i>endo</i>-<b>19b</b></td><td class="colsep0 rowsep0" align="center">1170</td><td class="colsep0 rowsep0" align="center">107</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S</i>,<i>R</i>-<i>exo</i>-<b>19b</b></td><td class="colsep0 rowsep0" align="center">21280</td><td class="colsep0 rowsep0" align="center">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>,<i>R</i>-<b>19a</b></td><td class="colsep0 rowsep0" align="center">12.9</td><td class="colsep0 rowsep0" align="center">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19c</b></td><td class="colsep0 rowsep0" align="center">22.5</td><td class="colsep0 rowsep0" align="center">101</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>,<i>S</i>-<i>exo</i>-<b>19c</b></td><td class="colsep0 rowsep0" align="center">276</td><td class="colsep0 rowsep0" align="center">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19n</b></td><td class="colsep0 rowsep0" align="center">7.4</td><td class="colsep0 rowsep0" align="center">101</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">EC<sub>50</sub> values are the average of three determinations.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Efficacy is expressed as a % of the signal produced by 100 μM niacin as positive control.</p></div></div></div><div class="NLM_p">The syntheses of compounds that generated mixtures of diastereomers afforded the opportunity to investigate the stereochemical requirements for agonism of GPR109a by these tricyclic pyrazole carboxylic acids. From the assay results of compounds <i>endo</i>-<b>19b</b> and <i>exo</i>-<b>19b</b>, it is clear that the <i>endo</i>-diastereomers show a propensity toward higher agonist potencies than the <i>exo</i>-diastereomers. This was found to be the case for every <i>endo</i>/<i>exo</i> pair that was synthesized other than <i>endo</i>- and <i>exo</i>-<b>19d</b>, which were both weak agonists of GPR109a. Within the <i>endo</i>-substituted series, there is a clear trend toward decreasing potency with increasing substituent size. Whereas the endomethyl substitution gives a compound that is nearly equipotent to the unsubstituted <b>19a</b>, the ethyl analogue <i>endo</i>-<b>19c</b> is slightly less potent and the <i>n</i>-propyl analogue <i>endo</i>-<b>19d</b> is considerably less potent. It is interesting that agonist potency improves in the <i>endo</i>-<i>n</i>-butyl <i>endo</i>-<b>19e</b> relative to <i>endo</i>-<i>n</i>-propyl <i>endo</i>-<b>19d</b>. Likewise, the endoisobutyl substituent in <i>endo</i>-<b>19h</b> was much more potent than the <i>endo</i>-<i>n</i>-propyl, whereas the <i>endo</i>-isopentyl derivative <i>endo</i>-<b>19i</b> was much less active than either. A similar SAR pattern was observed in a series of bicyclic pyrazole GPR109a agonists in which compounds with an ethyl substituent had low activity (4.6 μM) in a niacin binding assay, whereas the <i>n</i>-propyl and <i>n</i>-butyl substitutions resulted in higher potency (0.69 and 0.34 μM, respectively).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> All compounds were evaluated in a similar assay for GPR109b, and all produced no response other than the spirocyclic which were nearly equipotent agonists of GPR109a and GPR109b.</div><div class="NLM_p">The unexpected synthesis of the allyl compounds produced a highly potent analogue in the <i>endo</i>-allyl compound <i>endo</i>-<b>19l</b>. This is remarkable in that the chain length is the same as <i>n</i>-propyl, however, compound <i>endo</i>-<b>19l</b> is approximately 75-fold more potent than <i>endo</i>-<b>19d</b>. Because terminal double bonds are often metabolized in vivo, the cyclopropyl methyl analogue <i>endo</i>-<b>19n</b> was synthesized as an allyl surrogate to investigate this improvement in activity further. Although slightly less potent than <i>endo</i>-<b>19l</b>, compound <i>endo</i>-<b>19n</b> was among the most potent compounds synthesized. Reasoning that an increase in electron density resulting from introduction of the double bond and cyclopropane improved binding of these compounds to the receptor, compounds <b>19o</b>–<b>q</b> were synthesized, which incorporated ether and thioether linkages. Compounds <i>endo</i>-<b>19o</b>, <i>endo</i>-<b>19p</b>, and <i>endo</i>-<b>19q</b> were all more potent than the corresponding <i>n</i>-propyl derivatives, but none was as potent as the <i>endo</i>-allyl derivative <i>endo</i>-<b>19l</b>.</div><div class="NLM_p">Having established from the racemic <i>endo</i>- and <i>exo</i>-substituted compounds that <i>endo</i>-substituents provided superior agonist potency, all four stereoisomers of the methyl substituted compound <b>19b</b> were synthesized. A bias for agonism of GPR109a by one enantiomer was strongly favored over the others just as is observed for the pairs of diastereomers. For the methyl substituted compounds, the preferred stereoisomer was (1<i>R</i>,1a<i>R</i>,5a<i>S</i>)-1-methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic acid (<i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b>), which had an EC<sub>50</sub> of 16 nM and was approximately twice as potent as the racemate and 20-fold more potent than any of the other stereoisomers. This stereochemical orientation of the cyclopropyl was confirmed as an element of good agonist potency, as demonstrated by the unsubstituted cyclopropyl derivative <i>R</i>,<i>R</i>-<b>19a</b>, which was a highly potent agonist of GPR109a. The enantiomerically pure unsubstituted and <i>endo</i>-ethyl analogues <i>R</i>,<i>S</i>-<i>endo</i>-<b>19c</b> and <i>R</i>,<i>S</i>-<i>exo</i>-<b>19c</b> were both twice as potent as their corresponding racemates, and the <i>endo</i>-cyclopropylmethyl <i>R</i>,<i>S</i>-<i>endo</i>-<b>19n</b> was highly potent.</div><div class="NLM_p">Although the most potent of the chiral compounds was the <i>endo</i>-cyclopropyl methyl, <i>R</i>,<i>S</i>-<i>endo</i>-<b>19n</b>, compounds <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> were evaluated further because both exhibited good receptor potency and could be scaled up via more straightforward synthetic routes than a number of other analogues.</div><div class="NLM_p last">Compounds <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S-<b>endo</b></i>-<b>19b</b> were screened against a standard panel of GPCRs and ion channels (PanLabs) and were found to have IC<sub>50</sub> values of >10 μM for inhibition of binding of the paradigm ligands at any receptor or ion channel. The compounds were also not substrates for cytochrome P<sub>450</sub> (CYP) isoforms 2D6, 2C8, 2C9, or 3A4 nor were they time-dependent inhibitors of CYP 3A4 at concentrations of 10 and 50 μM.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Preclinical Studies</h3><div class="NLM_p">Pharmacokinetic properties of compounds <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> were evaluated in several species, and the data are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The pharmacokinetic parameters of <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> were good, with somewhat variable but acceptable oral absorption, clearance, and half-lives in all species.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetics of Compounds <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> in Several Species<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">Cl<sub>p</sub><br /></br>(mL/min/kg)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>V</i><sub>d</sub><br /></br>(L/kg)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>t</i><sub>1/2</sub><br /></br>(h)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>C</i><sub>max</sub>/dose<br /></br>(μM·kg/mg)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">AUCNpo <br /></br>(μM·h·kg/mg)</th><th class="rowsep1 colsep0" colspan="2" align="center"><i>F</i><br /></br>(%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>R</i>-<b>19a</b></th><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b></th><th class="colsep0 rowsep0" align="center" char="."><i>R</i>,<i>R</i>-<b>19a</b></th><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b></th><th class="colsep0 rowsep0" align="center" char="."><i>R</i>,<i>R</i>-<b>19a</b></th><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b></th><th class="colsep0 rowsep0" align="center" char="."><i>R</i>,<i>R</i>-<b>19a</b></th><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b></th><th class="colsep0 rowsep0" align="center" char="."><i>R</i>,<i>R</i>-<b>19a</b></th><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b></th><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>R</i>-<b>19a</b></th><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td><td class="colsep0 rowsep0" align="center">0.61</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="center">0.3</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="center">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="char" char=".">0.53</td><td class="colsep0 rowsep0" align="center">0.53</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="center">2.4</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="center">5.1</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="center">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">3.1</td><td class="colsep0 rowsep0" align="center">2.4</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="center">0.22</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="char" char=".">17.5</td><td class="colsep0 rowsep0" align="center">26</td><td class="colsep0 rowsep0" align="char" char=".">33.3</td><td class="colsep0 rowsep0" align="center">44.4</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="center">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rhesus</td><td class="colsep0 rowsep0" align="center">5.1</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="center">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Cl<sub>p</sub>, plasma clearance (blood clearance for mice); <i>V</i><sub>d</sub>, volume of distribution; <i>t</i><sub>1/2</sub>, terminal half-life; <i>C</i><sub>max</sub>, observed maximal plasma concentration following oral dosing; <i>T</i><sub>max</sub>, time to reach the <i>C</i><sub>max</sub>; <i>F</i>, oral bioavailability.</p></div></div></div><div class="NLM_p">The capacity of <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> to lower free fatty acids in vivo was tested in fasted, Sprague–Dawley rats by administration of the compound via oral gavage followed by the serial collection of plasma samples after dosing (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Both <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> lowered free fatty acids by approximately 90% of baseline levels at all doses tested except for the lowest dose (0.001 mg/kg), which was indistinguishable from the vehicle dose. At higher doses, the decrease was more sustained.</div><div class="NLM_p">Measurement of changes in cutaneous blood flow in the exposed ear of anesthetized mice using a laser Doppler instrument has been established as a surrogate for flushing and the propensity of compounds <i>R</i>,<i>R</i>-<b>19a</b> and R,S-<i>endo</i>-<b>19b</b> to induce flush was quantified using this model (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In this model, niacin has been shown to produce a 60–100% peak increase over baseline blood flow compared to vehicle treated mice after a 100 mg/kg dose. When anesthetized mice were give a 100 mg/kg dose of either <i>R</i>,<i>R</i>-<b>19a</b> or <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b>, a peak increase of approximately 30% in blood flow over baseline was observed after 5 min.</div><figure id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Quantification of the flushing response of niacin, <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> as measured by laser Doppler recordings of cutaneous blood flow in the ear of male C57/bl6 mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Seeing no pharmacological or toxicological signals that would distinguish <i>R</i>,<i>R</i>-<b>19a</b> from <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b>, it was decided to advance <i>R</i>,<i>R</i>-<b>19a</b> through the remaining preclinical testing because the synthesis of <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> required more steps and is less stereochemically controlled.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Human Clinical Studies</h3><div class="NLM_p">On the basis of the noteworthy preclinical data, compound <i>R</i>,<i>R</i>-<b>19a</b> (MK-1903) was advanced into a phase 1 safety and tolerability study (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compound <i>R</i>,<i>R</i>-<b>19a</b> was administered orally to healthy volunteers at single doses of 5, 10, 25, 50, 100, 150, and 200 mg. Flushing was the only major adverse effect and was observed at all doses, with 200 mg determined as the maximum tolerated dose. Plasma samples obtained from subjects following doses of 50, 150, and 200 mg and were analyzed for FFA levels. <i>R</i>,<i>R</i>-<b>19a</b> produced a decrease in FFA by approximately 90% relative to placebo at all doses examined by 1–2 h post dose. FFA levels remained suppressed for about 8 h before they began to return to baseline. The decrease in FFA and safety profile in humans was nearly identical to those observed in the animal models described above, confirming that the models were predictive of effects in humans. These data strongly suggest target engagement of GPR109a on adipocytes. GPR109a engagement on cells in the macrophage lineage results in the production of PGD<sub>2</sub>, which is responsible for vasodilation.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> To assess the effect of <i>R</i>,<i>R</i>-<b>19a</b> on GPR109a on immune cells in humans more quantitatively, urine was assessed for a PGD<sub>2</sub> metabolite (PGD-M, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The production of PGD-M was approximately dose linear and doses of 10 mg and greater resulted in production of more PGD-M than a 1 g dose of Niaspan, suggesting that higher doses of <i>R</i>,<i>R</i>-<b>19a</b> delivered more receptor activation on immune cells than a therapeutic dose of niacin. On the basis of these observations, <i>R</i>,<i>R</i>-<b>19a</b> was advanced to more extensive evaluation in humans.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetics Parameter Values from the Multiple Rising Dose Study in Humans</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>R</i>,<i>R</i>-<b>19a</b> dose</th><th class="colsep0 rowsep0" align="center">panel</th><th class="colsep0 rowsep0" align="center">day</th><th class="colsep0 rowsep0" align="center"><i>N</i></th><th class="colsep0 rowsep0" align="center">AUC<sub>0−τ</sub><a class="ref internalNav" href="#ti1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#ti1fn5" aria-label="e">e</a>(nM·h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub><a class="ref internalNav" href="#ti1fn1" aria-label="a">a</a>(nM)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>trough</sub><a class="ref internalNav" href="#ti1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#ti1fn6" aria-label="f">f</a>(nM)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub><a class="ref internalNav" href="#ti1fn2" aria-label="b">b</a>(h)</th><th class="colsep0 rowsep0" align="center" char="±">apparent <i>t</i><sub>1/2</sub><a class="ref internalNav" href="#ti1fn3" aria-label="c">c</a>(h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">50 mg BID</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0">6</td><td class="colsep0 rowsep0" align="left">29.4 ± 6.6</td><td class="colsep0 rowsep0" align="left">12.3 ± 3.6</td><td class="colsep0 rowsep0" align="left">BLOQ</td><td class="colsep0 rowsep0" align="left">1.0 (0.5–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">26.1 ± 5.7</td><td class="colsep0 rowsep0" align="left">12.3 ± 3.1</td><td class="colsep0 rowsep0" align="left">0.023 ± 0.026</td><td class="colsep0 rowsep0" align="left">1.25 (1.0–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">25.4 ± 5.0</td><td class="colsep0 rowsep0" align="left">16.2 ± 2.3</td><td class="colsep0 rowsep0" align="left">0.045 ± 0.038</td><td class="colsep0 rowsep0" align="left">0.5 (0.5–1.5)</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GMR<a class="ref internalNav" href="#ti1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">0.975</td><td class="colsep0 rowsep0" align="left">1.34</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">100 mg BID</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0">6</td><td class="colsep0 rowsep0" align="left">72.8 ± 11.6</td><td class="colsep0 rowsep0" align="left">31.5 ± 4.2</td><td class="colsep0 rowsep0" align="left">0.124 ± 0.81</td><td class="colsep0 rowsep0" align="left">1.0 (0.5–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">65.7 ± 9.6</td><td class="colsep0 rowsep0" align="left">33.1 ± 6.2</td><td class="colsep0 rowsep0" align="left">0.083 ± 0.063</td><td class="colsep0 rowsep0" align="left">1.0 (0.5–1.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">61.1 ± 9.0</td><td class="colsep0 rowsep0" align="left">32.5 ± 2.5</td><td class="colsep0 rowsep0" align="left">0.104 ± 0.042</td><td class="colsep0 rowsep0" align="left">0.5 (0.5–1.0)</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GMR<a class="ref internalNav" href="#ti1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">0.929</td><td class="colsep0 rowsep0" align="left">0.993</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">150 mg BID</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0">6</td><td class="colsep0 rowsep0" align="left">97.7 ± 12.9</td><td class="colsep0 rowsep0" align="left">41.2 ± 12.8</td><td class="colsep0 rowsep0" align="left">0.316 ± 0.342</td><td class="colsep0 rowsep0" align="left">1.25 (1.0–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">80.3 ± 22.9</td><td class="colsep0 rowsep0" align="left">31.7 ± 20.6</td><td class="colsep0 rowsep0" align="left">0.241 ± 0.187</td><td class="colsep0 rowsep0" align="left">1.5 (1.0–4.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">78.8 ± 20.8</td><td class="colsep0 rowsep0" align="left">27.7 ± 13.8</td><td class="colsep0 rowsep0" align="left">0.208 ± 0.116</td><td class="colsep0 rowsep0" align="left">1.0 (1.0–2.0)</td><td class="colsep0 rowsep0" align="char" char="±">8.9 ± 4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GMR<a class="ref internalNav" href="#ti1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">0.989</td><td class="colsep0 rowsep0" align="left">0.921</td><td class="colsep0 rowsep0" align="left">0.909</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">150 mg TID</td><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0">6</td><td class="colsep0 rowsep0" align="left">101.8 ± 13.4</td><td class="colsep0 rowsep0" align="left">48.4 ± 15.9</td><td class="colsep0 rowsep0" align="left">0.869 ± 0.642</td><td class="colsep0 rowsep0" align="left">0.5 (0.5–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">88.5 ± 4.0</td><td class="colsep0 rowsep0" align="left">52.6 ± 23.6</td><td class="colsep0 rowsep0" align="left">0.583 ± 0.343</td><td class="colsep0 rowsep0" align="left">0.5 (0.5–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">87.9 ± 3.1</td><td class="colsep0 rowsep0" align="left">44.9 ± 17.5</td><td class="colsep0 rowsep0" align="left">0.708 ± 0.179</td><td class="colsep0 rowsep0" align="left">1.0 (0.5–1.5)</td><td class="colsep0 rowsep0" align="char" char="±">11.0 ± 4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GMR<a class="ref internalNav" href="#ti1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">1.00</td><td class="colsep0 rowsep0" align="left">0.888</td><td class="colsep0 rowsep0" align="left">1.33</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">200 mg QD</td><td class="colsep0 rowsep0" align="left">E</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0">6</td><td class="colsep0 rowsep0" align="left">113.7 ± 17.5</td><td class="colsep0 rowsep0" align="left">56.3 ± 31.6</td><td class="colsep0 rowsep0" align="left">0.244 ± 0.088</td><td class="colsep0 rowsep0" align="left">1.5 (0.5–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">119.2 ± 12.3</td><td class="colsep0 rowsep0" align="left">49.8 ± 15.8</td><td class="colsep0 rowsep0" align="left">0.273 ± 0.151</td><td class="colsep0 rowsep0" align="left">1.25 (0.5–2.0)</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GMR<a class="ref internalNav" href="#ti1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">1.05</td><td class="colsep0 rowsep0" align="left">0.963</td><td class="colsep0 rowsep0" align="left">1.04</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">175 mg QID</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0">6</td><td class="colsep0 rowsep0" align="left">129.8 ± 22.3</td><td class="colsep0 rowsep0" align="left">52.6 ± 13.9</td><td class="colsep0 rowsep0" align="left">4.01 ± 0.31</td><td class="colsep0 rowsep0" align="left">1.25 (1.0–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">113.0 ± 13.9</td><td class="colsep0 rowsep0" align="left">49.9 ± 9.7</td><td class="colsep0 rowsep0" align="left">2.92 ± 1.21</td><td class="colsep0 rowsep0" align="left">1.0 (0.5–2.0)</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">122.8 ± 19.2</td><td class="colsep0 rowsep0" align="left">56.0 ± 14.3</td><td class="colsep0 rowsep0" align="left">2.86 ± 1.55</td><td class="colsep0 rowsep0" align="left">0.75 (0.5–1.5)</td><td class="colsep0 rowsep0" align="char" char="±">6.0 ± 3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GMR<a class="ref internalNav" href="#ti1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">1.08</td><td class="colsep0 rowsep0" align="left">1.11</td><td class="colsep0 rowsep0" align="left">0.91</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-ti1fn1"><div class="footnote" id="ti1fn1"><sup>a</sup><p class="last">Mean ± standard deviation.</p></div><div class="footnote" id="ti1fn2"><sup>b</sup><p class="last">Median (min – max).</p></div><div class="footnote" id="ti1fn3"><sup>c</sup><p class="last">Harmonic mean ± pseudo standard deviation.</p></div><div class="footnote" id="ti1fn4"><sup>d</sup><p class="last">Geometric mean ratio (GMR) = day 11/day 4, calculated by DMPK.</p></div><div class="footnote" id="ti1fn5"><sup>e</sup><p class="last">τ: 12 h for 50, 100, 150 mg BID doses; 24 h for 200 mg QD dose; 8 h for 150 mg TID dose; 6 h for 175 mg QID dose.</p></div><div class="footnote" id="ti1fn6"><sup>f</sup><p class="last"><i>C</i><sub>trough</sub>: <i>C</i><sub>12 h</sub> for 50, 100, 150 mg BID, and 200 mg QD doses; <i>C</i><sub>8 h</sub> for 150 mg TID dose; <i>C</i><sub>6 h</sub> for 175 mg QID dose</p></div></div></div><figure id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Human urinary prostaglandin D metabolite in urine following an oral dose of <i>R</i>,<i>R</i>-<b>19a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A double-blind, placebo-controlled, randomized, dose-escalation study was conducted to define the effects of <i>R</i>,<i>R</i>-<b>19a</b> on FFA levels, safety, tolerability, and pharmacokinetics following multiple oral doses for seven days to healthy male subjects. Volunteers were randomized into six cohorts each containing eight subjects (six on active treatment and two on placebo). Oral doses of <i>R</i>,<i>R</i>-<b>19a</b> were 50 mg bid, 100 mg bid, 150 mg bid, 150 mg tid, 200 mg qd, 175 mg qid, or placebo. Drug or placebo was administered on day 1, followed by a two-day washout period, after which dosing continued from day 4 through day 11. For the 200 mg qd dose, subjects were titrated to this dose over days 1–4 then dosed qd through day 11. Venous blood samples were collected predose and at 0.5, 1, 1.5, 2, 4, 6, 8, 10, and 12 h postdose on day 1, 4, and 11 and analyzed for concentrations of plasma <i>R</i>,<i>R</i>-<b>19a</b> and FFA. Additionally, venous blood samples were collected predose on days 5 through 10 for plasma trough level determinations.</div><div class="NLM_p">Compound <i>R</i>,<i>R</i>-<b>19a</b> was rapidly absorbed at all doses with <i>T</i><sub>max</sub> ranging from 0.5 to 1.5 h (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Pharmacokinetic parameter values are shown in tabular form in the <a class="ref internalNav" href="#sec4" aria-label="Experimental section">Experimental section</a>. The apparent half-life on day 11 increased from 1.9 to 11 h as total dose increased. There was little or no accumulation of drug after repeat dosing for 7 days. Analysis of urine samples indicated that 70–80% of drug was excreted intact.</div><figure id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma concentrations of <i>R</i>,<i>R</i>-<b>19a</b> in humans after oral administration on days 4 and 11 and trough levels on days 5 through 10.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <i>R</i>,<i>R</i>-<b>19a</b> significantly lowered free fatty acids at all doses tested (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The extent of the free fatty acid lowering was more variable on day 11 than on day 4 but statistically different from placebo. Baseline FFA levels were also higher than placebo on day 11 for all doses except the 200 mg qd dose, however, the relative decrease in FFA was equivalent on all days, indicating that <i>R</i>,<i>R</i>-<b>19a</b> does not cause significant tachyphylaxis of GPR109a. Compared to <b>1</b> and a 1 g dose of Niaspan, <i>R</i>,<i>R</i>-<b>19a</b> resulted in more durable FFA suppression.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma free fatty acid levels of <i>R</i>,<i>R</i>-<b>19a</b> on days 4 and 11 in humans.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unlike <b>1</b>, which was a partial and selective “biased” GPR109a agonist, <i>R</i>,<i>R</i>-<b>19a</b> induced considerable dose-dependent subject reported flushing after single doses. Using a flushing symptoms questionnaire (see ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">13</a>), doses of 10 mg and greater were associated with flushing that was qualitatively more severe than a 1 g dose of Niaspan. Repeat dosing resulted in rapid and marked attenuation of flushing, and volunteers generally reported no flushing on questionnaires after 1–2 days of dosing with divided daily dosing regimens.</div><div class="NLM_p last">On the basis of these data, a dose of 150 mg TID was selected for future human clinical trials. This dose was expected to provide nearly continuous and profound FFA suppression and GPR109a activation on adipocytes and immune cells greater than that of therapeutic doses of niacin. On the basis of these results, it was determined that <i>R</i>,<i>R</i>-<b>19a</b> warranted further clinical evaluation and it was advanced into a phase 2a study in humans.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Briefly, the above dose of <i>R</i>,<i>R</i>-<b>19a</b> produced the expected suppression of FFA and a robust flush in a four-week study in dyslipidemic patients. However, the effects on triglyceride (Tg) and HDL-c were modest (−10.3% and +4.6%, respectively), whereas the corresponding changes expected in Tg and HDL-c from a therapeutic 2 g dose of niacin are approximately −26% and +20%, respectively.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A series of tricyclic pyrazolecarboxylic acids has been identified as potent agonists of GRP109a and have been shown to activate both the antilipolytic and vasodilation pathways in rodents. <i>R</i>,<i>R</i>-<b>19a</b> is a much more potent agonist than <b>1</b> (12.9 vs 283 nM, respectively) and is more potent than niacin (51 nM) in the cell based assays employed. Compound <i>R</i>,<i>R</i>-<b>19a</b> was advanced through preclinical studies, was shown to be selective for GPR109a, well tolerated in several species, and presented no apparent safety concerns. On the basis of this remarkable preclinical profile, compound <i>R</i>,<i>R</i>-<b>19a</b> was advanced into clinical trials to assess the safety, tolerability, and ability of the compound to lower free fatty acid levels in humans. Administration of <i>R</i>,<i>R</i>-<b>19a</b> to humans resulted in a robust decrease in plasma free fatty acids and produced the expected flush response as predicted by the preclinical data but no other adverse effects. Thus, unlike <b>1</b>, which differed from niacin in its receptor activating properties (no flushing or activation of GPR109a on immune cells), <i>R</i>,<i>R</i>-<b>19a</b> closely resembled the actions of niacin on GPR109a in that it was a full agonist and activated the receptor both on adipocytes and immune cells. Using the criteria of FFA suppression, PGD-M release and qualitative assessment of flushing, doses of <i>R</i>,<i>R</i>-<b>19a</b> were identified that would be expected to produce niacin-like changes in serum lipids if GPR109a agonism is the mechanism by which niacin produces these changes.</div><div class="NLM_p last">That <i>R</i>,<i>R</i>-<b>19a</b> produced only a weak effect on HDL-c and Tg vs niacin in a phase 2 study in humans suggests that the hypothesis that GPR109a activation on adipocytes is sufficient to raise HDL-c is likely groundless. Likewise, that <i>R</i>,<i>R</i>-<b>19a</b> produced flush effects and production of prostaglandin D metabolites that were equivalent to or greater than those produced by Niaspan indicate that the activation of both GPR109a signaling pathways is also not sufficient to raise HDL-c. On the basis of these studies, we conclude that the contribution of GPR109a agonism toward the beneficial effects on serum lipids produced by niacin treatment is questionable. From the human data, we conclude that the beneficial effects are most likely the result of niacin acting on a GPR109a independent pathway that has yet to be defined.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26401" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26401" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p">Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Varian Mercury Vx-400 equipped with a four-nucleus auto switchable probe and <i>z</i>-gradient or a Bruker Avance-400 equipped with a QNP (Quad Nucleus Probe) or a BBI (Broad Band Inverse) and <i>z</i>-gradient. Chemical shifts are given in parts per million (ppm), with the residual solvent signal used as reference. NMR abbreviations are used as follows: s = singlet, d = doublet, dd = doublet of doublet, ddd = doublet of doublet of doublets, dt = doublet of triplet, t = triplet, tt = triplet of triplets, q = quartet, m = multiplet, br = broad. Microwave irradiations were carried out using the Emrys synthesizer (Personal Chemistry). Thin-layer chromatography (TLC) was performed on silica gel 60 F<sub>254</sub> (Merck), preparatory thin-layer chromatography (prep TLC) was preformed on PK6F silica gel 60 A 1 mm plates (Whatman), and column chromatography was carried out on a silica gel column using Kieselgel 60, 0.063–0.200 mm (Merck). Evaporation was done in vacuo on a Buchi rotary evaporator. Celite 545  was used during palladium filtrations.</div><div class="NLM_p">Analytical HPLC/MS was conducted on a PE Sciex API 150EX mass spectrometer with an electrospray source, using a Shimadzu Inc. LC-10A VP UV detector monitoring at 214 nm, Analyst 1.2 software, and either (a) a Gilson 215 autosampler and an Alltech Prevail C18 column (5 μm, 250 mm × 4.6 mm), using a gradient of 5% v/v CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) (<i>t</i> = 0.0 min) gradient to 95% v/v CH<sub>3</sub>CN in H<sub>2</sub>O (<i>t</i> = 6.0 min), 3.5 mL/min or (b) a PE 200 autosampler and a Supelco Discovery C18 column (5 μm, 50 mm × 2.1 mm), using a gradient of 5% v/v CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) (<i>t</i> = 0.0 min) gradient to 95% v/v CH<sub>3</sub>CN in H<sub>2</sub>O (<i>t</i> = 5.0 min), 0.75 mL/min. Preparative HPLC was conducted on a Varian Prostar reverse phase HPLC using either (a) a Phenomenex Luna C18 column (10 μm, 250 mm × 21.2 mm), 5% (v/v) CH<sub>3</sub>CN (containing 0.1% v/v TFA) in H<sub>2</sub>O (containing 0.1% v/v TFA) gradient to 95% CH<sub>3</sub>CN, 20 mL/min, λ = 220 nm or (b) a Phenomenex Luna C18 column (10 μm, 250 mm × 50 mm), 5% (v/v) CH<sub>3</sub>CN (containing 0.1% v/v TFA) in H<sub>2</sub>O (containing 0.1% v/v TFA) gradient to 95% CH<sub>3</sub>CN, 50 mL/min, λ = 220 nm. Purity of the tested compounds was ≥95% based on LCMS and/or <sup>1</sup>H NMR data unless stated otherwise.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> (±)-2-(Hept-3-enyl)oxirane (<b>5d</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 5.00 g, 50.9 mmol) in pent-1-ene (40.0 mL, 366 mmol) at rt was added Grubbs catalyst, second generation (1.08 g, 1.27 mmol). The mixture was stirred at for 48 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave 2-(hept-3-enyl)oxirane (<b>5d</b>, 915 mg, ca. 75% purity by <sup>1</sup>H NMR, 4.90 mmol, 10% yield), an inseparable mixture of <i>E</i> and <i>Z</i> isomers (ratio not determined), as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.60–5.53 (m, 2H), 2.92 (m, 1H), 2.75 (m, 1H), 2.49 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.15 (m, 2H), 1.98 (m, 2H), 1.60 (m, 2H), 1.35 (m, 2H), 0.90 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> (±)-2-(Oct-3-enyl)oxirane (<b>5e</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 5.00 g, 50.9 mmol) in hex-1-ene (50.0 mL, 403 mmol) at rt was added Grubbs catalyst, second generation (1.08 g, 1.27 mmol). The mixture was stirred at for 72 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5e</b>, 2.04 g, ca. 65% purity by <sup>1</sup>H NMR, 8.60 mmol, 17% yield), an inseparable mixture of <i>E</i> and <i>Z</i> isomers (ratio not determined), as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.60–5.53 (m, 2H), 2.90 (m, 1H), 2.72 (m, 1H), 2.45 (m, 1H), 2.13 (m, 2H), 1.97 (m, 2H), 1.56 (m, 2H), 1.30 (m, 4H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> (±)-(<i>Z</i>)-2-(Non-3-enyl)oxirane (<i>Z</i>-<b>5f</b>)</h4><div class="NLM_p last">To a solution of (<i>Z</i>)-dec-4-enal (<i>Z</i>-<b>6</b>, 2.50 g, 13.0 mmol) and dibromomethane (2.31 g, 13.3 mmol) in THF (60 mL) at −78 °C under N<sub>2</sub> atmosphere was added<i>n</i>-butyllithium (7.38 mL of a 1.6 M solution in hexanes, 11.8 mmol) slowly over 10 min. The mixture was warmed to rt, stirred for an additional 15 h, and poured into a NH<sub>4</sub>Cl (satd aq, 60 mL). The mixture was extracted with MTBE (2 × 60 mL), and the organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Column chromatography (0–5% EtOAc/hexanes, silica) gave the title compound (<i>Z</i>-<b>5f</b>, 1.28 g, 7.61 mmol, 59% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.45–5.32 (m, 2H), 2.93 (m, 1H), 2.76 (dd, <i>J</i> = 5.0, 4.1 Hz, 1H), 2.49 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.22 (q, <i>J</i> = 7.5 Hz, 2H), 2.04 (q, <i>J</i> = 6.9 Hz, 2H), 1.59 (m, 2H), 1.37–1.24 (m, 6H), 0.89 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> (±)-(<i>E</i>)-2-(Non-3-enyl)oxirane (<i>E</i>-<b>5f</b>)</h4><div class="NLM_p last">Prepared from (<i>E</i>)-dec-4-enal (<i>E</i>-<b>6</b>, 3.37 g, 21.8 mmol) in a similar manner as described for the synthesis of <i>Z</i>-<b>5f</b>. Column chromatography (0–5% EtOAc/hexanes, silica) gave the title compound (<i>E</i>-<b>5f</b>, 2.35 g, 14.0 mmol, 64% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.51–5.37 (m, 2H), 2.93 (m, 1H), 2.76 (dd, <i>J</i> = 5.0, 4.1 Hz, 1H), 2.49 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.16 (m, 2H), 1.98 (q, <i>J</i> = 7.0 Hz, 2H), 1.59 (m, 2H), 1.38–1.22 (m, 6H), 0.89 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> (±)-2-(5-Methylhex-3-enyl)oxirane (<b>5g</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 4.50 g, 45.8 mmol) in (<i>Z</i>)-4-methylpent-2-ene (10.0 g, 119 mmol) at rt was added Grubbs catalyst, second generation (973 mg, 1.15 mmol). The mixture was stirred at for 24 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5g</b>, 2.92 g, ca. 70% purity by <sup>1</sup>H NMR, 14.6 mmol, 32% yield), an inseparable mixture of <i>E</i> and <i>Z</i> isomers (ratio not quantified), as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.47–5.30 (m, 2H), 2.90 (m, 1H), 2.72 (m, 1H), 2.45 (m, 1H), 2.20 (m, 1H), 2.13 (m, 2H), 1.59 (m, 2H), 0.94 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (±)-2-(6-Methylhept-3-enyl)oxirane (<b>5h</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 5.00 g, 50.9 mmol) in 4-methylpent-1-ene (25.0 g, 297 mmol) at rt was added Grubbs catalyst, second generation (2.00 g, 2.36 mmol). The mixture was stirred at for 20 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5h</b>, 2.02 g, ca. 60% purity by <sup>1</sup>H NMR, 7.60 mmol, 15% yield), an inseparable mixture of <i>E</i> and <i>Z</i> isomers (ratio not quantified), as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.50–5.38 (m, 2H), 2.95 (m, 1H), 2.74 (dd, <i>J</i> = 4.8, 4.3 Hz, 1H), 2.48 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.18 (m, 2H), 1.87 (m, 2H), 1.60 (m, 3H), 0.90 (m, 6H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (±)-2-(7-Methyloct-3-enyl)oxirane (<b>5i</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 25.0 g, 255 mmol) and 5-methylhex-1-ene (25.1 g, 256 mmol) in DCM (50 mL) was added Zhan cat-1 (Zaanan Pharma Ltd. Cat. RC-301, 320 mg, 0.485 mmol). The mixture was stirred at rt for 20 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5i</b>, 4.53 g, ca. 60% purity by <sup>1</sup>H NMR, 16.1 mmol, 6% yield), an inseparable mixture of <i>E</i> and <i>Z</i> isomers (ratio not quantified), as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.59–5.36 (m, 2H), 2.94 (m, 1H), 2.75 (m, 1H), 2.48 (dd, <i>J</i> = 5.0, 2.8 Hz, 1H), 2.15 (m, 2H), 2.00 (m, 2H), 1.59 (m, 2H), 1.29 (m, 3H), 0.88 (m, 6H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (±)-2-(4-Methylpent-3-enyl)oxirane (<b>5j</b>)</h4><div class="NLM_p last">A solution of 2-(but-3-enyl)oxirane (<b>3</b>, 1.00 g, 10.2 mmol) in 2-methylbut-2-ene (10.0 g, 102 mmol) containing Zhan cat-1 (57.0 mg, 0.086 mmol) at rt was stirred for 20 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5j</b>, 1.20 g, 9.51 mmol, 93% yield) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.15 (m, 1H), 2.92 (m, 1H), 2.75 (dd, <i>J</i> = 5.0, 4.1 Hz, 1H), 2.48 (dd, <i>J</i> = 5.0, 2.8 Hz, 1H), 2.15 (q, <i>J</i> = 7.5 Hz, 2H), 1.70 (s, 3H), 1.60 (s, 3H), 1.54 (m, 2H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>E</i>)-<i>tert</i>-Butyldimethyl(5-(oxiran-2-yl)pent-2-enyloxy)silane (<i>E</i>-<b>5o</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 16.0 g, 163 mmol) and <i>cis</i>-1,4-bis(<i>tert</i>-butyldimethylsilyloxy)-2-butene (127 g, 326 mmol) in DCM (1.6 L) was added Grubbs catalyst, second generation (3.46 g, 4.08 mmol). The mixture was stirred for 20 h and concentrated in vacuo. Purification by column chromatography (1–10% EtOAc/hexanes, silica) gave the title compound (<i>E</i>-<b>5o</b>, 15.0 g, 61.9 mmol, 38% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.65 (dt, <i>J</i> = 15.3, 6.2 Hz, 1H,), 5.57 (dt, <i>J</i> = 15.3, 4.9 Hz, 1H), 4.11 (m, 2H), 2.91 (m, 1H), 2.73 (m, 1H), 2.46 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.19 (m, 2H), 1.61 (m, 2H), 0.89 (s, 9H), 0.05 (s, 6H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (±)-(<i>E</i>)-2-(5-Methylsulfanyl-pent-3-enyl)-oxirane (<b>5p</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 5.57 g, 56.7 mmol) and allyl methyl sulfide (1.00 g, 11.3 mmol) in DCM (115 mL) was added Zhan cat-1 (150 mg, 0.227 mmol). The mixture was stirred for 20 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5p</b>, 600 mg, 3.79 mmol, 34% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.60–5.43 (m, 2H), 3.07 (d, <i>J</i> = 7.2 Hz, 2H), 2.93 (m, 1H), 2.76 (m, 1H), 2.49 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.28–2.19 (m, 2H), 2.02 (s, 3H), 1.70–1.57 (m, 2H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (±)-2-(5-Ethoxypent-3-enyl)oxirane (<b>5q</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 5.00 g, 50.9 mmol) and ethyl allyl ether (13.2 g, 153 mmol) in DCM (350 mL) was added Zhan cat-1 (673 mg, 1.02 mmol). The mixture was stirred for 20 h and concentrated in vacuo. Purification by column chromatography (3–20% EtOAc/hexanes, silica) gave the title compound (<b>5q</b>, 2.44 g, ca. 60% purity by <sup>1</sup>H NMR, 11.2 mmol, 21% yield), an inseparable mixture of olefin isomers (<i>E</i>:<i>Z</i> = 10:1), as a clear oil. <i>E</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.73 (m, 1H), 5.63 (m, 1H), 3.98 (m, 1H), 3.91 (m, 1H), 3.48 (q, <i>J</i> = 7.0 Hz, 2H), 2.93 (m, 1H), 2.75 (m, 1H), 2.48 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.22 (m, 2H), 1.63 (m, 2H), 1.21 (t, <i>J</i> = 7.0 Hz, 3H). <i>Z</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.62 (m, 2H), 4.04 (m, 2H), 3.48 (q, <i>J</i> = 7.0 Hz, 2H), 2.93 (m, 1H), 2.75 (m, 1H), 2.49 (m, 1H), 2.22 (m, 2H), 1.63 (m, 2H), 1.22 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (±)-2-(3-Cyclopentylidenepropyl)oxirane (<b>5s</b>)</h4><div class="NLM_p last">To a solution of 2-(but-3-enyl)oxirane (<b>3</b>, 5.00 g, 50.9 mmol) in methylenecyclopentane (20.0 g, 244 mmol) at rt was added Grubbs catalyst, second generation (600 mg, 0.707 mmol). The mixture was stirred at for 72 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5s</b>, 572 mg, 3.76 mmol, 7% yield) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.25 (m, 1H), 2.93 (m, 1H), 2.75 (dd, <i>J</i> = 4.9, 4.1 Hz, 1H), 2.48 (dd, <i>J</i> = 5.0, 2.8 Hz, 1H), 2.25–2.10 (m, 6H), 1.70–1.55 (m, 6H).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (±)-2-(3-Cyclohexylidenepropyl)oxirane (<b>5t</b>)</h4><div class="NLM_p last">A solution of 2-(but-3-enyl)oxirane (<b>3</b>, 6.00 g, 61.1 mmol) in methylenecyclohexane (20.0 g, 208 mmol) containing Zhan cat-1 (400 mg, 0.605 mmol) at rt was stirred for 20 h and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5t</b>, 950 mg, ca. 30% purity by <sup>1</sup>H NMR, 1.71 mmol, 3% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.09 (m, 1H), 2.93 (m, 1H), 2.75 (m, 1H), 2.48 (m, 1H), 2.20–2.04 (m, 6H), 1.66–1.45 (m, 8H).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (±)-(<i>E</i>)-2-(4-Phenylbut-3-enyl)oxirane (<b>5u</b>)</h4><div class="NLM_p last">A solution of 2-(But-3-enyl)oxirane (<b>3</b>, 8.60 g, 87.6 mmol) in styrene (45.0 g, 432 mmol) containing Grubbs catalyst, second generation (1.10 g, 1.29 mmol) at rt was stirred for 20 h and concentrated in vacuo. Purification by column chromatography (0–20% EtOAc/hexanes, silica) gave the title compound (<b>5u</b>, 3.13 g, ca. 30% purity by <sup>1</sup>H NMR, 11.7 mmol, 13% yield) as a light brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.40–7.25 (m, 4H), 7.20 (tt, <i>J</i> = 7.1, 1.4 Hz, 1H), 6.44 (dd, <i>J</i> = 15.8 Hz, 1H), 6.24 (dt, <i>J</i> = 15.8, 6.9 Hz, 1H), 2.99 (m, 1H), 2.78 (dd, <i>J</i> = 5.0, 4.1 Hz, 1H), 2.52 (dd, <i>J</i> = 5.0, 2.8 Hz, 1H), 2.49 (m, 2H), 2.38 (m, 2H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (±)-2-(5-Phenylpent-3-enyl)oxirane (<b>5v</b>)</h4><div class="NLM_p last">To a solution of 2-(But-3-enyl)oxirane (<b>3</b>, 1.97 g, 21.1 mmol) and allylbenzene (10.2 g, 86.0 mmol) in DCM (30 mL) was added Grubbs catalyst, second generation (220 mg, 0.259 mmol). The mixture was heated to reflux, stirred for 20 h, and concentrated in vacuo. Purification by column chromatography (0–10% EtOAc/hexanes, silica) gave the title compound (<b>5v</b>, 2.01 g, ca. 30% purity by <sup>1</sup>H NMR, 6.40 mmol, 30% yield), an inseparable mixture of <i>E</i> and <i>Z</i> isomers (ratio not quantified) as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29 (m, 3H), 7.18 (m, 2H), 5.63 (m, 1H), 5.53 (m, 1H), 3.33 (d, <i>J</i> = 6.6 Hz, 2H), 2.92 (m, 1H), 2.75 (dd, <i>J</i> = 4.9, 4.2 Hz, 1H), 2.47 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.20 (m, 2H), 1.62 (m, 2H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (±)-4-(5-Cyclopropylpent-3-ynyl)-2,2-dimethyl-1,3-dioxolane (<b>8</b>)</h4><div class="NLM_p">To a solution of TMS-acetylene (8.01 mL, 56.7 mmol) in anhydrous THF (50 mL) containing DMPU (27.0 mL, 222 mmol) was slowly added <i>n</i>-BuLi (38.7 mL of a 1.6M soln in hexanes, 61.9 mmol) at −78 °C over 5 min. The mixture was stirred at −78 °C for 30 min, at which time (±)-4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane (<b>7</b>, 13.2 g, 51.5 mmol) was added. The mixture was slowly warmed to rt, and stirring was continued for 4 h, at which time the reaction mixture was quenched with water followed by extraction with EtOAc. The combined organics were washed with H<sub>2</sub>O and brine. The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Column chromatography (0–5% EtOAc/hexanes, silica) gave (±)-4-(2,2-dimethyl-1,3-dioxolan-4-yl)but-1-ynyl)trimethylsilane (8.78 g, 38.8 mmol, 75% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.19–4.12 (m, 1H), 4.07 (dd, <i>J</i> = 8.0, 6.0 Hz, 1H,), 3.57 (dd, <i>J</i> = 8.0, 6.9 Hz, 1H), 2.39–2.26 (m, 2H), 1.86–1.79 (m, 1H), 1.76–1.68 (m, 1H), 1.39 (s, 3H), 1.34 (s, 3H), 0.13 (s, 9H).</div><div class="NLM_p">To a solution of (±)-4-(2, 2-dimethyl-[1,3]dioxolan-4-yl)-but-1-ynyl]-trimethylsilane (10.0 g, 44.2 mmol) in MeOH (40 mL) was added K<sub>2</sub>CO<sub>3</sub> (7.00 g, 50.6 mmol). The mixture was stirred at rt for 4 h and concentrated in vacuo to remove MeOH. The crude material was partitioned between NH<sub>4</sub>Cl (satd aq) and EtOAc. The layers were separated, and the organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Column chromatography (5–15% EtOAc/hexanes, silica) gave afforded 4-(but-3-ynyl)-2,2-dimethyl-1,3-dioxolane (5.00 g, 32.4 mmol, 73% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.21–4.15 (m, 1H), 4.05 (dd, <i>J</i> = 8.0, 6.0 Hz, 1H), 3.55 (dd, <i>J</i> = 8.0, 6.9 Hz, 1H), 2.31–2.26 (m, 2H), 1.94 (t, <i>J</i> = 2.6 Hz, 1H), 1.80 (m, 1H), 1.70 (m, 1H), 1.38 (s, 3H), 1.33 (s, 3H).</div><div class="NLM_p last">To a solution of (±)-4-(but-3-ynyl)-2,2-dimethyl-1,3-dioxolane (3.88 g, 25.2 mmol) in anhydrous THF (100 mL) containing DMPU (9.10 mL, 75.5 mmol) was slowly added <i>n</i>-BuLi (14.0 mL of a 2.5<i>M</i> soln in hexanes, 35 mmol) at −78 °C over 5 min. The mixture was stirred at −78 °C for 30 min, at which time (bromomethyl)cyclopropane (4.40 g, 32.6 mmol) was added. The mixture was slowly warmed to rt, and stirring was continued for 48 h. The reaction mixture was quenched with NH<sub>4</sub>Cl (satd aq) and extracted with hexanes. Dried organics over MgSO<sub>4</sub>, filtered, and concentrated. Column chromatography (2–10% EtOAc/hexanes, silica) gave (±)-4-(5-cyclopropylpent-3-ynyl)-2,2-dimethyl-1,3-dioxolane (<b>8</b>, 2.60 g, 12.5 mmol, 50% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.18 (m, 1H), 4.07 (dd, <i>J</i> = 8.0, 6.0 Hz, 1H), 3.57 (dd, <i>J</i> = 7.9, 7.1 Hz, 1H), 2.29–2.23 (m, 2H), 2.18 (m, 2H), 1.80 (m, 1H), 1.67 (m, 1H), 1.40 (s, 3H), 1.35 (s, 3H), 0.88 (m, 1H), 0.43 (m, 2H), 0.19 (m, 2H).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (±)-(<i>Z</i>)-2-(5-Cyclopropylpent-3-enyl)oxirane (<b>5n</b>)</h4><div class="NLM_p">To a solution of (±)-4-(5-cyclopropyl-pent-3-ynyl)-2, 2-dimethyl-[1,3] dioxolane (<b>8</b>, 2.50 g, 12.0 mmol) in hexane (100 mL) was added quinoline (155 mg, 1.20 mmol), followed by addition of 5% Pd on BaSO<sub>4</sub> (250 mg). The mixture was stirred at room temperature under H<sub>2</sub> atmosphere for 4 h. The mixture was filtered through Celite and concentrated. The filtrates were diluted with hexanes and washed with NH<sub>4</sub>Cl (satd aq) and brine. Dried organics over MgSO<sub>4</sub>, filtered, and concentrated. Column chromatography (2–10% EtOAc/hexanes, silica) gave (±)-(<i>Z</i>)-4-(5-cyclopropylpent-3-enyl)-2,2-dimethyl-1,3-dioxolane (2.20 g, 10.5 mmol, 88% yield) as clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.49 (m, 1H), 5.37 (m,1H), 4.08 (m, 1H), 4.02 (dd, <i>J</i> = 8.0, 6.0 Hz, 1H), 3.51 (t, <i>J</i> = 7.5 Hz, 1H), 2.17–2.04 (m, 2H), 1.97 (t, <i>J</i> = 7.0 Hz, 2H), 1.74–1.66 (m, 1H), 1.58–1.49 (m, 1H), 1.41 (s, 3H), 1.35 (s, 3H), 0.70 (m, 1H), 0.41 (m, 2H), 0.06 (m, 2H).</div><div class="NLM_p">(±)-(<i>Z</i>)-4-(5-Cyclopropylpent-3-enyl)-2,2-dimethyl-1,3-dioxolane (2.00 g, 9.51 mmol) in AcOH/H<sub>2</sub>O (4:1, 50 mL) was stirred overnight at rt. The mixture was concentrated and purified by column chromatography (70–90% EtOAc/hexanes, silica) to give (±)-(<i>Z</i>)-7-cyclopropylhept-5-ene-1,2-diol (1.45 g, 8.52 mmol, 90% yield) as clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.50 (m, 1H), 5.37 (m, 1H), 3.73 (m, 1H), 3.66 (d, <i>J</i> = 11.2 Hz, 1H), 3.46 (dd, <i>J</i> = 11.2, 7.7 Hz, 1H), 2.19–2.10 (m, 2H), 1.97 (t, <i>J</i> = 7.1 Hz, 2H), 1.53–1.46 (m, 2H), 0.71 (m, 1H), 0.42 (m, 2H), 0.06 (m, 2H).</div><div class="NLM_p last">To a solution of 7-cyclopropyl-hept-5-ene-1,2-diol (1.45 g, 9.28 mmol) in THF (80 mL) was added sodium hydride (60 wt % dispersion oil, 1.11 g, 27.8 mmol) at 0 °C. The mixture was slowly warmed to room temperature and stirred for 1 h. TrisIm (3.41 g, 10.2 mmol) was added in one portion at 0 °C. The mixture was warmed to rt and stirred for 1.5 h. The mixture was quenched with water and extracted with Et<sub>2</sub>O. The organics were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (7–15% EtOAc/hexanes, silica) gave the (±)-(<i>Z</i>)-2-(5-cyclopropylpent-3-enyl)oxirane (<b>5n</b>, 1.20 g, 8.68 mmol, 94% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.51 (m, 1H), 5.40 (m, 1H), 2.93 (m, 1H), 2.75 (dd, <i>J</i> = 4.9, 4.1 Hz, 1H), 2.48 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.19 (q, <i>J</i> = 7.3 Hz, 2H), 1.98 (t, <i>J</i> = 7.0 Hz, 2H), 1.62–1.56 (m, 2H), 0.70 (m, 1H), 0.41 (m, 2H), 0.07 (m, 2H).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Representative Procedure for Intramolecular Cyclopropanation to Prepare Alcohols <b>9d</b>–<b>j</b>,<b>n</b>–<b>q</b>,<b>s</b>–<b>v</b>. Synthesis of (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-Propylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b>)</h4><div class="NLM_p last">To a solution of tetramethylpiperidine (1.85 g, 13.1 mmol) in MTBE (75 mL) at −78 °C under N<sub>2</sub> was added <i>n</i>-butyllithium (8.17 mL of a 1.6 M solution in hexanes, 13.1 mmol) dropwise over 5 min. After the addition was complete, the flask was stirred at −78 °C for 30 min and warmed to 0 °C for 10 min. The LiTMP solution was added via cannula to a solution of (±)-2-(hept-3-enyl)oxirane (<b>5d</b>, 915 mg, 6.54 mmol) in MTBE (20 mL) at 0 °C over 30 min. The reaction was slowly warmed to rt and stirred overnight. The mixture was quenched with MeOH (2 mL), and the mixture was washed with 1N HCl (100 mL) and brine. The aqueous phase was back-extracted with DCM (50 mL), and the combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Purification by column chromatography (1–25% EtOAc/hexanes, silica) gave the title compound (<i>exo</i>-<b>9d</b>:<i>endo</i>-<b>9d</b> = 4.2:1, 515 mg, 3.67 mmol, 56% yield), an inseparable mixture of diastereomers, as a clear oil. <i>Exo</i>-isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.21 (d, <i>J</i> = 4.8 Hz, 1H), 1.89 (m, 1H), 1.67 (dd, <i>J</i> = 12.5, 8.2 Hz, 1H), 1.53 (dd, <i>J</i> = 14.2, 8.3 Hz, 1H), 1.48–1.28 (m, 4H), 1.20–1.08 (m, 4H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H), 0.37 (m, 1H). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, partial spectra of distinguishable peaks) δ 4.18 (d, <i>J</i> = 4.8 Hz, 1H), 2.07 (1H, m), 1.74 (m, 1H), 0.75 (m, 1H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-Butylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9e</b>/<i>endo</i>-<b>9e</b>)</h4><div class="NLM_p last">Prepared from (±)-2-(oct-3-enyl)oxirane (<b>5e</b>, 2.04 g, 13.2 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9e</b>:<i>endo</i>-<b>9e</b> = 3.3:1, 1.20 g, 7.79 mmol, 59% yield), an inseparable mixture of diastereomers, as a clear oil. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.21 (d, <i>J</i> = 4.8 Hz, 1H), 1.89 (m, 1H), 1.69 (dd, <i>J</i> = 12.6, 8.0 Hz, 1H), 1.54 (dd, <i>J</i> = 11.6, 5.7 Hz, 1H), 1.48–1.25 (m, 6H), 1.25–1.08 (m, 3H), 0.89 (m, 3H), 0.36 (m, 1H). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, partial spectra of distinguishable peaks) δ 4.18 (d, <i>J</i> = 4.8, 1H), 2.07 (1H, m), 1.75 (m, 1H), 0.75 (m, 1H).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>,6<i>R</i>)-6-Pentylbicyclo[3.1.0]hexan-2-ol (<i>endo</i>-<b>9f</b>)</h4><div class="NLM_p last">Prepared from (±)-(<i>Z</i>)-2-(non-3-enyl)oxirane (<i>Z</i>-<b>5f</b>, 1.00 g, 5.94 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>endo</i>-<b>9f</b>, 600 mg, 3.56 mmol, 60% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.17 (dd, <i>J</i> = 5.0, 1.0 Hz, 1H), 2.08 (m, 1H), 1.75 (m, 1H), 1.70–1.49 (m, 2H), 1.40–1.25 (m, 8H), 1.18 (m, 2H), 0.88 (t, <i>J</i> = 6.9 Hz, 3H), 0.75 (m, 1H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>,6<i>S</i>)-6-Pentylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9f</b>)</h4><div class="NLM_p last">Prepared from (±)-(<i>E</i>)-2-(non-3-enyl)oxirane (<i>E</i>-<b>5f</b>, 2.00 g, 11.9 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9f</b>, 950 mg, 5.64 mmol, 48% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.21 (d, <i>J</i> = 4.8 Hz, 1H), 1.68 (dd, <i>J</i> = 12.5, 8.1 Hz, 1H), 1.54 (dd, <i>J</i> = 15.5, 8.5 Hz, 1H), 1.38–1.22 (m, 8H), 1.17 (m, 3H), 1.10 (m, 1H), 0.88 (t, <i>J</i> = 7.1 Hz, 3H), 0.37 (m, 1H).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>,6<i>S</i>)-6-Isopropylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9g</b>)</h4><div class="NLM_p last">Prepared from (±)-2-(5-methylhex-3-enyl)oxirane (<b>5g</b>, 2.04 g, 11.9 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9g</b>, 1.18 g, 8.42 mmol, 71% yield), predominately the <i>exo</i>-isomer, as a clear oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.19 (d, <i>J</i> = 4.8 Hz, 1H), 1.87 (m, 2H), 1.63 (dd, <i>J</i> = 12.5, 8.2 Hz, 1H), 1.51 (dd, <i>J</i> = 14.2, 8.4 Hz, 1H), 1.30 (m, 1H), 1.19 (m, 1H), 1.11 (m, 1H), 0.95–0.84 (m, 7H), 0.14 (m, 1H).</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>)-6-Isobutylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9h</b>/<i>endo</i>-<b>9h</b>)</h4><div class="NLM_p last">Prepared from (±)-2-(6-methylhept-3-enyl)oxirane (<b>5h</b>, 1.21 g, 7.86 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9h</b>:<i>endo</i>-<b>9h</b> = 3.3:1, 1.21 g, ca. 70% purity by <sup>1</sup>H NMR, 5.49 mmol, 70% yield), an inseparable mixture of diastereomers, as a clear oil. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.22 (m, 1H), 1.95 (m, 1H), 1.88 (m, 1H), 1.72–1.45 (m, 2H), 1.35 (m, 2H), 1.18 (m, 1H), 1.06 (m, 2H), 0.97–0.83 (m, 6H) 0.37 (m, 1H). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, partial spectra of distinguishable peaks) δ 4.18 (d, <i>J</i> = 4.8 Hz, 1H), 2.07 (m, 1H), 1.75 (m, 1H), 0.75 (m, 1H).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-Isopentylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9i</b>/<i>endo</i>-<b>9i</b>)</h4><div class="NLM_p last">Prepared from 2-(7-methyloct-3-enyl)oxirane (<b>5i</b>, 2.70 g, 16.0 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b>to give the title compound (<i>exo</i>-<b>9i</b>:<i>endo</i>-<b>9i</b> = 3.3:1, 3.30 g, ca. 60% purity by <sup>1</sup>H NMR, 11.8 mmol, 74% yield), an inseparable mixture of diastereomers, as a clear oil. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.22 (d, <i>J</i> = 4.4 Hz, 1H), 1.89 (m, 1H), 1.68 (dd, <i>J</i> = 12.5, 8.0 Hz, 1H), 1.60–1.49 (m, 2H), 1.40–1.15 (m, 6H), 1.10 (m, 1H), 0.86, (d, <i>J</i> = 6.7 Hz, 6H) 0.35 (m, 1H). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, partial spectra of distinguishable peaks) δ 4.18 (d, <i>J</i> = 4.8 Hz, 1H), 2.07 (m, 1H), 1.75 (m, 1H), 0.74 (m, 1H).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (±)-(1<i>S</i>,2<i>R</i>,5<i>R</i>)-6,6-Dimethylbicyclo[3.1.0]hexan-2-ol (<b>9j</b>)</h4><div class="NLM_p last">Prepared from (±)-2-(4-methylpent-3-enyl)oxirane (<b>5j</b>, 4.33 g, 34.3 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<b>9j</b>, 1.67 g, 13.3 mmol, 39% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.14 (m, 1H), 2.05 (m, 1H), 1.84 (m, 1H), 1.74 (m, 1H), 1.56 (ddd, <i>J</i> = 12.9, 9.5, 2.9 Hz, 1H), 1.28 (m, 1H), 1.14 (dd, <i>J</i> = 6.3, 1.2 Hz, 1H), 0.99 (s, 3H), 0.93 (s, 3H).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(Cyclopropylmethyl)bicyclo[3.1.0]hexan-2-ol (<i>endo</i>-<b>9n</b>)</h4><div class="NLM_p last">Prepared from (±)-(<i>Z</i>)-2-(4-cyclopropyl-but-2-enyl)-oxirane (<b>5n</b>, 350 mg, 2.30 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>endo</i>-<b>9n</b>, 219 mg, 1.44 mmol, 63% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.19 (d, <i>J</i> = 5.5 Hz, 1H), 2.10 (m, 1H), 1.75 (dd, <i>J</i> = 11.0, 9.7 Hz, 1H), 1.69–1.52 (m, 4H), 1.42 (dd, <i>J</i> = 8.1, 6.2 Hz, 1H), 0.98–0.87 (m, 2H), 0.71 (m, 1H), 0.43 (m, 2H), 0.03 (m, 2H).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>,6<i>S</i>)-6-((<i>tert</i>-Butyldimethylsilyloxy)methyl)bicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9o</b>)</h4><div class="NLM_p last">Prepared from (±)-(<i>E</i>)-<i>tert</i>-butyldimethyl-(5-oxiranyl-pent-2-enyloxy)-silane (<i>E</i>-<b>5o</b>, 1.80 g, 7.43 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9o</b>, 1.12 g, 4.62 mmol, 62% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.25 (d, <i>J</i> = 4.8 Hz, 1H), 3.49 (dd, <i>J</i> = 10.8, 6.2 Hz, 1H), 3.44 (dd, <i>J</i> = 10.8, 6.4 Hz, 1H), 1.93 (m, 1H), 1.72 (dd, <i>J</i> = 12.6, 8.1 Hz, 1H), 1.57 (dd, <i>J</i> = 14.5, 8.4 Hz, 1H), 1.38–1.24 (m, 3H), 0.89 (s, 9H), 0.71 (m, 1H), 0.04 (s, 6H).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (±)-(1<i>S</i>,2<i>R</i>,5<i>R</i>,6<i>S</i>)-6-(Methylthiomethyl)bicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9p</b>)</h4><div class="NLM_p last">Prepared from (±)-(<i>E</i>)-2-(5-methylsulfanyl-pent-3-enyl)-oxirane (<b>5p</b>, 600 mg, 4.20 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9p</b>, 40 mg, 0.28 mmol, 7% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.28 (t, <i>J</i> = 5.0 Hz, 1H), 2.41 (d, <i>J</i> = 7.0 Hz, 2H), 2.14 (s, 3H), 1.95 (m, 1H), 1.75 (dd, <i>J</i> = 12.7, 8.1 Hz, 1H), 1.58 (dd, <i>J</i> = 14.6, 8.6 Hz, 1H), 1.40–1.28 (m, 4H), 0.69 (m, 1H).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>)-6-(Ethoxymethyl)bicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9q</b>/<i>endo</i>-<b>9q</b>)</h4><div class="NLM_p last">Prepared from (±)-2-(5-ethoxypent-3-enyl)oxirane (<b>5q</b>, 1.76 g, 11.3 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9q</b>:<i>endo</i>-<b>9q</b> = 10:1, 298 mg, 1.91 mmol, 17% yield), an inseparable mixture of diastereomers, as a clear oil. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.29 (m, 1H), 3.47 (q, <i>J</i> = 7.1 Hz, 2H), 3.24 (m, 2H), 1.94 (m, 1H), 1.75 (dd, <i>J</i> = 12.6, 8.1 Hz, 1H), 1.56 (m, 1H), 1.40–1.28 (m, 3H), 1.20 (t, <i>J</i> = 7.1 Hz, 3H), 0.78 (m, 1H). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, partial spectra of distinguishable peaks) δ 3.90 (m, 1H), 2.17 (m, 1H), 1.66 (m, 1H), 1.21 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (±)-(1<i>S</i>,2<i>R</i>,5<i>R</i>)-Spiro[bicyclo[3.1.0]hexane-6,1′-cyclopentan]-2-ol (<b>9s</b>)</h4><div class="NLM_p last">Prepared from (±)-2-(3-cyclopentylidenepropyl)oxirane (<b>5s</b>, 572 mg, 3.76 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<b>9s</b>, 250 mg, 1.64 mmol, 44% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.11 (d, <i>J</i> = 4.8 Hz, 1H), 2.00 (m, 1H), 1.69–1.46 (m, 8H), 1.40–1.26 (m, 5H).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (±)-(1<i>S</i>,2<i>R</i>,5<i>R</i>)-Spiro[bicyclo[3.1.0]hexane-6,1′-cyclohexan]-2-ol (<b>9t</b>)</h4><div class="NLM_p last">Prepared from 2-(3-cyclohexylidenepropyl)oxirane (<b>5t</b>, 950 mg, 5.71 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<b>9t</b>, 406 mg, 2.44 mmol, 43% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.14 (m, 1H), 2.03 (m, 1H), 2.00–1.10 (m, 15H).</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>,6<i>S</i>)-6-Phenylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9u</b>)</h4><div class="NLM_p last">Prepared from (±)-(<i>E</i>)-2-(4-phenylbut-3-enyl)oxirane (<b>5u</b>, 3.13 g, 18.0 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9u</b>, 2.38 g, ca. 60% purity by <sup>1</sup>H NMR, 8.88 mmol, 49% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.25 (m, 2H), 7.14 (m, 1H), 7.02 (m, 2H), 4.41 (d, <i>J</i> = 4.7 Hz, 1H), 3.58 (d, <i>J</i> = 6.8 Hz, 1H), 2.09 (m, 1H), 1.89 (dd, <i>J</i> = 12.8, 8.0 Hz, 1H), 1.77–1.64 (m, 2H), 1.54 (m, 1H), 0.79 (m, 1H).</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>)-6-Benzylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9v</b>/<i>endo</i>-<b>9v</b>)</h4><div class="NLM_p last">Prepared from (±)-2-(5-phenylpent-3-enyl)oxirane (<b>5v</b>, 2.01 g, 10.7 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<i>exo</i>-<b>9v</b>:<i>endo</i>-<b>9v</b> = 4:1, 828 mg, 4.40 mmol, 41% yield), an inseparable mixture of diastereomers, as a clear oil. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.25 (m, 2H), 7.25–7.15 (m, 3H), 4.25 (d, <i>J</i> = 4.7 Hz, 1H), 2.54 (d, <i>J</i> = 6.9 Hz, 2H), 1.95 (m, 1H), 1.74 (dd, <i>J</i> = 12.5, <i>J</i> = 8.0 Hz, 1H), 1.57 (m, 1H), 1.39 (m, 2H), 1.31 (m, 1H), 0.71 (m, 1H). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, partial spectra of distinguishable peaks) δ 2.57 (m, 1H), 2.19 (m, 1H), 1.81 (m, 1H), 1.67 (m, 1H), 1.14 (m, 1H).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Representative Procedure for Alcohol Oxidation to Prepare <b>10d</b>–<b>j</b>,<b>n</b>–<b>q</b>,<b>s</b>–<b>v</b>. Synthesis of (±)-6-Propylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b>)</h4><div class="NLM_p last">To a solution of (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-propylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9d</b>:<i>endo</i>-<b>9d</b> = 4.2:1, 515 mg, 3.68 mmol) in DCM (15 mL) containing 4 Å molecular sieves (1.0 g) at 0 °C was added 4-methylmorpholine 4-oxide (862 mg, 7.36 mmol) followed by TPAP (78 mg, 0.23 mmol). The mixture was slowly warmed to rt and stirred for 1 h. The mixture was filtered through a plug of silica gel (DCM:Et<sub>2</sub>O, 5:1 as eluent) and concentrated to a light-yellow oil. Purification by column chromatography (10–25% EtOAc/hexanes, silica) gave the title compound (<i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b>, 251 mg, 1.82 mmol, 49% yield), an inseparable mixture of diastereomers (ratio not determined), as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.29–1.82 (m, 5H), 1.53 (d, <i>J</i> = 5.0 Hz, 1H), 1.48–1.21 (m, 5H), 0.91 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (±)-6-Butylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10e</b>/<i>endo</i>-<b>10e</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-butylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9e</b>:<i>endo</i>-<b>9e</b> = 3.3:1, 1.20 g, 7.79 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound <i>exo</i>-<b>10e</b>/<i>endo</i>-<b>10e</b>, 664 mg, 4.37 mmol, 56% yield), an inseparable mixture of diastereomers (ratio not determined), as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.29–1.82 (m, 5H), 1.53 (d, <i>J</i> = 5.0 Hz, 1H), 1.45–1.24 (m, 7H), 0.87 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (±)-<i>endo</i>-6-Pentylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10f</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>,6<i>R</i>)-6-pentylbicyclo[3.1.0]hexan-2-ol (<i>endo</i>-<b>9f</b>, 975 mg, 5.79 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>endo</i>-<b>10f</b>, 740 mg, 4.45 mmol, 77% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.34–2.19 (m, 2H), 2.14 (q, <i>J</i> = 5.9 Hz, 1H), 2.01–1.86 (m, 3H), 1.49–1.24 (m, 9H), 0.89 (t, <i>J</i> = 6.4 Hz, 3H).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (±)-<i>exo</i>-6-Pentylbicyclo[3.1.0]hexan-2-one (<i><b>exo</b></i><b>-10f</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>,6<i>S</i>)-6-pentylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9f</b>, 950 mg, 5.64 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10f</b>, 782 mg, 4.70 mmol, 83% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.15–1.98 (m, 4H), 1.87 (q, <i>J</i> = 4.5 Hz, 1H), 1.55 (dd, <i>J</i> = 5.0, 2.0 Hz, 1H), 1.42 (m, 2H), 1.34–1.22 (m, 7H), 0.89 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (±)-<i>exo</i>-6-Isopropylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10g</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>,6<i>S</i>)-6-isopropylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9g</b>, 1.18 g, 8.42 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d/</b><i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10g</b>, 737 mg, 5.33 mmol, 63% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.10–1.90 (m, 4H), 1.85 (m, 1H), 1.53 (d, <i>J</i> = 4.4 Hz, 1H), 1.04 (m, 2H), 0.98 (d, <i>J</i> = 5.1 Hz, 3H), 0.93 (d, <i>J</i> = 5.1 Hz, 3H).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (±)-6-Isobutylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10h</b>/<i>endo</i>-<b>10h</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>)-6-isobutylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9h</b>:<i>endo</i>-<b>9h</b> = 3.3:1, 847 mg, 5.49 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10h</b>:<i>endo</i>-<b>10h</b> = 3:1, 723 mg, ca. 70% purity by <sup>1</sup>H NMR, 3.33 mmol, 61% yield), an inseparable mixture of diastereomers, as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.25 (m, 1H from <i>endo</i>-isomer), 2.13–1.87 (m, 4H), 1.86 (q, <i>J</i> = 4.6 Hz, 1H from <i>exo</i>-isomer), 1.70 (m, 1H), 1.55 (d, <i>J</i> = 5.1 Hz, 1H from <i>exo</i>-isomer), 1.28 (m, 2H), 1.11 (m, 1H), 0.95 (d, <i>J</i> = 2.5 Hz, 3H), 0.92 (d, <i>J</i> = 2.5 Hz, 3H).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (±)-6-Isopentylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10i</b>/<i>endo</i>-<b>10i</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-isopentylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9i</b>:<i>endo</i>-<b>9i</b> = 3.3:1, 1.98 g, 11.8 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10i</b>/<i>endo</i>-<b>10i</b>, 1.71 g, 10.3 mmol, 87% yield), an inseparable mixture of diastereomers (ratio not determined), as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.25 (m, 1H from <i>endo</i> isomer), 2.17–1.85 (m, 6H), 1.55 (m, 2H), 1.45–1.22 (m, 4H), 0.95–0.86 (m, 6H).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (±)-6,6-Dimethylbicyclo[3.1.0]hexan-2-one (<b>10j</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>R</i>)-6,6-dimethylbicyclo[3.1.0]hexan-2-ol (<b>9j</b>, 1.67 g, 13.3 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<b>10j</b>, 1.49 g, 12.0 mmol, 90% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.35–2.16 (m, 2H), 2.04 (m, 1H), 1.94–1.86 (m, 2H), 1.65 (d, <i>J</i> = 4.7 Hz, 1H), 1.16 (s, 3H), 1.12 (s, 3H).</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (±)-<i>endo</i>-6-(Cyclopropylmethyl)bicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10n</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(cyclopropylmethyl)bicyclo[3.1.0]hexan-2-ol (<i>endo</i>-<b>9n</b>, 210 mg, 1.38 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>endo</i>-<b>10n</b>, 110 mg, 0.732 mmol, 53% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.32–2.20 (m, 2H), 2.16 (q, <i>J</i> = 5.4 Hz, 1H), 1.97–1.84 (m, 3H), 1.57 (m, 1H), 1.38–1.24 (m, 2H), 0.76 (m, 1H), 0.46 (m, 2H), 0.07 (m, 2H).</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (±)-<i>exo</i>-6-((<i>tert</i>-Butyldimethylsilyloxy)methyl)bicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10o</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>,6<i>S</i>)-6-((<i>tert</i>-butyldimethylsilyloxy)methyl)bicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9o</b>, 1.88 g, 7.76 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10o</b>, 1.59 g, 6.62 mmol, 85% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.69 (dd, <i>J</i> = 10.8, 4.8 Hz, 1H), 3.58 (dd, <i>J</i> = 10.8, 5.3 Hz, 1H), 2.15 (m, 1H), 2.05 (m, 4H), 1.72 (m, 1H), 1.51 (m, 1H), 0.87 (s, 9H), 0.04 (s, 6H).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (±)-<i>exo</i>-6-(Methylthiomethyl)bicyclo[3.1.0]hexan-2-one (<i><b>exo</b></i>-<b>10p</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>R</i>,6<i>S</i>)-6-(methylthiomethyl)bicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9p</b>, 40 mg, 0.25 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10p</b>, 35 mg, 0.22 mmol, 89% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.65 (dd, <i>J</i> = 13.5, 5.8 Hz, 1H), 2.38 (dd, <i>J</i> = 13.5, 7.7 Hz, 1H), 2.18 (s, 3H), 2.16–2.03 (m, 4H), 2.00 (dd, <i>J</i> = 9.1, 5.1 Hz, 1H), 1.78 (dd, <i>J</i> = 5.3, 2.5 Hz, 1H), 1.53 (m, 1H).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (±)-6-(Ethoxymethyl)bicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10q</b>/<i>endo</i>-<b>10q</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>)-6-(ethoxymethyl)bicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9q</b>:<i>endo</i>-<b>9q</b> = 10:1, 290 mg, 1.86 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10q</b>:<i>endo</i>-<b>10q</b> = 10:1, 186 mg, 0.829 mmol, 45% yield), an inseparable mixture of diastereomers, as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.60 (dd, <i>J</i> = 10.8, 6.3 Hz, 1H from <i>endo</i>-isomer), 3.46 (m, 3H), 3.27 (dd, <i>J</i> = 10.4, 6.7 Hz, 1H), 2.19–1.97 (m, 5H), 1.77 (m, 1H from <i>endo</i>-isomer), 1.70 (dd, <i>J</i> = 5.2, 2.6 Hz, 1H), 1.59 (m, 1H), 1.20 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (±)-Spiro[bicyclo[3.1.0]hexane-6,1′-cyclopentan]-2-one (<b>10s</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>R</i>)-spiro[bicyclo[3.1.0]hexane-6,1′-cyclopentan]-2-ol (<b>9s</b>, 266 mg, 1.74 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<b>10s</b>, 115 mg, 0.766 mmol, 44% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.23–2.11 (m, 2H), 2.02–1.90 (m, 3H), 1.77–1.73 (m, 3H), 1.70–1.50 (m, 5H), 1.48–1.24 (m, 1H).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (±)-Spiro[bicyclo[3.1.0]hexane-6,1′-cyclohexan]-2-one (<b>10t</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>R</i>)-spiro[bicyclo[3.1.0]hexane-6,1′-cyclohexan]-2-ol (<b>9t</b>, 406 mg, 2.44 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<b>10t</b>, 244 mg, 1.49 mmol, 61% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.39–2.28 (m, 1H), 2.28–2.14 (m, 1H), 2.10–1.99 (m, 2H), 1.97–1.82 (m, 2H), 1.64 (d, <i>J</i> = 5.2 Hz, 1H), 1.60–1.44 (m, 7H), 1.33–1.25 (m, 2H).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (±)-<i>exo</i>-6-Phenylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10u</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>,6<i>S</i>)-6-phenylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9u</b>, 1.55 g, 8.88 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10u</b>, 351 mg, 2.04 mmol, 23% yield) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.28 (m, 2H), 7.21 (m, 1H), 7.05 (m, 2H), 2.38 (m, 2H), 2.33–2.10 (m, 4H), 2.06 (dd, <i>J</i> = 5.0, 2.8 Hz, 1H).</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (±)-6-Benzylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10v</b>/<i>endo</i>-<b>10v</b>)</h4><div class="NLM_p last">Prepared from (±)-(1<i>S</i>,2<i>R</i>,5<i>S</i>)-6-benzylbicyclo[3.1.0]hexan-2-ol (<i>exo</i>-<b>9v</b>:<i>endo</i>-<b>9v</b> = 4:1, 828 mg, 4.40 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (<i>exo</i>-<b>10v</b>:<i>endo</i>-<b>10v</b> = 6:1, 641 mg, 3.44 mmol, 78% yield), an inseparable mixture of diastereomers, as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.28 (m, 2H), 7.25–7.20 (m, 3H), 2.78 (dd, <i>J</i> = 14.9, 6.1 Hz, 1H), 2.70 (dd, <i>J</i> = 15.1, 7.8 Hz, 1H from <i>endo</i>-isomer, 2.60 (dd, <i>J</i> = 14.9, 7.2 Hz, 1H from <i>exo</i>-isomer), 2.43–2.20 (m, 3H from <i>endo</i>-isomer), 2.16–2.00 (m, 5H), 1.73 (dd, <i>J</i> = 5.2, 2.4 Hz, 1H), 1.57 (m, 1H).</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (±)-6,6-Dichlorospiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<b>12</b>)</h4><div class="NLM_p last">To a solution of 2-cyclopenten-1-one ethylene ketal (<b>11</b>, 25.2 g, 200 mmol) in CHCl<sub>3</sub> (200 mL) and CH<sub>2</sub>Cl<sub>2</sub> (200 mL) was added benzyltriethylammonium chloride (100 mg, 0.44 mmol) and 50% NaOH solution (aq, 200 mL) at rt. This solution was vigorously stirred at 45 °C over 3 d. The reaction mixture was diluted with H<sub>2</sub>O (300 mL) and extracted with CHCl<sub>3</sub> (2 × 150 mL). The combined organics were concentrated in vacuo, and the residue was purified by column chromatography (0–50% EtOAc/hexanes, silica) to the give the title compound (<b>12</b>, 22.0 g, 105 mmol, 53% yield) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.06–3.93 (m, 4H), 2.25–2.01 (m, 5H), 1.86 (m, 1H).</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (±)-6-Chloro-6-methylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<b>13</b>)</h4><div class="NLM_p last">To a solution of (±)-6,6-dichloro-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<b>12</b>, 6.50 g, 31.1 mmol) in THF (140 mL) at −100 °C was added dropwise <i>tert</i>-butyllithium (22.0 mL of a 1.7 M solution in pentane, 37.4 mmol). After stirring for 20 min, methyl iodide (2.33 mL, 37.3 mmol) was added dropwise and the mixture was slowly warmed to rt over 2 h. The reaction was quenched with water and extracted with hexanes. The layers were separated, and the organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (0–20% EtOAc/hexanes, silica) gave the title compound (<b>13</b>, 3.20 g, 17.0 mmol, 55% yield) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.01–3.91 (m, 4 H), 2.20–2.07 (m, 2H), 1.90 (m, 2H). 1.63 (dd, <i>J</i> = 6.8, 5.3 Hz, 1H), 1.61 (s, 3H), 1.54 (dd, <i>J</i> = 7.6 Hz, 1.0 Hz, 1H).</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (±)-<i>exo</i>-6-Chlorospiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>exo</i>-14) and (±)-<i>endo</i>-6-Chlorospiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>14</b>)</h4><div class="NLM_p last">To a solution of (±)-6,6-dichloro-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<b>12</b>, 17.0 g, 81.3 mmol) and KOH (28.0 g, 499 mmol) in EtOH (200 mL) was added Zn dust (62.8 g, 960 mmol) at rt. The reaction mixture was heated at 80 °C under vigorous stirring for 20 h. The mixture was cooled to rt and filtered through Celite. The filtrate was cooled to 0 °C and treated with acetic anhydride (47.3 mL, 500 mmol). The solution was concentrated in vacuo and partitioned between (300 mL) and H<sub>2</sub>O (150 mL). The layers were separated, and the organics were washed with H<sub>2</sub>O and brine (150 mL). The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (20–70% DCM/hexanes, silica) gave the <i>exo</i>-chloride (<i>exo</i>-<b>14</b>, 7.20 g, 41.2 mmol, 51% yield) followed by the <i>endo</i>-chloride (<i>endo</i>-<b>14</b>, 3.70 g, 21.2 mmol, 26% yield), both colorless oils. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.05–3.86 (m, 4H), 2.92 (t, <i>J</i> = 1.9 Hz, 1H) 1.90 (m, 2H), 1.74 (m, 2H), 1.62 (m, 1H), 1.37 (m, 1H). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.03–3.86 (m, 4H), 3.42 (t, <i>J</i> = 7.5 Hz, 1H) 2.17 (m, 1H), 2.05–1.77 (m, 3H), 1.81 (m, 1H), 1.72 (m, 1H).</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> General Procedure for Lithiation/Electrophile Quench of <i>mono</i>-Chloride <b>13</b> or <i>mono</i>-Chloride <b>14</b> to Prepare <i>exo</i>-<b>10b</b> Ketal, <i>endo</i>-<b>10b</b> Ketal, <i>endo</i>-<b>10c</b> Ketal, <i>endo</i>-<b>15</b>, <i>exo</i>-<b>15</b></h4><div class="NLM_p last">To a solution of 4,4′-di-<i>tert</i>-butyl-biphenyl (5.0 equiv) in THF (0.5M) under N<sub>2</sub> was added portionwise lithium wire (5.0 equiv). The solution was vigorously stirred at 0 °C for 6 h and cooled to −78 °C. (±)-<i>Endo</i> or <i>exo</i>-<i>mono</i>-chloride (<b>13</b> or <b>14</b>, 1.0 equiv) dissolved in THF (2.0M) was added to the dark-green solution. After stirring for 15 min, the electrophile (5.0 equiv) was added dropwise to the solution. The mixture was slowly warmed to rt, and the resulting solution was poured into a mixture of hexanes/NH<sub>4</sub>Cl (satd aq) cooled at 0 °C. The phases were separated, and the organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Products were purified by column chromatography (EtOAc/hexanes, silica).</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (±)-<i>exo</i>-6-Methylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>exo</i>-<b>10b</b> Ketal)</h4><div class="NLM_p last">Prepared from (±)-6-chloro-6-methylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<b>13</b>) using the general procedure for lithiation/electrophile quench described above where EtOH is substituted as the electrophile to give the title compound (<i>exo</i>-<b>10b</b> ketal). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.05–3.87 (m, 4H), 1.85 (m, 1H), 1.76 (dd, <i>J</i> = 12.3, 8.0 Hz, 1H), 1.61 (dd, <i>J</i> = 13.8, 8.4 Hz, 1H), 1.45 (ddd, <i>J</i> = 13.8, 11.8, 8.2 Hz, 1H), 1.16 (m, 1H), 1.10 (ddd, <i>J</i> = 6.1, 2.9, 1.1 Hz, 1H), 1.00 (d, <i>J</i> = 6.0 Hz, 3H), 0.88 (m, 1H).</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (±)-<i>endo</i>-6-Methylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10b</b> Ketal)</h4><div class="NLM_p last">Prepared from a mixture of <i>exo</i>-<b>14</b> and <i>endo</i>-<b>14</b> (3.00 g, 17.2 mmol) by the general procedure using methyl iodide (5.36 mL, 85.9 mmol) as the electrophile to give the title compound (<i>endo</i>-<b>10b</b> ketal, 1.85 g, 12.0 mmol, 70% yield) as a clear oil after purification by column chromatography (0–20% EtOAc/hexanes, silica). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.99–3.86 (m, 4H), 2.05 (m, 1H), 1.91 (m, 1H), 1.70 (ddd, <i>J</i> = 13.2, 9.3, 1.4 Hz, 1H), 1.56 (m, 1H), 1.48 (m, 1H), 1.38 (ddd, <i>J</i> = 8.6, 6.5, 1.3 Hz, 1H), 1.15 (d, <i>J</i> = 6.6 Hz, 3H), 0.96 (m, 1H).</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (±)-<i>endo</i>-6-Ethylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10c</b> Ketal)</h4><div class="NLM_p last">Prepared from a mixture of <i>exo</i>-<b>14</b> and <i>endo</i>-<b>14</b> by the general procedure using ethyl iodide as the electrophile to give the title compound (<i>endo</i>-<b>10c</b> ketal). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.99–3.88 (m, 4H), 2.09–1.91 (m, 2H), 1.73–1.50 (m, 4H), 1.45–1.35 (m, 2H), 1.05 (t, <i>J</i> = 7.4 Hz, 3H), 0.78 (m, 1H).</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (±)-<i>endo</i>-Spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-carbaldehyde (<i>endo</i>-<b>15</b>) and (±)-<i>exo</i>-Spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-carbaldehyde (<i>exo</i>-<b>15</b>)</h4><div class="NLM_p last">Prepared by the generalprocedure using a mixture of <i>exo</i>-<b>14</b> and <i>endo</i>-<b>14</b> (8.00 g, 45.8 mmol) and dimethylformamide (14.2 mL, 183 mmol) as the electrophile. Purification by column chromatography (5–40% EtOAc/hexanes, silica) gave the title compound (<i>endo</i>-<b>15</b>:<i>exo</i>-<b>15</b> = 7:1, 4.10 g, 24.4 mmol, 53% yield), a clear oil, as a mixture of diastereomers. The isomers were partially separated by repeated and careful column chromatography under the same conditions to give pure fractions of the faster eluting <i>endo</i>-isomer followed by pure fractions of the <i>exo</i>-isomer. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.60 (d, <i>J</i> = 6.3 Hz, 1H), 4.05–3.93 (m, 4H), 2.34–2.19 (m, 2H), 2.15–2.06 (m, 3H), 1.91–1.76 (m, 2H). <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.27 (d, <i>J</i> = 4.0 Hz, 1H), 4.05 (m, 1H), 3.99–3.91 (m, 3H), 2.13–1.99 (m, 4H), 1.90 (dd, <i>J</i> = 12.7, 8.0 Hz, 1H), 1.72 (dd, <i>J</i> = 14.0, 8.7 Hz, 1H), 1.54 (m, 1H).</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Preparation of (±)-<i>endo</i>-6-Vinylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10k</b> Ketal)</h4><div class="NLM_p last">To a solution of methyltriphenylphosphonium bromide (2.55 g, 7.14 mmol) in THF (40 mL) was added <i>n</i>-butyllithium (4.46 mL of 1.6 M solution in hexanes, 7.14 mmol) at rt. After 2 h, a solution of (±)-<i>endo</i>-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-carbaldehyde (<i>endo</i>-<b>15</b>, 1.00 g, 5.95 mmol) in THF (8 mL) was added and the reaction was stirred for 20 h. The mixture was treated with H<sub>2</sub>O, and the product was extracted with hexanes. The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Column chromatography (0–20% EtOAc/hexanes, silica) gave the title compound (<i>endo</i>-<b>10k</b> ketal, 700 mg, 4.21 mmol, 71% yield) as an oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.87 (ddd, <i>J</i> = 17.0, 10.2, 8.6 Hz, 1H), 5.30 (ddd, <i>J</i> = 17.0, 2.0, 1.0 Hz, 1H), 5.18 (ddd, <i>J</i> = 10.2, 2.0, 1.0 Hz, 1H), 4.00–3.88 (m, 4H), 2.07 (m, 1H), 1.90 (m, 1H), 1.80–1.56 (m, 5H).</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (±)-<i>exo</i>-6-Vinylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>exo</i>-<b>10k</b> Ketal)</h4><div class="NLM_p last">Prepared from (±)-<i>exo</i>-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-carbaldehyde (<i>exo</i>-<b>15</b>, 2.00 g, 11.9 mmol) in a similar manner as described for the synthesis of <i>endo</i>-<b>10k</b> ketal to give the title compound (<i>exo</i>-<b>10k</b> ketal, 1.20 g, 7.22 mmol, 61% yield) as a clear oil. δ 5.35 (ddd, <i>J</i> = 17.0, 10.2, 8.6 Hz, 1H), 5.05 (ddd, <i>J</i> = 17.0, 1.5, 0.4 Hz, 1H), 4.96 (dd, <i>J</i> = 10.3, 1.6 Hz, 1H), 4.03 (m, 1H), 3.99–3.88 (m, 3H), 1.93 (m, 1H), 1.84 (dd, <i>J</i> = 12.1, 8.1 Hz, 1H), 1.66 (dd, <i>J</i> = 14.2, 8.8 Hz, 1H), 1.56–1.43 (m, 4H).</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (±)-<i>endo</i>-Spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-ylmethanol (<b>16</b>)</h4><div class="NLM_p last">Sodium borohydride (90.0 mg, 2.38 mmol) was dissolved in MeOH (2 mL) and added dropwise to a solution of (±)-<i>endo</i>/<i>exo</i>-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-carbaldehyde (<i>endo</i>-<b>15</b>:<i>exo</i>-<b>15</b> = 7:1, 400 mg, 2.38 mmol) dissolved in MeOH (8 mL). Reaction was stirred at ambient temperature for 10 min and then quenched with NaOH (aq 10%). The mixture was extracted with ether, and the organics were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Purification by column chromatography (50% EtOAc/hexanes, silica) gave the title compound (<b>16</b>, 200 mg, 1.09 mmol, 46% yield), a clear viscous oil, as a single diastereomer. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.07–3.88 (m, 5H), 3.64 (ddd, <i>J</i> = 12.5, 10.4, 2.2 Hz, 1H), 2.79 (dd, <i>J</i> = 11.0, 2.2 Hz, 1H), 2.18–2.05 (m, 2H), 1.82–1.60 (m, 4H), 1.35 (m, 1H).</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (±)-<i>endo</i>-6-(Methoxymethyl)spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10o</b> Ketal)</h4><div class="NLM_p last">To a solution of (±)-<i>endo</i>-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-ylmethanol (<b>16</b>, 200 mg, 1.18 mmol) in DMF (6 mL) cooled to 0 °C was added sodium hydride (60% dispersion in mineral oil, 94.0 mg, 2.35 mmol). The mixture was stirred for 10 min, at which time methyl iodide (341 mg, 2.40 mmol) was added. The mixture was warmed to rt and stirred overnight, quenched with H<sub>2</sub>O, and extracted with Et<sub>2</sub>O. The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (5–25% EtOAc/hexanes, silica) gave the title compound (<i>endo</i>-<b>10o</b> ketal, 180 mg, 1.02 mmol, 87% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.00–3.82 (m, 4H), 3.77 (dd, <i>J</i> = 10.5, 5.4 Hz, 1H), 3.44 (dd, <i>J</i> = 10.5, 8.5 Hz, 1H), 3.40 (s, 3H), 2.10 (m, 1H), 2.00 (m, 1H) 1.87–1.79 (m, 1H), 1.72–1.65 (m, 1H), 1.64–1.54 (m, 2H), 1.20 (m, 1H).</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (±)-<i>endo</i>-6-(Methylthiomethyl)spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10p</b> Ketal)</h4><div class="NLM_p">To a solution of (±)-<i>endo</i>-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-ylmethanol (<b>16</b>, 350 mg, 2.06 mmol) in DCM (12 mL) was added Et<sub>3</sub>N (561 μL, 4.11 mmol). The flask was cooled to 0 °C, and methanesulfonyl chloride (318 μL, 4.11 mmol) was added dropwise. After stirring for 5 min, the flask was warmed to rt and stirred for 1 h. The DCM was evaporated, and the mixture was partitioned between H<sub>2</sub>O and EtOAc. The aqueous phase was back-extracted with EtOAc, and the combined extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated to give (±)-<i>endo</i>-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-ylmethyl methanesulfonate (500 mg, 2.01 mmol, 98% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.63 (dd, <i>J</i> = 11.2, 6.3 Hz, 1H), 4.34 (dd, <i>J</i> = 11.2, 9.3 Hz, 1H), 4.01–3.85 (m, 4H), 3.04 (s, 3H), 2.11 (m, 2H), 1.89 (m, 1H), 1.78 (m, 1H), 1.70 (m, 1H), 1.63 (m, 1H), 1.35 (m, 1H).</div><div class="NLM_p last">To a solution of the mesylate (250 mg, 1.01 mmol) in DMF (5.0 mL) was added sodium thiomethoxide (176 mg, 2.52 mmol). The solution became quite viscous initially and was stirred at rt overnight. The mixture was partitioned between EtOAc and H<sub>2</sub>O. The layers were separated, and the aqueous phase was back-extracted with EtOAc. The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (3–12% EtOAc/hexanes, silica) gave the title compound (<i>endo</i>-<b>10p</b> ketal, 173 mg, 0.821 mmol, 81% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.99–3.87 (m, 4H), 2.87 (dd, <i>J</i> = 13.5, 5.4 Hz, 1H), 2.54 (dd, <i>J</i> = 13.4, 8.8 Hz, 1H), 2.19 (s, 3H), 2.14–1.96 (m, 2H), 1.80 (m, 1H), 1.68–1.53 (m, 3H), 1.18 (qd, <i>J</i> = 8.6, 5.4 Hz, 1H).</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (±)-<i>endo</i>-6-Cyclopropylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10m</b> Ketal)</h4><div class="NLM_p last">To a solution of (±)-<i>endo</i>-6-vinylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10k</b> ketal, 800 mg, 4.81 mmol) in Et<sub>2</sub>O (15 mL) containing Pd(OAc)<sub>2</sub> (10 mg, 0.044 mmol) was added a diazomethane solution (45 mL of 1 M solution in Et<sub>2</sub>O, 45 mmol) dropwise over 1 h. Additional Pd(OAc)<sub>2</sub> (10 mg, 0.044 mmol) and diazomethane solution (45 mL of 1 M solution in Et<sub>2</sub>O, 45 mmol) was added four additional times until the reaction was complete by TLC. Purification by column chromatography (50–90% DCM/hexanes, silica) gave the title compound (<i>endo</i>-<b>10m</b> ketal, 680 mg, 3.77 mmol, 78% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.02–3.88 (m, 4H), 2.04 (m, 1H), 1.91–1.50 (m, 3H), 1.48–1.39 (m, 2H), 1.20 (m, 1H), 0.74 (m, 1H), 0.65–0.52 (m, 2H), 0.33–0.26 (m, 2H).</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (±)-<i>endo</i>-6-(Phenoxymethyl)spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10r</b> Ketal)</h4><div class="NLM_p last">A mixture of (±)-<i>endo</i>-spiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane]-6-ylmethanol (<b>16</b>, 178 mg, 0.966 mmol), phenol (141 mg, 1.50 mmol), PyPh<sub>2</sub>P (395 mg, 1.50 mmol), and D<i>t</i>-BAD (345 mg, 1.50 mmol) in THF (5 mL) was stirred at rt overnight. The mixture was partitioned between Et<sub>2</sub>O and HCl (1N aq). The layers were separated, and the aqueous phase was back-extracted with Et<sub>2</sub>O. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography (0–25% EtOAc/hexanes, silica) to give the title compound (<i>endo</i>-<b>10r</b> ketal, 120 mg, 0.487 mmol, 50% yield) as clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31–7.25 (m, 2H), 6.99–6.92 (m, 3H), 4.41 (dd, <i>J</i> = 10.6, 5.2 Hz, 1H), 4.03–3.89 (m, 5H), 2.13 (m, 1H), 2.04 (m, 1H), 1.89 (m, 1H), 1.78 (m, 1H), 1.68 (m, 1H), 1.60 (m, 1H), 1.40 (m, 1H).</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> General Method for Ketal Deprotection</h4><div class="NLM_p last">A solution of ketal in acetone/H<sub>2</sub>O (4/1, 0.15M) was treated with TsOH (5 mol %) at rt. The solution was stirred until reaction was complete as judged by TLC. The acetone was removed in vacuo, and the product was extracted with hexanes (2×). The combined organic layers were washed with NaHCO<sub>3</sub> (satd, aq) and brine. The organics were dried organics over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford the product ketones. All ketones obtained in ≥90% yield as clear oils.</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (±)-<i>endo</i>-6-Methylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.32–2.21 (m, 2H), 2.10 (m, 1H), 1.97–1.84 (m, 3H), 1.51 (m, 1H), 1.15 (d, <i>J</i> = 6.6 Hz, 3H).</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (±)-<i>exo</i>-6-Methylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.14–1.98 (m, 4H), 1.85 (q, <i>J</i> = 4.8 Hz, 1H), 1.52 (dd, <i>J</i> = 5.0, 2.5 Hz, 1H), 1.33 (m, 1H), 1.12 (d, <i>J</i> = 6.0 Hz, 3H).</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (±)-<i>endo</i>-6-Ethylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.34–2.20 (m, 2H), 2.15 (q, <i>J</i> = 6.0 Hz, 1H), 2.00–1.87 (m, 3H), 1.48–1.36 (m, 3H), 1.04 (t, <i>J</i> = 6.5 Hz, 3H).</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (±)-<i>endo</i>-6-Vinylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10k</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.67 (ddd, <i>J</i> = 17.0, 10.3, 8.5 Hz, 1H), 5.37 (dt, <i>J</i> = 17.0, 1.4 Hz, 1H), 5.27 (dt, <i>J</i> = 10.3, 1.5 Hz, 1H), 2.32–2.21 (m, 3H), 2.16 (m, 1H), 2.09 (m, 1H), 2.03–1.93 (m, 2H).</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (±)-<i>exo</i>-6-Vinylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10k</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.35 (ddd, <i>J</i> = 17.0, 10.2, 8.5 Hz, 1H), 5.15 (ddd, <i>J</i> = 17.0, 1.2, 0.4 Hz, 1H), 4.99 (dd, <i>J</i> = 10.2, 1.1 Hz, 1H), 2.20–2.05 (m, 5H), 1.93 (m, 1H), 1.83 (dd, <i>J</i> = 5.1, 2.4 Hz, 1H).</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (±)-<i>endo</i>-6-Cyclopropylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10m</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.32–2.09 (m, 5H), 1.84 (m, 1H), 1.16–1.09 (m, 1H), 0.68 (m, 1H), 0.61–0.56 (m, 2H), 0.39–0.29 (m, 2H).</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (±)-<i>endo</i>-6-(Methoxymethyl)bicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10o</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.55 (dd, <i>J</i> = 10.8, 6.4 Hz, 1H), 3.45 (dd, <i>J</i> = 10.8, 8.5 Hz, 1H), 3.37 (s, 3H), 2.36–2.23 (m, 3H), 2.05–1.98 (m, 3H), 1.78 (m, 1H).</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (±)-<i>endo</i>-6-(Methylthiomethyl)bicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10p</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.63 (dd, <i>J</i> = 13.6, 6.5 Hz, 1H), 2.53 (dd, <i>J</i> = 13.6 8.6 Hz, 1H), 2.32 (m, 2H), 2.24 (m, 1H), 2.17 (s, 3H), 1.99 (m, 3H), 1.75 (m, 1H).</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (±)-<i>endo</i>-6-(Phenoxymethyl)bicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10r</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.25 (m, 2H), 7.00–6.94 (m, 1H), 6.92–6.88 (m, 2H), 4.19 (dd, <i>J</i> = 10.6, 6.1 Hz, 1H), 3.96 (dd, <i>J</i> = 10.6, 8.9 Hz, 1H), 2.38–2.32 (m, 3H), 2.13–1.94 (m, 4H).</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Cyclobutyldiphenylsulfonium Trifluoromethanesulfonate (<b>17</b>)</h4><div class="NLM_p last">A solution of cyclobutanol (1.00 g, 13.9 mmol) in DCM (25 mL) was chilled to −20 °C and dry pyridine (1.35 mL, 16.6 mmol) was added followed by a solution of trifluoromethanesulfonic anhydride (2.33 mL, 13.9 mmol) in DCM (5 mL). The solution was allowed to warm to room temperature over 1 h. Pentane (40 mL) was added and the resulting mixture shaken and filtered. The filtrate was concentrated in vacuo. The residual oil was chilled to −20 °C, and diphenylsulfane (10.2 mL, 61.0 mmol) was added. The mixture was warmed to 25 °C and stirred for 20 h followed by heating to 45 °C for 30 min. The mixture was cooled to rt, and pentane was added. The resulting solid collected by vacuum filtration to give the title compound (<b>17</b>, 1.82 g, 4.86 mmol, 35% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (dt, <i>J</i> = 7.8, 3.1 Hz, 4H), 7.84–7.72 (m, 6H), 5.84 (m, 1H), 5.15 (ddd, <i>J</i> = 14.9, 10.3, 1.4 Hz, 2H), 4.48 (t, <i>J</i> = 14.2 Hz, 2H), 2.45 (dd, <i>J</i> = 13.8, 7.1 Hz, 2H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 241 [C<sub>16</sub>H<sub>17</sub>S]<sup>+</sup>.</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (±)-6-Allylbicyclo[3.1.0]hexan-2-one (<b>10l</b>)</h4><div class="NLM_p last">A solution of cyclobutyldiphenylsulfonium trifluoromethanesulfonate (<b>17</b>, 1.82 g, 4.86 mmol) in THF (30 mL) was chilled to −78 °C, and <i>tert</i>-butyllithium, (2.70 mL of 1.7 M soln in pentane, 4.59 mmol) was added dropwise. After 30 min, cyclopent-2-enone (0.190 mL, 2.35 mmol) in THF (3 mL) was added and the solution stirred at −78 °C for 2 h. The reaction was quenched with the addition of NaHCO<sub>3</sub> (satd aq) and warmed to room temperature. The product was extracted with DCM and the solvent removed under reduced pressure. Purification by column chromatography (0–20% EtOAc/hexanes, silica) gave the title compound (<i>endo</i>-<b>10l</b>:<i>exo</i>-<b>10l</b> = 1:1, 178 mg, 1.31 mmol, 56%), a clear oil, as an inseparable mixture of diastereomers. Isomer mixture: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.95–5.75 (m, 1H), 5.20–5.00 (m, 2H), 2.35–1.88 (m, 7.5H), 1.60 (m, 0.5 H), 1.52 (m, 0.5H), 1.36 (m, 0.5H).</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Bicyclo[3.1.0]hexan-3-one (<b>20</b>)</h4><div class="NLM_p">To a solution of cyclopentene-4-ol (5.00 g, 59.5 mmol) and Et<sub>2</sub>Zn (12.4 mL, 121 mmol) in DCM (25 mL) under N<sub>2</sub> atmosphere at 0 °C was added CH<sub>2</sub>I<sub>2</sub> (9.76 mL, 121 mmol) over 30 min using a syringe pump. The reaction was slowly warmed to rt and stirred overnight, at which time the mixture was opened to air and slowly quenched by the addition of dilute HCl (aq, 50 mL). The mixture was diluted with EtOAc (100 mL) and filtered. The organic layer was separated and washed with H<sub>2</sub>O (100 mL) and brine (100 mL). The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated to an oil, which was purified by column chromatography (0–20% EtOAc/hexanes, silica) to give <i>endo</i>-bicyclo[3.1.0]hexan-3-ol (3.47 g, 35.4 mmol, 59% yield) as clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.37 (t, <i>J</i> = 6.5 Hz, 1H), 2.10 (m, 2H), 1.72 (d, <i>J</i> = 14.2 Hz, 1H, 1.39 (br s, 1H), 1.27 (m, 2H), 0.56–0.45 (m, 2H).</div><div class="NLM_p last"><i>endo</i>-Bicyclo[3.1.0]hexan-3-ol (3.47 g, 35.4 mmol)) was dissolved in DCM (250 mL) and treated sequentially with basic alumina (10 g) and PCC (15.2 g, 70.6 mmol) at rt. After stirring for 18 h, the solution was filtered through a pad of Celite atop silica gel using DCM/Et<sub>2</sub>O (3:1) as eluent. The solvent was removed in vacuo (250 mbar, 20 °C bath temperature), and the product was purified by bulb-to-bulb distillation at reduced pressure (100 mbar) to give the title compound (<b>20</b>, 2.48 g, 25.8 mmol, 73% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.60 (m, 2H), 2.16 (d, <i>J</i> = 20.0 Hz, 2H), 1.54 (m, 2H), 0.90 (dt, <i>J</i> = 6.0, 1.6 Hz, 1H), −0.05 (dt, <i>J</i> = 6.0, 4.0 Hz, 1H).</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (±)-5-Ethylbicyclo[3.1.0]hexan-2-one (<b>25</b>)</h4><div class="NLM_p last">Sodium hydride (1.40 g of a 60% dispersion in mineral oil, 35.0 mmol) was added to DMSO (75 mL). Trimethylsulfoxionium iodide (8.21 g, 37.3 mmol) was added and the mixture was stirred for 0.5 h, at which time a solution of 3-ethylcyclopent-2-enone (<b>23</b>, 2.57 g, 23.3 mmol) in DMSO (25 zmL) was added dropwise via addition funnel. The mixture was stirred at rt for 2 h, quenched with H<sub>2</sub>O, and extracted with EtOAc. The organics were washed with H<sub>2</sub>O and brine. Dried organics over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (5–25% EtOAc/hexanes, silica) gave the title compound (<b>25</b>, 1.54 g, 12.4 mmol, 53% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.20–2.03 (m, 3H), 1,95 (m, 1H), 1.73–1.60 (m, 2H), 1.53 (m, 1H), 1.15 (ddt, <i>J</i> = 9.0, 4.7, 1.1 Hz, 1H), 1.10 (m, 1H), 0.97 (t, <i>J</i> = 7.5 Hz, 3H).</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> (±)-1-Methylbicyclo[3.1.0]hexan-2-one (<b>26</b>)</h4><div class="NLM_p last">Prepared from 2-methylcyclopent-2-enone (<b>24</b>, 1.00 g, 10.4 mmol) in a similar manner as described for the synthesis of <b>25</b> to give the title compound (<b>26</b>, 492 mg, 4.47 mmol, 44% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.20–2.00 (m, 3H), 1.97–1.87 (m, 2H), 1.23 (s, 3H), 1.02 (m, 2H).</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Representative Procedure for Synthesis of Pyrazole Ethyl Esters <b>18</b>. Preparation of (±)-1a,2,5,5a-Tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<b>18a</b>)</h4><div class="NLM_p last">To a solution of bicyclo[3.1.0]hexan-2-one (2.20 g, 22.9 mmol) and diethyl oxalate (3.10 mL, 22.9 mmol) in EtOH (50 mL) was added KO<i>t</i>-Bu (22.9 mL of a 1 M soln in THF, 22.9 mmol). Stirring was continued for 2.5 h, at which time hydrazine monohydrochloride (1.88 g, 27.5 mmol) was added to a solution in H<sub>2</sub>O (10 mL). The mixture was stirred overnight and concentrated in vacuo to remove EtOH, diluted with EtOAc, and washed with H<sub>2</sub>O and brine. The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (25–50% EtOAc/hexanes, silica) gave the title compound (<b>18a</b>, 2.44 g, 12.7 mmol, 55% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.55 (br s, 1H), 4.32 (q, <i>J</i> = 6.8 Hz, 2H), 2.96 (dd, <i>J</i> = 16.8, 6.0 Hz, 1H), 2.80 (d, <i>J</i> = 17.2 Hz, 1H), 2.23–2.13 (m, 2H), 1.35 (t, <i>J</i> = 7.2 Hz, 3H), 1.15 (m, 1H), 0.34 (m, 1H). <sup>13</sup>C APT NMR (100 MHz, CDCl<sub>3</sub>, partial spectra) δ up, 23.0, 15.4, 14.5; down, 127.4, 61.2, 26.8, 16.8. LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.62 min; <i>m</i>/<i>z</i> 193.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> (±)-<i>endo</i>-1-Methyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18b</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>endo</i>-6-methylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10b</b>, 500 mg, 4.55 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>endo</i>-<b>18b</b>, 403 mg, 1.96 mmol, 43% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.37–4.30 (m, 2H), 2.92 (dd, <i>J</i> = 17.5, 6.8 Hz, 1H), 2.65 (d, <i>J</i> = 17.5 Hz, 1H), 2.33 (m, 1H), 2.17 (m, 1H), 1.36 (t, <i>J</i> = 7.2 Hz, 3H), 1.32 (m, 1H), 0.71 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 207.1 [M + H]<sup>+</sup>, 229.2 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (±)-<i>exo</i>-1-Methyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18b</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>exo</i>-6-methylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10b</b>, 88 mg, 1.25 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18b</b>, 49 mg, 0.22 mmol, 18% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.37–4.31 (m, 2H), 2.97 (dd, <i>J</i> = 17.1, 5.7 Hz, 1H), 2.86 (d, <i>J</i> = 17.1 Hz, 1H), 1.98 (m, 2H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H), 1.13 (d, <i>J</i> = 6.1 Hz, 3H), 0.73 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 207.2 [M + H]<sup>+</sup>, 229.4 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> (±)-<i>endo</i>-1-Ethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18c</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>endo</i>-6-ethylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10c</b>, 503 mg, 4.04 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>endo</i>-<b>18c</b>, 374 mg, 1.70 mmol, 42% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.39–4.27 (m, 2H), 2.90 (dd, <i>J</i> = 17.5, 6.9 Hz, 1H), 2.65 (d, <i>J</i> = 17.5 Hz, 1H), 2.33 (ddd, <i>J</i> = 7.6, 6.2, 1.3 Hz, 1H), 2.20 (m, 1H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H), 1.17 (m, 1H), 1.05 (m, 1H), 0.91–0.83 (m, 4H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 221.3 [M + H]<sup>+</sup>, 243.3 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> (±)-<i>exo</i>/<i>endo</i>-1-Propyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18d</b>/<i>endo</i>-<b>18d</b>)</h4><div class="NLM_p last">Prepared from (±)-6-propylbicyclo[3.1.0]hexan-2-one (<i>exo</i>/<i>endo</i>-<b>10d</b>, 251 mg, 1.82 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18d</b>:<i>endo</i>-<b>18d</b> = 3.3:1, 280 mg, 1.20 mmol, 66% yield) as a mixture of diastereomers. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.31 (q, <i>J</i> = 7.1 Hz, 2H), 2.91 (dd, <i>J</i> = 17.1, 6.2 Hz, 1H), 2.80 (d, <i>J</i> = 17.1 Hz, 1H), 1.98 (m, 1H), 1.88 (m, 1H), 1.42 (m, 2H), 1.37–1.17 (m, 5H), 0.90 (t, <i>J</i> = 7.1 Hz, 3H), 0.65 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 235 [M + H]<sup>+</sup>, 257 [M + Na]<sup>+</sup>, 189 [M – OEt]<sup>+</sup>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.33 (m, 2H), 2.89 (dd, <i>J</i> = 17.4, 6.9 Hz, 1H), 2.63 (d, <i>J</i> = 17.4 Hz, 1H), 2.32 (m, 1H), 2.18 (m, 1H), 1.48–1.16 (m, 6H), 1.02 (m, 1H), 0.81 (m, 4H).</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> (±)-<i>exo</i>/<i>endo</i>-1-Butyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18e</b>/<i>endo</i>-<b>18e</b>)</h4><div class="NLM_p last">Prepared from (±)-6-butylbicyclo[3.1.0]hexan-2-one (<i>exo</i>/<i>endo</i>-<b>10e</b>, 664 mg, 4.37 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18e</b>:<i>endo</i>-<b>18e</b> = 2.5:1, 460 mg, 1.85 mmol, 42% yield) as a mixture of diastereomers. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.31 (q, <i>J</i> = 7.2 Hz, 2H), 2.91 (dd, <i>J</i> = 17.0, 6.2 Hz, 1H), 2.79 (d, <i>J</i> = 17.0 Hz, 1H), 1.96 (m, 1H), 1.88 (m, 1H), 1.45–1.15 (m, 9H), 0.87 (t, <i>J</i> = 6.8 Hz, 3H), 0.65 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 249 [M + H]<sup>+</sup>, 203 [M – OEt]<sup>+</sup>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.32 (m, 2H), 2.88 (dd, <i>J</i> = 17.4, 6.9 Hz, 1H), 2.62 (d, <i>J</i> = 17.4 Hz, 1H), 2.30 (m, 1H), 2.17 (m, 1H), 1.44–1.15 (m, 8H), 1.03 (m, 1H), 0.85–0.75 (m, 4H).</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> (±)-<i>endo</i>-1-Pentyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18f</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>endo</i>-6-pentylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10f</b>, 730 mg, 4.39 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>endo</i>-<b>18f</b>, 731 mg, 2.91 mmol, 66% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.40–4.30 (m, 2H), 2.90 (dd, <i>J</i> = 17.5, 6.8 Hz, 1H), 2.64 (d, <i>J</i> = 17.5 Hz, 1H), 2.33 (ddd, <i>J</i> = 7.7, 6.2, 1.2 Hz, 1H), 2.20 (m, 1H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H), 1.35–1.15 (m, 7H), 1.03 (m, 1H), 0.89–0.78 (m, 4H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 263 [M + H]<sup>+</sup>, 217 [M – OEt]<sup>+</sup>.</div></div><div id="sec4_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> (±)-<i>exo</i>-1-Pentyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18f</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>exo</i>-6-pentylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10f</b>, 780 mg, 4.69 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18f</b>, 562 mg, 2.14 mmol, 46% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 2.93 (dd, <i>J</i> = 17.1, 6.2 Hz, 1H), 2.81 (d, <i>J</i> = 17.1 Hz, 1H), 1.98 (ddd, <i>J</i> = 6.0, 2.9, 1.1 Hz, 1H), 1.90 (m, 1H), 1.88 (m, 1H), 1.47–1.23 (m, 10H), 0.87 (t, <i>J</i> = 6.9 Hz, 3H), 0.66 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 263 [M + H]<sup>+</sup>, 217 [M – OEt]<sup>+</sup>.</div></div><div id="sec4_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> (±)-<i>exo</i>-1-Isopropyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18g</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>exo</i>-6-isopropylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10g</b>, 200 mg, 1.45 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18g</b>, 385 mg crude without purification, ca. 30% purity by <sup>1</sup>H NMR, 1.02 mmol, 70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.33 (q, <i>J</i> = 7.2 Hz, 2H), 2.90 (dd, <i>J</i> = 7.1, <i>J</i> = 5.3 Hz, 1H), 2.77 (d, <i>J</i> = 17.1 Hz, 1H), 1.90 (m, 1H), 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.21 (m, 1H), 1.05 (m, 1H), 0.97 (d, <i>J</i> = 11.5 Hz, 6H), 0.45 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 235 [M + H]<sup>+</sup>, 189 [M – OEt]<sup>+</sup>.</div></div><div id="sec4_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> (±)-<i>exo</i>/<i>endo</i>-1-Isobutyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18h</b>/<i>endo</i>-<b>18h</b>)</h4><div class="NLM_p last">Prepared from (±)-6-isobutylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10h</b>:<i>endo</i>-<b>10h</b> = 3.3:1, 200 mg, 1.31 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18h</b>:<i>endo</i>-<b>18h</b> = 2.5:1, 330 mg crude without purification, ca. 50% purity by <sup>1</sup>H NMR, 0.66 mmol, 51% yield) as a mixture of diastereomers. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.33 (m, 2H), 2.90 (dd, <i>J</i> = 17.1, 6.2 Hz, 1H), 2.80 (d, <i>J</i> = 17.0 Hz, 1H), 1.95 (m, 1H), 1.87 (m, 1H), 1.70 (m, 1H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 1.32 (m, 1H), 1.10 (m, 1H), 0.92–0.85 (m, 6H), 0.64 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 249 [M + H]<sup>+</sup>, 203 [M – OEt]<sup>+</sup>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.35 (m, 2H), 2.85 (dd, <i>J</i> = 17.0, 6.2 Hz, 1H), 2.61 (d, <i>J</i> = 17.0 Hz, 1H), 2.32 (m, 1H), 2.18 (m, 1H), 1.53 (m, 1H), 1.34 (t, <i>J</i> = 6.9 Hz, 3H), 1.32 (m, 1H), 0.95 (m, 1H), 0.84 (d, <i>J</i> = 6.6 Hz, 3H), 0.78 (d, <i>J</i> = 6.6 Hz, 3H), 0.69 (m, 1H).</div></div><div id="sec4_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (±)-<i>exo</i>-1-Isopentyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18i</b>) and (±)-<i>endo</i>-1-Isopentyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18i</b>)</h4><div class="NLM_p last">Prepared from (±)-6-isopentylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10i</b>:<i>endo</i>-<b>10i</b> = 3.3:1, 850 mg, 5.11 mmol) in a similar manner as described for the synthesis of <b>18a</b> with the exception that 2.20 equiv of KO<i>t</i>-Bu were used, and the hydrazine condensation step was performed at 80 °C for 24 h. Purification by reverse phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 100 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 50% H<sub>2</sub>O, 60 mL/min, λ = 254 nm] gave <i>endo</i>-<b>18i</b> (24.0 mg, 0.091 mmol, 2% yield) followed by <i>exo</i>-<b>18i</b> (446 mg, 1.70 mmol, 33% yield). <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.97 (dd, <i>J</i> = 17.1, 5.8 Hz, 1H), 2.84 (d, <i>J</i> = 17.1 Hz, 1H), 2.02 (m, 2H), 1.55 (m, 1H), 1.42–1.23 (m, 7H), 0.88 (d, <i>J</i> = 6.6 Hz, 6H), 0.70 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 263 [M + H]<sup>+</sup>, 285 [M + Na]<sup>+</sup>, 217 [M – OEt]<sup>+</sup>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.34 (m, 2H), 2.94 (m, 1H), 2.66 (d, <i>J</i> = 17.0 Hz, 1H), 2.35 (m, 1H), 2.24 (m, 1H), 1.72 (m, 1H), 1.36 (t, <i>J</i> = 7.0 Hz, 3H), 1.30–1.00 (m, 4H), 0.81 (m, 1H), 0.76 (d, <i>J</i> = 6.9 Hz, 3H), 0.73 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 263 [M + H]<sup>+</sup>, 285 [M + Na]<sup>+</sup>, 217 [M – OEt]<sup>+</sup>.</div></div><div id="sec4_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> (±)-1,1-Dimethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<b>18j</b>)</h4><div class="NLM_p last">Prepared from (±)-6,6-dimethylbicyclo[3.1.0]hexan-2-one (<b>10j</b>, 1.49 g, 12.0 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<b>18j</b>, 1.32 g, 5.99 mmol, 50% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.32 (m, 2H), 2.89 (dd, <i>J</i> = 17.5, 6.9 Hz, 1H), 2.64 (d, <i>J</i> = 17.5 Hz, 1H), 2.07 (m, 1H), 1.94 (m, 1H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H), 1.12 (s, 3H), 0.73 (s, 3H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 221 [M + H]<sup>+</sup>, 243 [M + Na]<sup>+</sup>, 175 [M – OEt]<sup>+</sup>.</div></div><div id="sec4_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> (±)-<i>endo</i>-1-Vinyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18k</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>endo</i>-6-vinylspiro[bicyclo[3.1.0]hexane-2,2′-[1,3]dioxolane] (<i>endo</i>-<b>10k</b>, 101 mg, 0.83 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>endo</i>-<b>18k</b>, 144 mg, 0.66 mmol, 80% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.26 (m, 1H), 5.05–4.95 (m, 2H), 4.34 (m, 2H), 2.98 (dd, <i>J</i> = 17.5, 6.7 Hz, 1H), 2.76 (d, <i>J</i> = 17.5 Hz, 1H), 2.60 (ddd, <i>J</i> = 7.6, 6.0, 1.2 Hz, 1H), 2.42 (m, 1H), 1.98 (m, 1H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 219.2 [M + H]<sup>+</sup>, 241.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> (±)-<i>exo</i>-1-Vinyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18k</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>exo</i>-6-vinylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10k</b>, 350 mg, 2.87 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18k</b>, 300 mg, 1.38 mmol, 48% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.48 (ddd, <i>J</i> = 17.1, 10.3, 8.6 Hz, 1H), 5.04 (dd, <i>J</i> = 17.1, 1.0 Hz, 1H), 4.92 (dd, <i>J</i> = 10.3, 1.4 Hz, 1H), 4.33 (q, <i>J</i> = 7.2 Hz, 2H), 3.02 (dd, <i>J</i> = 17.3, 6.1 Hz, 1H), 2.90 (d, <i>J</i> = 17.3 Hz, 1H), 2.32 (m, 1H), 2.19 (m, 1H), 1.34 (t, <i>J</i> = 7.2 Hz, 3H), 1.30 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 219.3 [M + H]<sup>+</sup>, 241.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> (±)-<i>endo</i>-1-Allyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18l</b>) and (±)-<i>exo</i>-1-Allyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18l</b>)</h4><div class="NLM_p last">Prepared from (±)-6-allylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10l</b>:<i>endo</i>-<b>10l</b> = 1:1, 80.0 mg, 0.587 mmol) in a similar manner as described for the synthesis of <b>18a</b>. Separation of the diastereomers was accomplished by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 21.2 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 95% H<sub>2</sub>O, 20 mL/min, λ = 214 nm] to give <i>endo</i>-<b>18l</b> (41.4 mg, 0.177 mmol, 30% yield) followed by <i>exo</i>-<b>18l</b> (17.5 mg, 0.0747 mmol, 13% yield). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.79 (m, 1H), 5.00 (dd, <i>J</i> = 17.2, 1.7 Hz, 1H), 4.95 (dd, <i>J</i> = 10.2, 1.5 Hz, 1H), 4.38 (m, 2H), 2.95 (dd, <i>J</i> = 17.5, 6.9 Hz, 1H), 2.70 (d, <i>J</i> = 17.5, 1H), 2.44 (t, <i>J</i> = 7.6 Hz, 1H), 2.31 (dd, <i>J</i> = 14.5, 6.5 Hz, 1H), 1.79–1.66 (m, 2H), 1.42–1.33 (m, 4H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 233 [M + H]<sup>+</sup>, 255 [M + Na]<sup>+</sup>; 187 [M – OEt]<sup>+</sup>. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.88 (m, 1H), 5.02 (dd, <i>J</i> = 17.2, 1.6 Hz, 1H), 4.92 (dd, <i>J</i> = 10.3, 1.6 Hz, 1H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 2.97 (dd, <i>J</i> = 17.1, 6.3 Hz, 1H), 2.86 (d, <i>J</i> = 17.1 Hz, 1H), 2.22–2.14 (m, 2H), 2.11–2.00 (m, 2H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H), 0.80 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 233 [M + H]<sup>+</sup>, 255 [M + Na]<sup>+</sup>, 187 [M – OEt]<sup>+</sup>.</div></div><div id="sec4_1_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> (±)-<i>endo</i>-1-Cyclopropyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18m</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>endo</i>-6-vinylbicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10m</b>, 220 mg, 1.62 mmol) in a similar manner as described for the synthesis of <b>18</b>a to give the title compound (<i>endo</i>-<b>18m</b>, 150 mg, 0.646 mmol, 40% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.34 (m, 2H), 2.98 (dd, <i>J</i> = 17.4, 6.4 Hz, 1H), 2.88 (d, <i>J</i> = 17.4 Hz, 1H), 2.35 (m, 1H), 2.20 (m, 1H), 1.37 (t, <i>J</i> = 7.2 Hz, 3H), 0.74 (m, <i>J</i> = 8.4 Hz, 1H), 0.45 (m, 1H), 0.32–0.14 (m, 3H), −0.08 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 233.4 [M + H]<sup>+</sup>, 255.4 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> (±)-<i>endo</i>-1-Cycloproylmethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18n</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>endo</i>-6-(cyclopropylmethyl)bicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10n</b>, 500 mg, 3.40 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>endo</i>-<b>18n</b>, 300 mg, 1.22 mmol, 36% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.36 (m, 2H), 2.94 (dd, <i>J</i> = 17.4, 6.8 Hz, 1H), 2.67 (d, <i>J</i> = 17.4 Hz, 1H), 2.45 (m, 1H), 2.31 (m, 1H), 1.42 (m, 1H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H), 1.00 (m, 1H), 0.74 (m, 1H), 0.65 (m, 1H), 0.36 (m, 2H), −0.05 (m, 1H), −0.12 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 247.3 [M + H]<sup>+</sup>, 269.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> (±)-1-<i>endo</i>-Methoxymethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18o</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>endo</i>-6-(methoxymethyl)bicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10o</b>, 60.0 mg, 0.428 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>endo</i>-<b>18o</b>, 90.0 mg, 0.381 mmol, 89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.44–4.29 (m, 2H), 3.23 (s, 3H), 3.07 (m, 2H), 2.96 (dd, <i>J</i> = 17.6, 6.8 Hz, 1H), 2.77 (d, <i>J</i> = 17.6 Hz, 1H), 2.48 (m, 1H), 2.36 (m, 1H), 1.59 (m, 1H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.84 min; <i>m</i>/<i>z</i> 236.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> (±)-<i>exo</i>-1-Hydroxymethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18o</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>exo</i>-6-((<i>tert</i>-butyldimethylsilyloxy)methyl)bicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10o</b>, 7.45 g, 31.0 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18o</b>, 5.30 g, 23.8 mmol, 77% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.23 (q, <i>J</i> = 7.1 Hz, 2H), 3.41 (dd, <i>J</i> = 11.4, 5.9 Hz, 1H), 3.28 (dd, <i>J</i> = 11.4, 6.8 Hz, 1H), 2.84 (dd, <i>J</i> = 16.9, 6.2 Hz, 1H), 2.69 (d, <i>J</i> = 16.9 Hz, 1H), 2.05 (m, 2H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H), 0.78 (m, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.54 min; <i>m</i>/<i>z</i> 223.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> (±)-<i>endo</i>-1-(Methylthiomethyl)-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18p</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>endo</i>-6-(methylthiomethyl)bicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10p</b>, 52.0 mg, 0.333 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>endo</i>-<b>18p</b>, 34.0 mg, 0.135 mmol, 41% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.2–9.4 (br s, 1H), 4.34 (m, 2H), 2.96 (dd, <i>J</i> = 17.7, 6.8 Hz, 1H), 2.75 (d, <i>J</i> = 17.7 Hz, 1H), 2.50 (m, 1H), 2.32 (m, 1H), 2.15 (m, 2H), 2.08 (s, 3H), 1.57 (m, 1H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 2.29 min; <i>m</i>/<i>z</i> 253.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> (±)-<i>exo-</i>1-(Methylthiomethyl)-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18p</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>exo</i>-6-(methylthiomethyl)bicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10p</b>, 80.0 mg, 0.512 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18p</b>, 40.0 mg, 0.159 mmol, 31% yield). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 2.35 min; <i>m</i>/<i>z</i> 253.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> (±)-1-<i>endo</i>-Phenoxymethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>endo</i>-<b>18r</b>)</h4><div class="NLM_p last">Prepared from (±)-<i>exo</i>-6-(phenoxymethyl)bicyclo[3.1.0]hexan-2-one (<i>endo</i>-<b>10r</b>, 43.0 mg, 0.213 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>endo</i>-<b>18r</b>, 28.0 mg, 0.084 mmol, 39% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.27–7.21 (m, 2H), 6.91 (t, <i>J</i> = 7.3 Hz, 1H), 6.83–6.79 (m, 2H), 4.39–4.25 (m, 2H), 3.85 (m, 1H), 3.48 (dd, <i>J</i> = 10.4, 8.3 Hz, 1H), 3.02 (dd, <i>J</i> = 17.8, 6.8 Hz, 1H), 2.84 (d, <i>J</i> = 17.8 Hz, 1H), 2.58 (m, 1H), 2.45 (m, 1H), 1.80 (m, 1H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 2.56 min; <i>m</i>/<i>z</i> 299.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> (±)-Spiro[1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-1,1′-cyclopentan]-4-carboxylic Acid Ethyl Ester (<b>18s</b>)</h4><div class="NLM_p last">Prepared from (±)-spiro[bicyclo[3.1.0]hexane-6,1′-cyclopentan]-2-one (<b>10s</b>, 115 mg, 0.761 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<b>18s</b>, 87 mg, 0.353 mmol, 46% yield). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 247 [M + H]<sup>+</sup>, 269.1 [M + Na]<sup>+</sup>, 201 [M – OEt]<sup>+</sup>.</div></div><div id="sec4_1_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> (±)-Spiro[1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-1,1′-cyclohexan]-4-carboxylic Acid Ethyl Ester (<b>18t</b>)</h4><div class="NLM_p last">Prepared from (±)-spiro[bicyclo[3.1.0]hexane-6,1′-cyclohexan]-2-one (<b>10t</b>, 120 mg, 0.73 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<b>18t</b>, 152 mg, 0.58 mmol, 79% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.35 (m, 2H), 2.93 (dd, <i>J</i> = 17.5, 6.9 Hz, 1H), 2.68 (d, <i>J</i> = 17.5 Hz, 1H), 2.15 (m, 2H), 1.59–1.24 (m, 11H), 1.08 (m, 1H), 0.98 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 261 [M + H]<sup>+</sup>, 283 [M + Na]<sup>+</sup>, 215 [M – OEt]<sup>+</sup>.</div></div><div id="sec4_1_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> (±)-<i>exo</i>-1-Phenyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>-<b>18u</b>)</h4><div class="NLM_p last">Prepared from (±)-6-phenylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10u</b>, 224 mg, 1.30 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18u</b>, 120 mg, 0.447 mmol, 34% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.02 (br s, 1H), 7.27 (m, 2H), 7.17 (tt, <i>J</i> = 7.4, 1.8 Hz, 1H), 7.05 (m, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 3.12 (dd, <i>J</i> = 17.4, 6.0 Hz, 1H), 3.02 (d, <i>J</i> = 17.4 Hz, 1H), 2.57 (ddd, <i>J</i> = 6.1, 2.9, 1.0 Hz, 1H), 2.46 (m, 1H), 1.78 (t, <i>J</i> = 3.3 Hz, 1H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> (±)-<i>endo</i>/<i>exo</i>-1-Benzyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<i>exo</i>/<i>endo</i>-<b>18v</b>)</h4><div class="NLM_p last">Prepared from (±)-6-benzylbicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10v</b>:<i>endo</i>-<b>10v</b> = 4:1, 641 mg, 3.44 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<i>exo</i>-<b>18v</b>:<i>endo</i>-<b>18v</b> = 5:1, 582 mg, 2.06 mmol, 60% yield) as a mixture of diastereomers. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.15 (m, 5H), 4.31 (q, <i>J</i> = 7.1 Hz, 2H), 2.97 (dd, <i>J</i> = 17.2, 6.2 Hz, 1H), 2.86 (d, <i>J</i> = 17.2 Hz, 1H), 2.82 (dd, <i>J</i> = 15.0, 6.3 Hz, 1H), 2.59 (dd, <i>J</i> = 15.0, 7.5 Hz, 1H), 2.18 (ddd, <i>J</i> = 6.0, 2.9, 1.1 Hz, 1H), 2.08 (m, 1H), 1.34 (t, <i>J</i> = 7.1 Hz, 3H), 0.99 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 283 [M + H]<sup>+</sup>, 305 [M + Na]<sup>+</sup>, 237 [M – OEt]<sup>+</sup>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29–7.13 (m, 5H), 4.35 (m, 2H), 3.00 (dd, <i>J</i> = 17.6, 6.9 Hz, 1H), 2.77 (d, <i>J</i> = 17.6 Hz, 1H), 2.47 (m, 1H), 2.40–2.30 (m, 2H), 2.23 (m, 1H), 1.55 (m, 1H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> (±)-3b,4,4a,5-Tetrahydro-1<i>H</i>-cyclopropa[3,4]cyclopenta[1,2-<i>c</i>]pyrazole-3-carboxylic Acid Ethyl Ester (<b>21</b>)</h4><div class="NLM_p last">Prepared from bicyclo[3.1.0]hexan-3-one (<b>20</b>, 1.49 g, 15.5 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<b>21</b>, 1.70 g, 8.84 mmol, 57% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.38 (m, 2H), 2.98 (ddd, <i>J</i> = 16.6, 6.4, 1.8 Hz, 1H), 2.79 (d, <i>J</i> = 16.6 Hz, 1H), 2.25 (m, 1H), 2.11 (m, 1H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 1.20 (m, 1H), 0.30 (m, 1H).</div></div><div id="sec4_1_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> (±)-5a-Ethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<b>27</b>-Et Ester)</h4><div class="NLM_p last">Prepared from (±)-5-ethylbicyclo[3.1.0]hexan-2-one (<b>25</b>) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (<b>27</b>-<b>Et</b> ester). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.60 (br s, 1H), 4.33 (q, <i>J</i> = 7.1 Hz, 2H), 2.85 (dd, <i>J</i> = 17.0, 0.9 Hz, 1H), 2.78 (d, <i>J</i> = 17.0 Hz, 1H), 2.00 (ddd, <i>J</i> = 7.9, 3.3, 1.0 Hz, 1H), 1.76 (m, 1H), 1.55 (m, 1H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H), 1.07 (dd, <i>J</i> = 8.0, 4.8 Hz, 1H), 1.02 (t, <i>J</i> = 7.4 Hz, 3H), 0.49 (m, 1H).</div></div><div id="sec4_1_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> (±)-1a-Methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<b>28</b>-Et Ester)</h4><div class="NLM_p last">Prepared from (±)-1-methylbicyclo[3.1.0]hexan-2-one (<b>26</b>, 492 mg, 4.47 mmol) in a similar manner as described for the synthesis of <b>18a</b> give the title compound (<b>28</b>-Et ester, 513 mg, 2.49 mmol, 56% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.32 (q, <i>J</i> = 7.2 Hz, 2H), 2.97 (dd, <i>J</i> = 17.1, 6.2 Hz, 1H), 2.74 (d, <i>J</i> = 17.1 Hz, 1H), 1.89 (m, 1H), 1.52 (s, 3H), 1.34 (t, <i>J</i> = 7.2 Hz, 3H), 1.05 (dd, <i>J</i> = 8.2, 4.8 Hz, 1H), 0.50 (t, <i>J</i> = 4.5 Hz, 1H).</div></div><div id="sec4_1_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> General Procedure for Ester Hydrolyses Prepare to Pyrazole Acids <b>19</b></h4><div class="NLM_p last">To a solution of the corresponding ester in dioxane or THF (0.1 M) or THF/MeOH (3: 1, 0.1 M) was added a solution of LiOH, NaOH, or KOH (2N aq, 5–10 equiv) at rt. In some cases, the reaction mixtures were heated to 55 °C to facilitate the hydrolysis. The reaction was stirred until the ester was consumed and the mixture was acidified to pH = 1 with HCl (6N, aq). Purification by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 21.2 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 95% H<sub>2</sub>O, 20 mL/min, λ = 214 nm] gave the free acids white solids in high yields after lyophilization.</div></div><div id="sec4_1_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> (±)-1a,2,5,5a-Tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (<b>19a</b>)</h4><div class="NLM_p last">Prepared from ester <b>18a</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.84 (m, 1H), (d, <i>J</i> = 16.8 Hz, 1H), 2.13 (m, 2H), 1.09 (m, 1H), 0.19 (q, <i>J</i> = 4.1 Hz, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.09 min; <i>m</i>/<i>z</i> 165.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> (±)-<i>endo</i>-1-Methyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19b</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18b</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.89 (dd, <i>J</i> = 17.3, 6.7 Hz, 1H), 2.64 (d, 1H, <i>J</i> = 17.2 Hz), 2.30–2.18 (m, 2H), 1.34 (m, 1H). 0.69 (d, <i>J</i> = 6.4 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.54 min; <i>m</i>/<i>z</i> 179.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_112" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> (±)-<i>exo</i>-1-Methyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19b</b>)</h4><div class="NLM_p last">Prepared from <i>exo</i>-<b>18b</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.02 (dd, <i>J</i> = 18.5, 6.3 Hz, 1H), 2.91 (d, <i>J</i> = 18.5 Hz, 1H), 2.09 (m, 1H), 1.78 (m, 1H), 1.17 (d, <i>J</i> = 6.0 Hz, 3H), 0.74 m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 179.1 [M + H]<sup>+</sup>, 201.5 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_113" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> (±)-<i>endo</i>-1-Ethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19c</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18c</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.80 (dd, <i>J</i> = 17.2, 6.8 Hz, 1H), 2.49 (d, <i>J</i> = 17.2 Hz, 1H), 2.24 (ddd, <i>J</i> = 7.6, 6.2, 1.0 Hz, 1H), 2.15 (m, 1H), 1.14 (m, 1H), 0.97 (m, 1H), 0.81 (t, <i>J</i> = 6.9 Hz, 3H), 0.73 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 193.0 [M + H]<sup>+</sup>, 215.0 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_114" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> (±)-<i>endo</i>-1-Propyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-19d) and (±)-<i>exo</i>-1-Propyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19d</b>)</h4><div class="NLM_p last">Prepared from a mixture of <i>exo</i>-<b>18d</b> and <i>endo</i>-<b>18d</b> (3.3:1 respectively) by the general procedure. Separation by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 21.2 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 95% H<sub>2</sub>O, 20 mL/min, λ = 214 nm] gave pure <i>endo</i>-<b>19d</b> followed by pure <i>exo</i>-<b>19d</b>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.87 (dd, <i>J</i> = 17.1, 6.6 Hz, 1H), 2.63 (d, <i>J</i> = 17.1 Hz, 1H), 2.26 (m, 2H), 1.40–1.32 (m, 2H), 1.09 (m, 1H), 0.91 (m, 1H), 0.84 (t, <i>J</i> = 7.2 Hz, 3H), 0.76 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 207 [M + H]<sup>+</sup>, 229 [M + Na]<sup>+</sup>, 189 [M – OH]<sup>+</sup>. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.91 (m, 1H), 2.79 (d, <i>J</i> = 16.8 Hz, 1H), 1.95 (m, 2H), 1.47 (m, <i>J</i> = 7.1 Hz, 2H), 1.32 (m, 2H), 0.96 (t, <i>J</i> = 7.3 Hz, 3H), 0.63 (m, 1H).</div></div><div id="sec4_1_115" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> (±)-<i>endo</i>-1-Butyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-19e) and (±)-<i>exo</i>-1-Butyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19e</b>)</h4><div class="NLM_p last">Prepared from a mixture of <i>exo</i>-<b>18e</b> and <i>endo</i>-<b>18e</b> (2.5:1 respectively) by the general procedure. Separation by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 21.2 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 95% H<sub>2</sub>O, 20 mL/min, λ = 214 nm] gave <i>endo</i>-<b>19e</b> followed by <i>exo</i>-<b>19e</b>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.88 (dd, <i>J</i> = 17.1, 6.7 Hz, 1H), 2.63 (d, <i>J</i> = 17.1 Hz, 1H), 2.27 (m, 2H), 1.40–1.13 (m, 4H), 1.10 (m, 1H), 0.91 (m, 1H), 0.83–0.74 (m, 4H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 221 [M + H]<sup>+</sup>, 203 [M – OH]<sup>+</sup>. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.90 (m, 1H), 2.78 (d, <i>J</i> = 16.9 Hz, 1H), 1.95 (m, 2H), 1.48–1.25 (m, 6H), 0.93 (t, <i>J</i> = 7.0 Hz, 3H), 0.62 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 221 [M + H]<sup>+</sup>, 203 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_116" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> (±)-<i>endo</i>-1-Pentyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19f</b>)</h4><div class="NLM_p last">Prepared from ester <i>endo</i>-<b>18f</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.86 (dd, <i>J</i> = 17.2, 6.7 Hz, 1H), 2.40 (d, <i>J</i> = 17.2 Hz, 1H), 2.30 (m, 1H), 2.24 (m, 1H), 1.40–1.15 (m, 7H), 1.09 (m, 1H), 0.86 (m, 3H), 0.78 (m, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 2.38 min; <i>m</i>/<i>z</i> 235.3 [M + H]<sup>+</sup>, 217.4 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_117" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> (±)-<i>exo</i>-1-Pentyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19f</b>)</h4><div class="NLM_p last">Prepared from <i>exo</i>-<b>18f</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.91 (m, 1H), 2.79 (d, <i>J</i> = 16.8 Hz, 1H), 1.95 (m, 2H), 1.46 (m, 2H), 1.40–1.28 (m, 6H), 0.92 (t, <i>J</i> = 5.8 Hz, 3H), 0.61 (m, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 2.59 min; <i>m</i>/<i>z</i> 235.3 [M + H]<sup>+</sup>, 217.4 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_118" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> (±)-<i>exo</i>-1-Isopropyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19g</b>)</h4><div class="NLM_p last">Prepared from <i>exo</i>-<b>18g</b> by the general procedure. <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 2.95–2.93 (m, 1H), 2.90 (d, <i>J</i> = 16.7 Hz, 1H), 2.00 (m, 2H), 1.08–1.03 (m, 7H), 0.43 (m, <i>J</i> = 4.1, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 207 [M + H]<sup>+</sup>, 189 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_119" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> (±)-<i>endo</i>-1-Isobutyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19h</b>) and (±)-<i>exo</i>-1-Isobutyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19h</b>)</h4><div class="NLM_p last">Prepared from a mixture <i>exo</i>-<b>18g</b> and <i>endo</i>-<b>18g</b> (2.5:1 respectively) by the general procedure. Separation by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 21.2 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 95% H<sub>2</sub>O, 20 mL/min, λ = 214 nm] gave <i>endo</i>-<b>19h</b> followed by <i>exo</i>-<b>19h</b>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.91 (dd, <i>J</i> = 6.7 Hz, 1H), 2.65 (d, <i>J</i> = 17.5, 1H), 2.33 (m, 1H), 2.26 (m, 1H), 1.58 (m, 1H), 1.30 (m, 1H), 1.03 (m, 1H) 0.90 (d, <i>J</i> = 6.6 Hz, 3H), 0.84 (d, <i>J</i> = 6.6 Hz, 3H), 0.66 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 221 [M + H]<sup>+</sup>, 203 [M – OH]<sup>+</sup>. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.93 (m, 1H), 2.80 (d, <i>J</i> = 16.9 Hz, 1H), 1.96 (m, 2H), 1.75 (m, 1H), 1.24 (m, 2H), 0.98–0.94 (m, 6H), 0.62 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 221 [M + H]<sup>+</sup>, 203 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_120" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> (±)-<i>endo</i>-1-Isopentyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19i</b>) and (±)-<i>exo</i>-1-Isopentyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19i</b>)</h4><div class="NLM_p last">Compounds were isolated as side products during HPLC separation of the corresponding esters <i>endo</i>-<b>18i</b> and <i>exo</i>-<b>18i</b> without the need for an additional hydrolysis step. <i>endo</i>-<b>19i</b> eluted prior to <i>exo</i>-<b>19i</b>. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 2.92 (dd, <i>J</i> = 18.5, 6.9 Hz, 1H), 2.66 (d, <i>J</i> = 18.5 Hz, 1H), 2.32 (m, 1H), 2.00 (m, 1H), 1.46 (m, 1H), 1.31–1.10 (m, 4H), 0.93 (m, 1H), 0.78 (d, <i>J</i> = 6.7 Hz, 3H), 0.76 (d, <i>J</i> = 6.7 Hz, 3H). <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 2.92 (dd, <i>J</i> = 18.1, 6.4 Hz, 1H), 2.77 (d, <i>J</i> = 18.1 Hz, 1H), 2.03 (m, 1H), 1.76 (m, 1H), 1.56 (m, 1H), 1.38–1.24 (m, 4H), 0.87 (d, <i>J</i> = 6.6 Hz, 6H), 0.64 (m, 1H).</div></div><div id="sec4_1_121" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> (±)-1,1-Dimethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<b>19j</b>)</h4><div class="NLM_p last">Prepared from <b>18j</b> by the general procedure. <sup>1</sup>H NMR (CD<sub>3</sub>CN) δ 2.91 (dd, <i>J</i> = 17.4, 6.8 Hz, 1H), 2.66 (d, <i>J</i> = 17.4 Hz, 1H), 2.11 (dd, <i>J</i> = 6.3, 1.2 Hz, 1H), 2.00 (m, 1H), 1.19 (s, 3H), 0.77 (d, <i>J</i> = 2.0 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 193 [M + H]<sup>+</sup>, 215 [M + Na]<sup>+</sup>, 175 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_122" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> (±)-<i>endo</i>-1-Vinyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19k</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18k</b> by the general procedure (90% purity by <sup>1</sup>H NMR). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.25 (dd, <i>J</i> = 16.9, 2.3 Hz, 1H), 4.99 (dd, <i>J</i> = 10.4, 2.4 Hz, 1H), 4.85 (ddd, <i>J</i> = 16.9, 10.4, 9.2 Hz, 1H), 2.88 (dd, <i>J</i> = 17.3, 6.6 Hz, 1H), 2.57–2.50 (m, 2H), 2.39 (m, 1H), 1.94 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 191.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_123" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> (±)-<i>exo</i>-1-Vinyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19k</b>)</h4><div class="NLM_p last">Prepared from <i>exo</i>-<b>18k</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.53 (m, 1H), 5.13 (dd, <i>J</i> = 17.1, 1.6 Hz, 1H), 4.97 (dd, <i>J</i> = 10.3, 1.7 Hz, 1H), 2.98 (dd, <i>J</i> = 18.2, 6.3 Hz, 1H), 2.80 (d, <i>J</i> = 18.2 Hz, 1H), 2.36 (dd, <i>J</i> = 6.1, 2.6 Hz, 1H), 2.05 (m, 1H), 1.37 (dt, <i>J</i> = 8.8, 3.1 Hz, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 191.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_124" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> (±)-<i>endo</i>-1-Allyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19l</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18l</b> by the general procedure. <sup>1</sup>H NMR (CD<sub>3</sub>CN) δ 5.68–5.56 (m, 1H), 4.81 (dq, <i>J</i> = 15.5, 1.7 Hz, 1H), 5.03 (dq, <i>J</i> = 10.2, 1.4 Hz, 1H), 2.68 (dd, <i>J</i> = 17.4, 6.8 Hz, 1H), 2.43 (d, <i>J</i> = 17.3 Hz, 1H), 2.14 (m, 1H), 2.06 (m, 1H), 1.55 (m, 1H), 1.40 (m, 1H), 1.13 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 205 [M + H]<sup>+</sup>, 227 [M + Na]<sup>+</sup>, 187 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_125" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> (±)-<i>exo</i>-1-Allyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19l</b>)</h4><div class="NLM_p last">Prepared from <i>exo</i>-<b>18l</b> by the general procedure (90% purity by <sup>1</sup>H NMR). <sup>1</sup>H NMR (CD<sub>3</sub>CN) δ 5.94 (m, 1H), 5.13 (dq, <i>J</i> = 17.2, 1.7 Hz, 1H), 5.03 (dq, <i>J</i> = 10.3, 2.1 Hz, 1H), 2.92 (dd, <i>J</i> = 16.8, 5.8 Hz, 1H), 2.78 (d, <i>J</i> = 17.0 Hz, 1H), 2.30–2.00 (m, 4H), 0.71 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 205 [M + H]<sup>+</sup>, 227 [M + Na]<sup>+</sup>, 187 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_126" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> (±)-<i>endo</i>-1-Cyclopropyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19m</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18 m</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.06 (dd, <i>J</i> = 18.9, 5.9 Hz, 1H), 2.99 (d, <i>J</i> = 18.7 Hz, 1H), 2.43 (t, <i>J</i> = 8.2 Hz, 1H), 2.05 (q, <i>J</i> = 6.1 Hz, 1H), 0.85 (q, <i>J</i> = 8.3 Hz, 1H), 0.52 (m, 1H), 0.38 (m, 1H), 0.29–0.21 (m, 2H), 0.04 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 205.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_127" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> (±)-<i>endo</i>-1-Cyclopropylmethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19n</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18n</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.95 (dd, <i>J</i> = 18.5, 6.9 Hz, 1H), 2.69 (d, <i>J</i> = 18.5 Hz, 1H), 2.40 (t, <i>J</i> = 6.9 Hz, 1H), 2.17 (dd, <i>J</i> = 14.0, 6.7 Hz, 1H), 1.44 (m, 1H), 1.13 (m, 1H), 0.84 (m, 1H), 0.72 (m, 1H), 0.44–0.36 (m, 2H), 0.00 (m, 1H), −0.06 (m, 1H). MS <i>m</i>/<i>z</i> (ES<sup>+</sup>): 219.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_128" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> 1-<i>endo</i>-Methoxymethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19o</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18o</b> by the general procedure (93% purity by LC/MS). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.17 min; <i>m</i>/<i>z</i> 209.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_129" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> (±)-<i>endo</i>-1-(Methylthiomethyl)-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19p</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18p</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.6–12.1 (br s, 1H), 2.82 (dd, <i>J</i> = 17.4, 6.8 Hz, 1H), 2.57 (d, <i>J</i> = 17.4 Hz, 1H), 2.40 (m, 1H), 2.23 (m, 1H), 2.08 (dd, <i>J</i> = 13.4, 7.1 Hz, 1H), 1.99 (m, 4H), 1.48 (m, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.59 min; <i>m</i>/<i>z</i> 225.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_130" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> (±)-<i>exo</i>-1-(Methylthiomethyl)-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19p</b>)</h4><div class="NLM_p last">Prepared from <i>exo</i>-<b>18p</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.94 (dd, <i>J</i> = 16.9, 5.9 Hz, 1H), 2.82 (d, <i>J</i> = 16.9 Hz, 1H), 2.53 (m, 2H), 2.14 (s, 3H), 2.16–2.08 (m, 2H), 0.89 (m, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.64 min; <i>m</i>/<i>z</i> 225.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_131" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> (±)-1-<i>endo</i>-Phenoxymethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19r</b>)</h4><div class="NLM_p last">Prepared from <i>endo</i>-<b>18r</b> by the general procedure. LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 2.01 min; <i>m</i>/<i>z</i> 271.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_132" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> (±)-Spiro[1a,3,5,5a-Tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-1,1′-cyclopentan]-4-carboxylic Acid (<b>19s</b>)</h4><div class="NLM_p last">Prepared from <b>18s</b> by the general procedure. <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 2.94 (dd, <i>J</i> = 17.1, 2.1 Hz, 1H), 2.72 (d, <i>J</i> = 17.1 Hz, 1H), 2.17 (s, 2H), 1.78–1.53 (m, 6H), 1.29 (m, 1H), 0.89 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 219 [M + H]<sup>+</sup>, 201 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_133" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> (±)-Spiro[1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-1,1′-cyclohexan]-4-carboxylic Acid (<b>19t</b>)</h4><div class="NLM_p last">Prepared from <b>18t</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 2.89 (dd, <i>J</i> = 18.5, 7.0 Hz, 1H), 2.65 (d, <i>J</i> = 18.5 Hz, 1H), 2.07 (d, <i>J</i> = 6.2 Hz, 1H), 1.79 (m, 1H), 1.58–1.24 (m, 8H), 1.18 (ddd, <i>J</i> = 13.7, 8.1, 3.8 Hz, 1H), 1.18 (ddd, <i>J</i> = 13.7, 7.2, 3.8 Hz, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 233 [M + H]<sup>+</sup>, 255 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_134" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> (±)-<i>exo</i>-1-Phenyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19u</b>)</h4><div class="NLM_p last">Prepared from <i>exo</i>-<b>18u</b> by the general procedure. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 7.27 (m, 2H), 7.18 (m, 1H), 7.09 (m, 2H), 3.05 (dd, <i>J</i> = 17.2, 5.8 Hz, 1H), 2.95 (d, <i>J</i> = 17.2 Hz, 1H), 2.65–2.32 (m, 2H), 1.74 (t, <i>J</i> = 3.4 Hz, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 241 [M + H]<sup>+</sup>, 263 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_135" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> (±)-<i>exo</i>/<i>endo</i>-1-Benzyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>/<i>endo</i>-<b>19v</b>)</h4><div class="NLM_p last">Prepared from a mixture of <i>exo</i>-<b>18v</b> and <i>endo</i>-<b>18v</b> (5:1 respectively) by the general procedure. The product was obtained as a mixture of diastereomers (<i>exo</i>-<b>19v</b>:<i>endo</i>-<b>19v</b> = 5:1). <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 7.33–7.15 (m, 5H), 2.90 (dd, <i>J</i> = 17.0, 5.8 Hz, 1H), 2.75 (d, <i>J</i> = 17.0 Hz, 1H), 2.66 (m, 2H), 2.12 (m, 2H), 0.91 (m, 1H). <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) (partial spectra of distinguishable peaks) δ 2.91 (dd, <i>J</i> = 17.4, 6.9 Hz, 1H), 2.42–2.17 (m, 3H), 1.54 (m, 1H). LCMS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 255 [M + H]<sup>+</sup>, 277 [M + Na]<sup>+</sup>, 237 [M – OH]<sup>+</sup>.</div></div><div id="sec4_1_136" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> (±)-3b,4,4a,5-Tetrahydro-2<i>H</i>-cyclopropa[3,4]cyclopenta[1,2-<i>c</i>]pyrazole-3-carboxylic Acid (<b>22</b>)</h4><div class="NLM_p last">Prepared from <b>21</b> by the general procedure. LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.24 min; <i>m</i>/<i>z</i> 165.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_137" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> (±)-5a-Ethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<b>27</b>)</h4><div class="NLM_p last">Prepared from <b>27</b>-Et ester by the general procedure. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.74 (dd, <i>J</i> = 17.0, 0.7 Hz, 1H), 2.66 (d, <i>J</i> = 17.0 Hz, 1H), 1.92 (m, 1H), 1.71 (m, 1H), 1.51 (m, 1H), 1.04 (dd, <i>J</i> = 7.8, 4.4 Hz, 1H), 0.96 (t, <i>J</i> = 7.4 Hz, 3H), 0.34 (t, <i>J</i> = 3.9 Hz, 1H).</div></div><div id="sec4_1_138" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> (±)-1a-Methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<b>28</b>)</h4><div class="NLM_p last">Prepared from <b>28</b>-Et ester by the general procedure. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.94 (dd, <i>J</i> = 16.8, 6.1 Hz, 1H), 2.70 (d, <i>J</i> = 16.8 Hz, 1H), 1.92 (m, 1H), 1.49 (s, 3H), 1.07 (m, 1H), 0.44 (m, 1H).</div></div><div id="sec4_1_139" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> (±)-<i>endo</i>-1-Ethoxymethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>endo</i>-<b>19q</b>) and (±)-<i>exo</i>-1-Ethoxymethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19q</b>)</h4><div class="NLM_p last">To a solution of ethoxymethyl)bicyclo[3.1.0]hexan-2-one (<i>exo</i>-<b>10q</b>:<i>endo</i>-<b>10q</b> = 10:1, 298 mg, 1.93 mmol) and diethyl oxalate (282 mg, 193 mmol) in EtOH (5 mL) was added potassium <i>tert</i>-butoxide (2.0 mL of a 1.0 M solution in THF, 2.0 mmol). The mixture was stirred for 5 h at rt, at which time hydrazine monohydrochloride (172 mg, 2.51 mmol) was added as a solution in water (1.5 mL). The mixture was stirred overnight, at which time 1N NaOH (3 mL) was added followed by stirring for an additional 2 h. The mixture was acidified with 1N HCl and purified by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 21.2 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 95% H<sub>2</sub>O, 20 mL/min, λ = 214 nm] to give <i>endo</i>-<b>19q</b> (6.0 mg, 0.027 mmol, 1% yield, 90% purity by <sup>1</sup>H NMR) followed by <i>exo</i>-<b>19q</b> (80.0 mg, 0.36 mmol, 19% yield), isolated as white solids after lyophilization. <i>endo</i>-Isomer: <sup>1</sup>H NMR ((400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.30–3.15 (m, 2H), 3.01 (dd, <i>J</i> = 10.7, 6.8 Hz, 1H), 2.91 (dd, <i>J</i> = 10.7, 7.6 Hz, 1H), 2.80 (dd, <i>J</i> = 17.3, 6.8 Hz, 1H), 2.57 (d, <i>J</i> = 17.3 Hz, 1H), 2.35 (m, 1H), 2.24 (m, 1H), 1.45 (m, 1H), 1.00 (t, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.42 min; <i>m</i>/<i>z</i> 223.2 [M + H]<sup>+</sup>. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, DMSO- <i>d</i><sub>6</sub>) δ 13.50–12.03 (bs, 1H), 3.42 (q, <i>J</i> = 7.0 Hz, 2H), 3.35 (dd, <i>J</i> = 10.5, 6.2 Hz, 1H), 3.23 (dd, <i>J</i> = 10.5, 7.3 Hz, 1H), 2.84 (dd, <i>J</i> = 16.9, 6.2 Hz, 1H), 2.69 (d, <i>J</i> = 17.0 Hz, 1H), 2.09 (m, 1H), 2.03 (m, 1H), 1.11 (t, <i>J</i> = 7.0 Hz, 3H), 0.83 (m, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.56 min; <i>m</i>/<i>z</i> 223.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_140" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> (±)-<i>exo</i>-1-Methoxymethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>exo</i>-<b>19o</b>)</h4><div class="NLM_p">(±)-<i>exo</i>-1-Hydroxymethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic acid ethyl ester (<i>exo</i>-<b>18o</b>, 1.50 g, 6.75 mmol) was dissolved in DMF (20 mL), and K<sub>2</sub>CO<sub>3</sub> (1.84 g, 13.5 mmol) was added followed by benzyl bromide (1.73 g, 10.1 mmol). The reaction stirred for 20 h at rt. The mixture was diluted with EtOAc, and the organics were washed with water and brine. The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness in vacuo. Purification by column chromatography (25–50% EtOAc/hexanes, silica) gave the <i>N</i>-benzylated product (300 mg, 1.04 mmol, 15% yield) as a white solid. A second slower eluting alternate <i>N</i>-benzyl regiosiomer was also isolated but not carried forward. Isomer 1: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38 (m, 3H), 7.30 (m, 2H), 5.42 (d, <i>J</i> = 14.9 Hz, 1H), 5.29 (d, <i>J</i> = 14.9 Hz, 1H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 3.14 (m, 1H), 2.91 (dd, <i>J</i> = 16.7, 6.3 Hz, 1H), 2.82 (d, <i>J</i> = 16.7 Hz, 1H), 2.03 (m, 1H), 1.67 (m, 1H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H), 0.85 (m, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 2.11 min; <i>m</i>/<i>z</i> 313.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">To a solution of the alcohol from above (300 mg, 1.04 mmol) in DMF (5 mL) was added NaH (88.0 mg of a 60% dispersion in mineral oil, g, 2.20 mmol) at 0 °C under N<sub>2</sub>. The mixture was stirred for 10 min and methyl iodide (239 mg, 1.68 mmol) was added. The reaction mixture stirred at ambient temperature for 20 h, and quenched with water. The mixture was extracted with EtOAc (2 × 10 mL), and the combined organic layers were washed with water (10 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. Purification by column chromatography (40% EtOAc/hexanes, silica) gave the corresponding methyl ether (150 mg, 0.460 mmol, 44% yield). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 2.65 min; <i>m</i>/<i>z</i> 327.4 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Air was bubbled through a stirring solution of the ether (75 mg, 0.23 mmol) and KO<i>t</i>-Bu (2.3 mL of a 1 M solution in THF, 2.3 mmol) in DMSO (2.5 mL) for 1 h at rt. The remaining THF was removed in vacuo, and the reaction was acidified by the addition of HCl (3 M aq). Purification by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 21.2 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 95% H<sub>2</sub>O, 20 mL/min, λ = 214 nm] to give title compound (<i>exo</i>-<b>19o</b>, 3.5 mg, 0.018 mmol, 8% yield, 92% purity by LC/MS) as a white solid after lyophilization. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.0 (br s, 1H), 3.31 (dd, <i>J</i> = 16.7, 6.4 Hz, 1H), 3.24 (s, 3H), 3.22 (dd, <i>J</i> = 10.5, 7.2 Hz, 1H), 2.84 (dd, <i>J</i> = 16.9, 6.2 Hz, 1H), 2.69 (d, <i>J</i> = 14.8 Hz, 1H), 2.09 (m, 1H), 2.04 (m, 1H), 0.84 (m, 1H). LCMS (ESI<sup>+</sup>): <i>t</i><sub>r</sub> = 1.36 min; <i>m</i>/<i>z</i> 208.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_141" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> (<i>R</i>)-2-(Pent-3-enyl)oxirane (<i>R</i>-<b>5b</b>)</h4><div class="NLM_p last">To a suspension of ethyltriphenylphosphonium bromide (5.57 g, 15.0 mmol) in THF (15 mL) at 0 °C was added lithium bis(trimethylsilyl)amide (15.0 mL of a 1 M solution in THF, 15.0 mmol). The solution was stirred for 0.5 h, at which time the (<i>R</i>)-5-(chloromethyl)tetrahydrofuran-2-ol (<i>R</i>-<b>29</b>, 1.00 g, 7.32 mmol) was added at 0 °C as a solution in THF (15 mL). The resulting solution was allowed to warm to rt and stirred overnight. The mixture was quenched with H<sub>2</sub>O and extracted with Et<sub>2</sub>O (2×), dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (1–5% Et<sub>2</sub>O/pentane, silica) gave the title compound (<i>R</i>-<b>5b</b>, 467 mg, 4.16 mmol, 57% yield), an inseparable mixture of olefin isomers (<i>Z</i>:<i>E</i> = 2.3:1), as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.55–5.35 (m, 2H), 2.93 (m, 1H), 2.76 (m, 1H), 2.49 (dd, <i>J</i> = 6.0, 2.8 Hz, 1H from <i>Z</i>-isomer), 2.48 (dd, <i>J</i> = 6.0, 2.8 Hz, 1H from <i>E</i>-isomer), 2.21 (q, <i>J</i> = 7.6 Hz, 2H from <i>Z</i>-isomer), 2.14 (m, 2H from <i>E</i>-isomer), 1.67–1.53 (m, 5H).</div></div><div id="sec4_1_142" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> (1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-Methylbicyclo[3.1.0]hexan-2-ol (1<i>R</i>,2<i>R</i>,5<i>S</i>-<b>9b</b>)</h4><div class="NLM_p last">Prepared from (<i>R</i>)-2-(pent-3-enyl)oxirane (<i>R</i>-<b>5b</b>, <i>Z</i>:<i>E</i> = 2.3:1, 980 mg, 8.74 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (1<i>R</i>,2<i>R</i>,5<i>S</i>-<i>endo</i>-<b>9b</b>:1<i>R</i>,2<i>R</i>,5<i>S</i>-<i>exo</i>-<b>9b</b> = 2:1, 647 mg, 5.77 mmol, 66% yield), an inseparable mixture of diastereomers, as a clear oil. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.15 (d, <i>J</i> = 4.8 Hz, 1H), 2.08 (m, 1H), 1.75–1.25 (m, 5H), 0.92–0.85 (m, 4H). <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.21 (d, <i>J</i> = 4.8 Hz, 1H), 1.88 (m, 1H), 1.75–1.25 (m, 3H), 1.15 (m, 1H), 1.07 (m, 1H), 0.96 (d, <i>J</i> = 6.0 Hz, 3H), 0.41 (m, 1H).</div></div><div id="sec4_1_143" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> (1<i>R</i>,5<i>S</i>)-<i>endo</i>/<i>exo</i>-6-Methylbicyclo[3.1.0]hexan-2-one (1<i>R</i>,5<i>S</i>-<b>10b</b>)</h4><div class="NLM_p last">Prepared from (1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-methylbicyclo[3.1.0]hexan-2-ol (1<i>R</i>,2<i>R</i>,5<i>S</i>-<i>endo</i>-<b>9b</b>:1<i>R</i>,2<i>R</i>,5<i>S</i>-<i>exo</i>-<b>9b</b> = 2:1, 658 mg, 5.87 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (1<i>R</i>,5<i>S</i>-<i>endo</i>-<b>10b</b>:1<i>R</i>,5<i>S</i>-<i>exo</i>-<b>10b</b> = 2:1, 580 mg, 5.26 mmol, 90% yield), an inseparable mixture of diastereomers, as a light-yellow oil. The <sup>1</sup>H NMR spectral data were identical to that of the racemic compounds <i>endo</i>-<b>10b</b> and <i>exo</i>-<b>10b</b> as shown previously.</div></div><div id="sec4_1_144" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> (1<i>R</i>,1a<i>R</i>,5a<i>S</i>)-1-Methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>18b</b>) and (1<i>S</i>,1a<i>R</i>,5a<i>S</i>)-1-Methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (1a<i>R</i>,5a<i>S</i>-<i>exo</i>-<b>18b</b>)</h4><div class="NLM_p last">Prepared from 1<i>R</i>,5<i>S</i>-<b>10b</b> (1<i>R</i>,5<i>S</i>-<i>endo</i>-<b>10b</b>:1<i>R</i>,5<i>S</i>-<i>exo</i>-<b>10b</b> = 2:1, 570 mg, 5.18 mmol) in a similar manner as described for the synthesis of <b>18a</b>. Separation of the isomers was performed by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 100 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 50% H<sub>2</sub>O, 100 mL/min, λ = 254 nm] to give the <i>endo</i>-isomer (1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>18b</b>, 211 mg, 1.02 mmol, 30% yield) followed by the <i>exo</i>-isomer (1a<i>R</i>,5a<i>S</i>-<i>exo</i>-<b>18b</b>, 78 mg, 0.38 mmol, 22% yield). The <sup>1</sup>H NMR spectral data for these compounds was identical to that of the racemic compounds <i>endo</i>-<b>18b</b> and <i>exo</i>-<b>18b</b> as shown previously.</div></div><div id="sec4_1_145" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> (1<i>R</i>,1a<i>R</i>,5a<i>S</i>)-1-Methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>19b</b>)</h4><div class="NLM_p last">Prepared from 1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>18b</b> by the general ester hydrolysis procedure. [α]<sup>25</sup><sub>D</sub> + 67.6 (<i>c</i> 0.52, MeOH). The <sup>1</sup>H NMR spectral data was identical to the racemic material <i>endo</i>-<b>19b</b> shown previously. <sup>13</sup>C APT NMR (HCl salt, partial) (100 MHz, CD<sub>3</sub>OD) δ up, 28.0, 20.4, 17.9, 7.1; down, 131.0, 22.9.</div></div><div id="sec4_1_146" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> (1<i>S</i>,1a<i>R</i>,5a<i>S</i>)-1-Methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic acid (1a<i>R</i>,5a<i>S</i>-<i>exo</i>-<b>19b</b>)</h4><div class="NLM_p last">Prepared from 1a<i>R</i>,5a<i>S</i>-<i>exo</i>-<b>18b</b> by the general ester hydrolysis procedure. The <sup>1</sup>H NMR spectral data was identical to the racemic material <i>exo</i>-<b>19b</b> shown previously.</div></div><div id="sec4_1_147" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> (1<i>S</i>,1a<i>S</i>,5a<i>R</i>)-1-Methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (1a<i>S</i>,5a<i>R</i>-<i>endo</i>-<b>19b</b>) and (1<i>R</i>,1a<i>S</i>,5a<i>R</i>)-1-Methyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (1a<i>S</i>,5a<i>R</i>-<i>exo</i>-<b>19b</b>)</h4><div class="NLM_p last">The title compounds were prepared as pure enantiomers from (<i>S</i>)-5-(chloromethyl)dihydrofuran-2(3<i>H</i>)-one (<i>S</i>-<b>29</b>) by the identical synthetic route as described for the preparation of 1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>19b</b> and 1a<i>R</i>,5a<i>S</i>-<i>exo</i>-<b>19b</b> from <i>R</i>-<b>29</b>. Rotation data for 1a<i>S</i>,5a<i>R</i>-<i>endo</i>-<b>19b</b>: [α]<sup>25</sup><sub>D</sub> – 93.0 (<i>c</i> 0.55, MeOH). Anal. Calcd for 1a<i>S</i>,5a<i>R</i>-<i>endo</i>-<b>19b</b> C<sub>9</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>: C, 60.66; H, 5.66; N, 15.72. Found: C, 60.49; H, 5.38; N, 15.57.</div></div><div id="sec4_1_148" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> (<i>R</i>)-4-(Hex-3-ynyl)-2,2-dimethyl-1,3-dioxolane (<b>30</b>)</h4><div class="NLM_p last">To a flask cooled to −78 °C under N<sub>2</sub> was added 2-butyne gas via syringe needle until approximately ∼3 mL of liquid had condensed in the flask. THF (120 mL) was then added followed by DMPU (18.9 mL, 156 mmol). The flask was purged with N<sub>2</sub>, and <i>n</i>-butyllithium (18.7 mL of a 2.5 M solution in hexanes, 46.9 mmol) was added via syringe over 5 min and stirred for an additional 15 min, at which time (<i>R</i>)-4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane (<i>R</i>-<b>7</b>, 10.0 g, 39.1 mmol) was added as a solution in THF (30 mL). The reaction was slowly warmed to rt and stirred a total of 3 h. The mixture was quenched with satd NH<sub>4</sub>Cl and extracted with Et<sub>2</sub>O (2×). The organics were washed with H<sub>2</sub>O and brine. Dried organics over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (5–15% EtOAc/hexanes, silica) gave the title compound (<b>30</b>, 5.92 g, 32.5 mmol, 83% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.19 (m, 1H), 4.08 (dd, <i>J</i> = 8.0, 6.0 Hz, 1H), 3.58 (dd, <i>J</i> = 7.6, 6.8 Hz, 1H), 2.26 (m, 2H), 2.15 (qt, <i>J</i> = 5.2, 2.4 Hz, 2H), 1.81 (m, 1H), 1.68 (m, 1H), 1.40 (s, 3H), 1.36 (s, 3H), 1.11 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_149" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> (<i>R</i>,<i>Z</i>/<i>E</i>)-2-(Hex-3-enyl)oxirane (<i><b>R</b></i>-<b>5c</b>)</h4><div class="NLM_p">To a solution of (<i>R</i>)-4-(hex-3-ynyl)-2,2-dimethyl-1,3-dioxolane (<b>30</b>, 5.30 g, 29.1 mmol) in hexanes (80 mL) was added 5% palladium on BaSO<sub>4</sub> (928 mg), and quinoline (freshly distilled from Zn dust, 563 mg, 4.36 mmol). The flask was then purged with H<sub>2</sub> and stirred under an H<sub>2</sub> atmosphere for 2 h. The reaction mixture was filtered through Celite and washed sequentially with HCl (1<i>N</i> aq, 2×) and brine. The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated to give (<i>R</i>,<i>Z</i>/<i>E</i>)-4-(hex-3-enyl)-2,2-dimethyl-1,3-dioxolane (4.84 g, 26.3 mmol, 90% yield). This material contained approximately 8% of the inseparable <i>E</i>-isomer (data not shown). <i>Z</i>-isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.40 (m, 1H), 5.31 (m, 1H), 4.06 (m, 2H), 3.52 (t, <i>J</i> = 4.8 Hz, 1H), 2.09 (m, 4H), 1.71 (m, 1H), 1.54 (m, 1H), 1.41 (s, 3H), 1.35 (s, 3H), 0.96 (t, <i>J</i> = 7.6 Hz, 3H).</div><div class="NLM_p">(<i>R</i>,<i>Z</i>/<i>E</i>)-4-(Hex-3-enyl)-2,2-dimethyl-1,3-dioxolane (4.84 g, 26.3 mmol) was stirred in AcOH/H<sub>2</sub>O (4:1, 50 mL) at rt for 20 h. The mixture was concentrated in vacuo and purified by column chromatography (40–70% EtOAc/hexanes, silica) to give (<i>R</i>,<i>Z</i>/<i>E</i>)-oct-5-ene-1,2-diol (3.59 g, 24.9 mmol, 95% yield) as a clear oil. <i>Z</i>-isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.45 (m, 1H), 5.36 (m, 1H), 3.75 (m, 1H), 3.67 (dd, <i>J</i> = 10.8, 2.8 Hz, 1H), 3.45 (dd, <i>J</i> = 11.2, 7.6 Hz, 1H), 2.16 (m, 2H), 2.04 (m, 2H), 1.50 (m, 2H), 0.96 (t, <i>J</i> = 7.6 Hz, 3H).</div><div class="NLM_p last">To a solution of (<i>R</i>,<i>Z</i>/<i>E</i>)-oct-5-ene-1,2-diol (8.50 g, 58.9 mmol) in THF (230 mL) at 0 °C was added NaH (7.06 g of a 60% dispersion in mineral oil, 177 mmol) in portions over 5 min. The mixture was warmed to rt and stirred for 40 min. The reaction was recooled to 0 °C, and triisopropylbenzenesulfonyl imidazole (20.7 g, 61.8 mmol) was added. The reaction was warmed to rt, stirred for 1 h, and quenched H<sub>2</sub>O. The mixture was extracted with Et<sub>2</sub>O, and the organics were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (2–8% Et<sub>2</sub>O/pentane, silica) gave the title compound (<i>R</i>-<b>5c</b>, 5.04 g, 40.0 mmol, 68% yield),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>a clear oil, which contained approximately 8% of the <i>E</i>-isomer. <i>Z</i>-isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.41 (m, 1H), 5.35 (m, 1H), 2.93 (m, 1H), 2.75 (dd, <i>J</i> = 5.2, 4.4 Hz, 1H), 2.49 (dd, <i>J</i> = 5.2, 2.8 Hz, 1H), 2.20 (q, <i>J</i> = 6.8 Hz, 2H), 2.06 (quin, <i>J</i> = 7.6 Hz, 2H), 1.59 (m, 2H), 0.97 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_1_150" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> Optional Enantioenrichment of (<i>R</i>,<i>Z</i>/<i>E</i>)-2-(Hex-3-enyl)oxirane (<i>R</i>-<b>5c</b>)</h4><div class="NLM_p last">To (<i>R</i>,<i>Z</i>/<i>E</i>)-2-(hex-3-enyl)oxirane (<i>R</i>-<b>5c</b>, 84% <i>ee</i> material, 6.30 g, 49.9 mmol) was added THF (0.40 mL), (<i>R</i>,<i>R</i>)-Co-Salen (150 mg, 0.248 mmol), and AcOH (60 mg, 1.00 mmol). The flask was cooled to 0 °C, and H<sub>2</sub>O (130 mg, 7.22 mmol) was added. The mixture was stirred in open air overnight, diluted with Et<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (2–10% Et<sub>2</sub>O/pentane, silica) gave the title compound (<i>R</i>-<b>5c</b>, >96% <i>ee</i>, 3.00 g, 23.8 mmol, 48% yield).</div></div><div id="sec4_1_151" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> (1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-Ethylbicyclo[3.1.0]hexan-2-ol (1<i>R</i>,2<i>R</i>,5<i>S</i>-<b>9c</b>)</h4><div class="NLM_p last">Prepared from (<i>R</i>,<i>Z</i>/<i>E</i>)-2-(hex-3-enyl)oxirane (<i>R</i>-<b>5c</b>, 3.00 g, 23.8 mmol)in a similar manner as described for the synthesis of <i>exo</i>-<b>9d</b>/<i>endo</i>-<b>9d</b> to give the title compound (<b>1</b><i>R</i>,2<i>R</i>,5<i>S</i>-<i>endo</i>-<b>9c</b>:1<i>R</i>,2<i>R</i>,5<i>S</i>-<i>exo</i>-<b>9c</b> = 12:1, 647 mg, 5.77 mmol, 66% yield), an inseparable mixture of diastereomers, as a clear oil. <i>endo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.18 (t, <i>J</i> = 5.6 Hz, 1H), 2.08 (m, 1H), 1.79–1.49 (m, 4H), 1.42 (d, <i>J</i> = 5.5 Hz, 1H), 1.37 (m, 1H), 1.22 (m, 2H), 0.96 (t, <i>J</i> = 7.6 Hz, 3H), 0.74 (1H, m). <i>exo</i>-Iisomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, partial spectra of distinguishable peaks) δ 4.21 (t, <i>J</i> = 5.0 Hz, 1H), 1.90 (m, 1H), 0.36 (m, 1H).</div></div><div id="sec4_1_152" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> (1<i>R</i>,5<i>S</i>)-6-Ethylbicyclo[3.1.0]hexan-2-one (1<i>R</i>,5<i>S</i>-<b>10c</b>)</h4><div class="NLM_p last">Prepared from (1<i>R</i>,2<i>R</i>,5<i>S</i>)-6-ethylbicyclo[3.1.0]hexan-2-ol (1<i>R</i>,2<i>R</i>,5<i>S</i>-<i>endo</i>-<b>9c</b>:1<i>R</i>,2<i>R</i>,5<i>S</i>-<i>exo</i>-<b>9c</b> = 13:1, 1.75 g, 13.9 mmol) in a similar manner as described for the synthesis of <i>exo</i>-<b>10d</b>/<i>endo</i>-<b>10d</b> to give the title compound (1<i>R</i>,5<i>S</i>-<i>endo</i>-<b>10c</b>:1<i>R</i>,5<i>S</i>-<i>exo</i>-<b>10c</b> = 12:1, 1.62 g, 13.0 mmol, 94% yield), an inseparable mixture of diastereomers, as a light-yellow oil. The <sup>1</sup>H NMR spectral data for 1<i>R</i>,5<i>S</i>-<i>endo</i>-<b>10c</b> was identical to that of the racemic compound <i>endo</i>-<b>10c</b>. The only distinguishable peak assigned to 1<i>R</i>,5<i>S</i>-<i>exo</i>-<b>10c</b> in the <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectra was a peak for the terminal methyl group at δ 0.99 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_1_153" class="NLM_sec NLM_sec_level_3"><div id="ac_i166" class="anchor-spacer"></div><h4 class="article-section__title" id="_i166"> <i>endo</i>/<i>exo</i>-(1a<i>R</i>,5a<i>S</i>)-1-Ethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (1a<i>R</i>,5a<i>S</i>-<i>endo</i>/<i>exo</i>-<b>18c</b>)</h4><div class="NLM_p last">Prepared from (<i>endo</i>-1<i>R</i>,5<i>S</i>-<b>10c</b>:<i>exo</i>-1<i>R</i>,5<i>S</i>-<b>10c</b> = 12:1, 1.62 g, 13.0 mmol) in a similar manner as described for the synthesis of <b>18a</b> to give the title compound (1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>18c</b>:1a<i>R</i>,5a<i>S</i>-<i>exo</i>-<b>18c</b> = 12:1, 2.10 g, 9.53 mmol, 73% yield) as a mixture of diastereomers. The <sup>1</sup>H NMR spectral data for 1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>18c</b> was identical to that of the racemic compound <i>endo</i>-<b>18c</b>. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, partial spectra of distinguishable peaks) δ 2.95 (dd, <i>J</i> = 17.2, 6.2 Hz, 1H), 2.82 (d, <i>J</i> = 17.2 Hz, 1H), 1.99 (m, 1H), 1.91 (m, 1H), 0.65 (m, 1H).</div></div><div id="sec4_1_154" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> (1<i>R</i>,1a<i>R</i>,5a<i>S</i>)-1-Ethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>19c</b>) and (1<i>S</i>,1a<i>R</i>,5a<i>S</i>)-1-Ethyl-1a,2,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid Ethyl Ester (1a<i>R</i>,5a<i>S</i>-<i>exo</i>-<b>19c</b>)</h4><div class="NLM_p last">Prepared from 1a<i>R</i>,5a<i>S</i>-<i>endo</i>/<i>exo</i>-<b>18c</b> by the general ester hydrolysis procedure. Separation of the isomers was performed by reverse-phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 50 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 50% H<sub>2</sub>O, 60 mL/min, λ = 254 nm] to give gave 1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>19c</b> followed by 1a<i>R</i>,5a<i>S</i>-<i>exo</i>-<b>19c</b>. The <sup>1</sup>H NMR and LCMS (ESI<sup>+</sup>) data for 1a<i>R</i>,5a<i>S</i>-<i>endo</i>-<b>19c</b> was identical to that of the racemic compound <i>endo</i>-<b>19c</b>. <i>exo</i>-Isomer: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.79 (dd, <i>J</i> = 17.2, 6.7 Hz, 1H), 2.48 (d, <i>J</i> = 17.2 Hz, 1H), 2.23 (m, 1H), 2.15 (m, 1H), 1.14 (m, 1H), 0.98 (m, 1H), 0.80 (t, <i>J</i> = 7.5 Hz, 3H), 0.71 (m, 1H).</div></div><div id="sec4_1_155" class="NLM_sec NLM_sec_level_3"><div id="ac_i168" class="anchor-spacer"></div><h4 class="article-section__title" id="_i168"> (<i>R</i>)-4-(5-Cyclopropylpent-3-ynyl)-2,2-dimethyl-1,3-dioxolane (<i>R</i>-<b>8</b>)</h4><div class="NLM_p last">The title compound was prepared as a single enantiomer from (<i>R</i>)-4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane (<i><b>R</b></i>-<b>7</b>) by the identical synthetic route as described for the preparation of <b>8</b> from racemic (±)-4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane (<b>7</b>). The <sup>1</sup>H NMR spectral data for <i>R</i>-<b>8</b> was identical to that of the racemic compound <b>8</b>.</div></div><div id="sec4_1_156" class="NLM_sec NLM_sec_level_3"><div id="ac_i169" class="anchor-spacer"></div><h4 class="article-section__title" id="_i169"> (<i>R</i>,<i>Z</i>)-2-(5-Cyclopropylpent-3-enyl)oxirane (<i>R</i>-<b>5n</b>)</h4><div class="NLM_p">(<i>R</i>)-4-(5-Cyclopropylpent-3-ynyl)-2,2-dimethyl-1,3-dioxolane (<i>R</i>-<b>8</b>, 7.20 g, 34.6 mmol) was stirred in AcOH/H<sub>2</sub>O (4:1, 25 mL) at rt for 20 h. The mixture was concentrated in vacuo, dissolved in THF (100 mL), and cooled to 0 °C. NaH (1.49 g of a 60% dispersion in mineral oil, 62.3 mmol) was added in portions over 5 min. The mixture was warmed to rt and stirred for 1 h. The reaction was recooled to 0 °C, and triisopropylbenzenesulfonyl imidazole (13.9 g, 41.5 mmol) was added. The reaction was warmed to rt, stirred for 1.5 h, and quenched with H<sub>2</sub>O. The mixture was extracted with Et<sub>2</sub>O, and the organics were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (7–14% EtOAc/hexanes, silica) gave (<i>R</i>)-2-(5-cyclopropylpent-3-ynyl)oxirane (4.00 g, 26.6 mmol, 77% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.05 (m, 1H), 2.79 (dd, <i>J</i> = 5.0, 4.1 Hz, 1H), 2.54 (dd, <i>J</i> = 5.0, 2.7 Hz, 1H), 2.32 (tt, <i>J</i> = 7.1, 2.3 Hz, 2H), 2.20 (m, 2H), 1.72 (m, 2H), 0.89 (m, 1H), 0.44 (m, 2H), 0.20 (m, 2H).</div><div class="NLM_p last">To a solution of (<i>R</i>)-2-(5-cyclopropylpent-3-ynyl)oxirane (4.00 g, 26.6 mmol) in hexanes (50 mL) was added 5% palladium on BaSO<sub>4</sub> (567 mg) and quinoline (freshly distilled from Zn dust, 344 mg, 2.66 mmol). The flask was then purged with H<sub>2</sub> and stirred under an H<sub>2</sub> atmosphere for 2 h. The reaction mixture was filtered through Celite and washed sequentially with HCl (1N aq, 2×) and brine. The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (4–20% EtOAc/hexanes, silica) gave the title compound (<i>R</i>-<b>5n</b>, 3.40 g, 22.3 mmol, 84% yield) as a clear oil. The <sup>1</sup>H NMR spectral data were identical to the racemic material <b>5n</b> as shown previously.</div></div><div id="sec4_1_157" class="NLM_sec NLM_sec_level_3"><div id="ac_i170" class="anchor-spacer"></div><h4 class="article-section__title" id="_i170"> Enantioenrichment of (<i>R</i>,<i>Z</i>)-2-(5-Cyclopropylpent-3-enyl)oxirane (<i>R</i>-<b>5n</b>)</h4><div class="NLM_p last">To (±)-(<i>Z</i>)-2-(5-cyclopropylpent-3-enyl)oxirane (<i>R</i>-<b>5n</b>, 2.00 g, 13.1 mmol) was added THF (0.50 mL), (<i>R</i>,<i>R</i>)-Co-Salen (11.2 mg, 0.020 mmol), and AcOH (15.7 mg, 0.26 mmol). The flask was cooled to 0 °C, and H<sub>2</sub>O (250 mg, 13.9 mmol) was added. The mixture was stirred in open air overnight, diluted with Et<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (4–20% EtOAc/hexanes, silica) gave the title compound (<i>R</i>-<b>5c</b>, 1.50 g, 9.83 mmol, 75% yield) as a clear oil.</div></div><div id="sec4_1_158" class="NLM_sec NLM_sec_level_3"><div id="ac_i171" class="anchor-spacer"></div><h4 class="article-section__title" id="_i171"> (1<i>R</i>,1a<i>R</i>,5a<i>S</i>)-1-Cyclopropylmethyl-1a,3,5,5a-tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>R</i>,<i>S</i>-<i>endo</i>-<b>19n</b>)</h4><div class="NLM_p last">The title compound was prepared as a single enantiomer from (<i>R</i>,<i>Z</i>)-2-(5-cyclopropylpent-3-enyl)oxirane (<i>R</i>-<b>5n</b>) by the identical synthetic route as described for the preparation of <i>endo</i>-<b>19n</b> from racemic (±)-(<i>Z</i>)-2-(5-cyclopropylpent-3-enyl)oxirane (<b>5n</b>). The <sup>1</sup>H NMR spectral data were identical to the racemic material <i>endo</i>-<b>19n</b> as shown previously.</div></div><div id="sec4_1_159" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> Multigram Scale Synthesis of (+)-(1a<i>R</i>,5a<i>S</i>)-1a,2,5,5a-Tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (<i>R</i>,<i>R</i>-<b>19a</b>)</h4><div class="NLM_p last">To a solution of diethyl oxalate (71.3 mL, 525 mmol) in EtOH (1.00 L) under N<sub>2</sub> was added potassium <i>tert</i>-butoxide (551 mL of a 1.0 M solution in THF, 551 mmol). The mixture was cooled to 0 °C, and (1<i>R</i>,5<i>S</i>)-bicyclo[3.1.0]hexan-2-one (50.4 g, 525 mmol) was added as a solution in EtOH (150 mL) over 15 min. The mixture was warmed slowly to rt and stirred mechanically overnight. H<sub>2</sub>O (approximately 100 mL) and HCl (6N aq, added until acidic, ∼100 mL) were added followed by the addition of hydrazine monohydrochloride (39.5 g, 577 mmol). The mixture was mechanically stirred at rt for 12 h and concentrated in vacuo to approximately 300 mL in order to remove volatiles. The remaining material was partitioned between H<sub>2</sub>O and EtOAc. The layers were separated, and the aqueous phase was back-extracted with EtOAc. The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. The resultant yellow solid was dissolved in dioxane (900) mL and H<sub>2</sub>O (400 mL). Lithium hydroxide (25.1 g, 1.05 mol) was added, and the mixture was stirred overnight via mechanical stirrer and concentrated to approximately 300 mL. HCl (6N aq, added until acidic) was added, and a light-brown solid crashed out. The mixture was filtered, and the filtrate was extracted with EtOAc (2×). The filtrate was concentrated and combined with the light-brown solid. The crude solid was suspended in EtOAc/MeOH (20:1, approximately 500 mL), heated gently, and filtered to remove colored impurities. This process was repeated (2×). The remaining filtrates were combined, concentrated, and purified by reverse phase HPLC [Phenomenex Luna C18 column (10 μ, 250 mm × 100 mm), 5% (v/v) CH<sub>3</sub>CN (containing 1% v/v TFA) in H<sub>2</sub>O (containing 1% v/v TFA) gradient to 50% H<sub>2</sub>O, 100 mL/min,λ = 254 nm]. The product was isolated by extraction from HPLC solvents with EtOAc, followed by brine wash, drying over MgSO<sub>4</sub>, filtration, and concentration. In total, the pyrazole acid (<i>R</i>,<i>R</i>-<b>19a</b>, 53.4 g, 325 mmol, 62% yield) was obtained as a white solid (mp 238 °C). The LC/MS (ESI<sup>+</sup>), and <sup>1</sup>H NMR spectral data were identical to the racemic material <b>19a</b> as shown previously. <sup>13</sup>C APT NMR (partial) (100 MHz, CD<sub>3</sub>OD) δ up: 22.5, 14.7; down: 162.1, 161.0, 129.5, 126.2, 26.1, 16.5. IR (KBr) 3279, 3053, 2941, 2502, 1703, 1479, 1446, 1339, 1308, 1261, 1138, 1052, 1005, 943, 792 cm<sup>–1</sup>. [α]<sup>25</sup><sub>D</sub> + 37.5 (<i>c</i> 1.01, MeOH). Anal. Calcd for C<sub>8</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>: C, 58.53; H, 4.91; N, 17.06. Found: C, 58.37; H, 4.82; N, 16.78.</div></div><div id="sec4_1_160" class="NLM_sec NLM_sec_level_3"><div id="ac_i173" class="anchor-spacer"></div><h4 class="article-section__title" id="_i173"> Measurement of cAMP Inhibition</h4><div class="NLM_p last">GPR109a with an N-terminal HA tag was cloned into pHM6 (Invitrogen) and GPR109a CHO stable cell lines were generated by G418 selection. Positive clones were selected by anti-HA immunostaining. Compound potencies were determined by the 384 well cAMP Dynamic2 homogenous time-resolved fluorescence (HTRF) assay from CisBio International as described by the manufacturer’s one-step protocol. The HTRF cAMP assay was optimized for the GPR109 stable clone no. 46, 5 μM forskolin was used for stimulation, and 3700 cells were used for each well. Positive controls (200%) were defined as cAMP generated by 5 μM forskolin stimulated cells with 100 μM of niacin. Negative controls (100%) were defined as cAMP generated by 5 μM forskolin stimulated cells.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i174" class="anchor-spacer"></div><h3 class="article-section__title" id="_i174"> Rat Pharmacokinetics</h3><div class="NLM_p last">Male Sprague–Dawley rats were dosed orally or intravenously at 10 and 2 mg/kg, respectively, in 80% PEG400 and 20% phosphate buffeted saline. Animals were fasted overnight prior to oral dose administration. Whole blood samples were collected from the jugular vein over a 24 h period postdose. Plasma was prepared from sodium heparin treated whole blood and separated by centrifugation. Plasma samples were assayed using a selective HPLC/MS/MS method. The HPLC/MS/MS was operated in multiple reaction monitoring (MRM) mode under optimized conditions for detection of selected compounds and the internal standard using positive ions formed by electrospray ionization. Quantitation was determined using a weighted regression analysis of peak area ratios of analyte and internal standard. This method provided a lower limit of quantitation of 1 ng/mL and an upper limit of quantitation of 2000 ng/mL. Serial sampling [at 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 18, and 21 h post dosing] was used to define the plasma concentration vs time profile.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i175" class="anchor-spacer"></div><h3 class="article-section__title" id="_i175"> In Vivo Assays. Animals</h3><div class="NLM_p last">Animal studies were performed according to the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences (1996) and approved by the Arena Pharmaceuticals and Merck Research Laboratories Animal Care and Use Committees. All mice used were C57Bl/6 males, at least 8 weeks old (The Jackson Laboratories West, Sacramento, CA). Animals were housed under standard laboratory conditions with a 12 h dark, 12 h light cycle with constant temperature and humidity. Mice were fed a standard rodent diet and had ad libitum access to food and water.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i176" class="anchor-spacer"></div><h3 class="article-section__title" id="_i176"> In Vivo Mouse Lipolysis</h3><div class="NLM_p last">Prior to study, mice were fasted for 16 h. Compound or vehicle (0.5% methylcellulose) was administered by oral gavage (po), and animals were euthanized 20 min postdose by CO<sub>2</sub> asphyxiation. Blood was collected via the inferior vena cava, anticoagulated in EDTA, and plasma separated by centrifugation on a tabletop microcentrifuge. Plasma was used for the measurement of FFA using an enzymatic method (NEFA C Free Fatty-Acid Assay; WAKO Chemicals USA, Richmond, VA) and for the measurement of compound levels by API-4000 LCMS/MS after acetonitrile precipitation.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i177" class="anchor-spacer"></div><h3 class="article-section__title" id="_i177"> In Vivo Mouse Vasodilation</h3><div class="NLM_p last">Mouse vasodilation was measured by laser Doppler flowmetry as previously described.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Briefly, male C57/Bl6 mice (8–10 weeks old; ∼25 g) were anesthetized with Nembutal via ip injection (80 mg/10 mL/kg). After 10 min, the mouse was placed under an LDPI laser Doppler (PeriScan PIM II; Perimed, Stockholm) and a needle and syringe containing vehicle (PBS; 40% hydroxypropyl-β-cyclodextrin (HPBCD) or 0.5% methylcellulose) or drug was placed in the intraperitoneal space and a slight back pressure was applied to prevent premature delivery of compound. The mouse’s right ear was turned inside-out to expose the ventral side using forceps. The laser Doppler was focused in the center of the ventral right ear and adjusted as follows: repeated data collection, 15 × 15 image format, auto interval start, 20 s delay, medium resolution, very fast scan speed, and 8–9 V intensity (∼4.5 cm from ear). After a 3 min baseline reading, vehicle or compound was administered into the ip space (5 mL/kg through the preinserted syringe) and readings continued for approximately 15 min. Vasodilation was expressed as “% change of perfusion over baseline values”. At the end of the studies, mice were euthanized and a blood sample was collected by cardiac puncture and anticoagulated in EDTA. Plasma was obtained by centrifugation and used for determination of compound concentration by LC-MS/MS.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm2010964" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">P. Douglas Boatman</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a1d1c5c3cec0d5ccc0cfe1d8c0c9cece8fc2cecc"><span class="__cf_email__" data-cfemail="3b4b5f59545a4f565a557b425a53545415585456">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brett Lauring</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas O. Schrader</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Kasem</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin R. Johnson</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Skinner</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jae-Kyu Jung</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jerry Xu</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin C. Cherrier</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter J. Webb</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graeme Semple</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carleton R. Sage</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens Knudsen</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruoping Chen</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen-Lin Luo</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luzelena Caro</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josee Cote</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eseng Lai</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Wagner</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew K. Taggart</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ester Carballo-Jane</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Milton Hammond</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven L. Colletti</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Tata</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel T. Connolly</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Gerard Waters</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremy G. Richman</span> - <span class="hlFld-Affiliation affiliation">†Departments of Medicinal Chemistry and ‡Discovery Biology, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, Rahway, New Jersey, United
States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i178" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i178"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i179" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i179"> Abbreviations Used</h2><tr><td class="NLM_term">Tg</td><td class="NLM_def"><p class="first last">triglycerides</p></td></tr><tr><td class="NLM_term">HDLc</td><td class="NLM_def"><p class="first last">high-density lipoprotein cholesterol</p></td></tr><tr><td class="NLM_term">LDL-c</td><td class="NLM_def"><p class="first last">low-density lipoprotein cholesterol</p></td></tr><tr><td class="NLM_term">VLDL-c</td><td class="NLM_def"><p class="first last">very low-density lipoprotein cholesterol</p></td></tr><tr><td class="NLM_term">LiDBB</td><td class="NLM_def"><p class="first last">lithium 4,4′-di-<i>tert</i>-butyl-biphenyl</p></td></tr><tr><td class="NLM_term">TrisIm</td><td class="NLM_def"><p class="first last">triisopropylsulfonylimidazole</p></td></tr><tr><td class="NLM_term">HKR</td><td class="NLM_def"><p class="first last">hydrolytic kinetic resolution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i180">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75134" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75134" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawken, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ounpuu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avezum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budaj, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pais, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varigos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisheng, L.</span><span> </span><span class="NLM_article-title">Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=937-952&author=S.+Yusufauthor=S.+Hawkenauthor=S.+Ounpuuauthor=T.+Dansauthor=A.+Avezumauthor=F.+Lanasauthor=M.+McQueenauthor=A.+Budajauthor=P.+Paisauthor=J.+Varigosauthor=L.+Lisheng&title=Effect+of+potentially+modifiable+risk+factors+associated+with+myocardial+infarction+in+52+countries+%28the+INTERHEART+study%29%3A+case-control+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DHawken%26aufirst%3DS.%26aulast%3DOunpuu%26aufirst%3DS.%26aulast%3DDans%26aufirst%3DT.%26aulast%3DAvezum%26aufirst%3DA.%26aulast%3DLanas%26aufirst%3DF.%26aulast%3DMcQueen%26aufirst%3DM.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DPais%26aufirst%3DP.%26aulast%3DVarigos%26aufirst%3DJ.%26aulast%3DLisheng%26aufirst%3DL.%26atitle%3DEffect%2520of%2520potentially%2520modifiable%2520risk%2520factors%2520associated%2520with%2520myocardial%2520infarction%2520in%252052%2520countries%2520%2528the%2520INTERHEART%2520study%2529%253A%2520case-control%2520study%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D937%26epage%3D952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ford, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajani, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croft, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Critchley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labarthe, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottke, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capewell, S.</span><span> </span><span class="NLM_article-title">Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2398</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1056%2FNEJMsa053935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=17554120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Wnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2388-2398&author=E.+S.+Fordauthor=U.+A.+Ajaniauthor=J.+B.+Croftauthor=J.+A.+Critchleyauthor=D.+R.+Labartheauthor=T.+E.+Kottkeauthor=W.+H.+Gilesauthor=S.+Capewell&title=Explaining+the+Decrease+in+U.S.+Deaths+from+Coronary+Disease%2C+1980%E2%80%932000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Explaining the decrease in U.S. deaths from coronary disease, 1980-2000</span></div><div class="casAuthors">Ford, Earl S.; Ajani, Umed A.; Croft, Janet B.; Critchley, Jula A.; Labarthe, Darwin R.; Kottke, Thomas E.; Giles, Wayne H.; Capewell, Simon</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2388-2398</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Mortality from coronary heart disease in the United States has decreased substantially in recent decades.  We conducted a study to det. how much of this de- crease could be explained by the use of medical and surgical treatments as opposed to changes in cardiovascular risk factors.  METHODS We applied a previously validated statistical model, IMPACT, to data on the use and effectiveness of specific cardiac treatments and on changes in risk factors between 1980 and 2000 among U.S. adults 25 to 84 years old.  The difference between the obsd. and expected no. of deaths from coronary heart disease in 2000 was distributed among the treatments and risk factors included in the analyses.  RESULTS From 1980 through 2000, the age-adjusted death rate for coronary heart disease fell from 542.9 to 266.8 deaths per 100,000 population among men and from 263.3 to 134.4 deaths per 100,000 population among women, resulting in 341,745 fewer deaths from coronary heart disease in 2000.  Approx. 47% of this decrease was attributed to treatments, including secondary preventive therapies after myocardial infarction or revascularization (11%), initial treatments for acute myocardial infarction or unstable angina (10%), treatments for heart failure (9%), revascularization for chronic angina (5%), and other therapies (12%).  Approx. 44% was attributed to changes in risk factors, including redns. in total cholesterol (24%), systolic blood pressure (20%), smoking prevalence (12%), and phys. inactivity (5%), although these redns. were partially offset by increases in the body-mass index and the prevalence of diabetes, which accounted for an increased no. of deaths (8% and 10%, resp.).  CONCLUSIONS Approx. half the decline in U.S. deaths from coronary heart disease from 1980 through 2000 may be attributable to redns. in major risk factors and approx. half to evidence-based medical therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfR8YfvG_1x7Vg90H21EOLACvtfcHk0lhmppc1DivSDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Wnsbs%253D&md5=7e9da2fecd73213796adac2ea6b6c10e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMsa053935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMsa053935%26sid%3Dliteratum%253Aachs%26aulast%3DFord%26aufirst%3DE.%2BS.%26aulast%3DAjani%26aufirst%3DU.%2BA.%26aulast%3DCroft%26aufirst%3DJ.%2BB.%26aulast%3DCritchley%26aufirst%3DJ.%2BA.%26aulast%3DLabarthe%26aufirst%3DD.%2BR.%26aulast%3DKottke%26aufirst%3DT.%2BE.%26aulast%3DGiles%26aufirst%3DW.%2BH.%26aulast%3DCapewell%26aufirst%3DS.%26atitle%3DExplaining%2520the%2520Decrease%2520in%2520U.S.%2520Deaths%2520from%2520Coronary%2520Disease%252C%25201980%25E2%2580%25932000%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2388%26epage%3D2398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Bruckert, E</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labreuche, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amarenco, P.</span><span> </span><span class="NLM_article-title">Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis</span> <span class="citation_source-journal">Atherosclerosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">210</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2010&pages=353-361&author=E+Bruckertauthor=J.+Labreucheauthor=P.+Amarenco&title=Meta-analysis+of+the+effect+of+nicotinic+acid+alone+or+in+combination+on+cardiovascular+events+and+atherosclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruckert%26aufirst%3DE%26aulast%3DLabreuche%26aufirst%3DJ.%26aulast%3DAmarenco%26aufirst%3DP.%26atitle%3DMeta-analysis%2520of%2520the%2520effect%2520of%2520nicotinic%2520acid%2520alone%2520or%2520in%2520combination%2520on%2520cardiovascular%2520events%2520and%2520atherosclerosis%26jtitle%3DAtherosclerosis%26date%3D2010%26volume%3D210%26spage%3D353%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hiatt, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shamsie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schectman, G.</span><span> </span><span class="NLM_article-title">Discontinuation rates of cholesterol-lowering medications: implications for primary care</span> <span class="citation_source-journal">Am. J. Managed Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=10387383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A280%3ADyaK1M3ntlylsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=437-444&author=J.+G.+Hiattauthor=S.+G.+Shamsieauthor=G.+Schectman&title=Discontinuation+rates+of+cholesterol-lowering+medications%3A+implications+for+primary+care"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discontinuation rates of cholesterol-lowering medications: implications for primary care</span></div><div class="casAuthors">Hiatt J G; Shamsie S G; Schectman G</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of managed care</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-44</span>
        ISSN:<span class="NLM_cas:issn">1088-0224</span>.
    </div><div class="casAbstract">OBJECTIVE:  To evaluate long-term continuation rates for cholesterol-lowering therapy (niacin, sequestrants, statins) in a multidisciplinary lipid clinic and to evaluate the effectiveness of 2 different dosing strategies designed to improve long-term continuation of therapy.  STUDY DESIGN:  An observational study was done at the Milwaukee Department of Veterans Affairs Medical Center Lipid Clinic, where healthcare personnel were trained to improve patient tolerance to cholesterol-lowering medications.  Primary outcomes were recorded prospectively.  PATIENTS AND METHODS:  Patients were 970 consecutive veterans who began therapy with niacin, sequestrants, or statins between March 1988 and December 1995.  In 1992, two different dosing strategies were initiated to reduce the discontinuation rates for niacin and sequestrants: (1) the niacin titration schedule was lengthened from 3 to 6 weeks and (2) the initial sequestrant dose was reduced from four to two scoops daily.  RESULTS:  Discontinuation rates for niacin and sequestrants were both very high.  For niacin, 48% and 71% of all patients who began therapy discontinued the drug by 1 and 4 years, respectively.  For sequestrants, drug discontinuation rates were 59% and 83% at 1 and 4 years, respectively.  On the other hand, statin discontinuation rates at 1 and 4 years were only 10% and 28%, respectively.  Neither the longer niacin titration schedule nor the lower sequestrant initiation dose reduced these high discontinuation rates.  CONCLUSIONS:  Despite initiation of niacin and sequestrant therapy in the setting of a multidisciplinary lipid clinic, drug discontinuation rates were high and were similar to rates observed in primary-care settings.  Neither the specialized resources available in a lipid clinic nor protocols designed to improve tolerance to therapy reduced the high drug discontinuation rate.  Unless more tolerable niacin and sequestrant formulations become available, reliance on statins as the preferred cholesterol-lowering agents will continue because they have fewer side effects and lower discontinuation rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRX_kW4SNRgIWhHGZei4OW9fW6udTcc2eZgcz6Tla1QVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3ntlylsA%253D%253D&md5=cc9feb4ea6ce733c5b3e5581b66da762</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHiatt%26aufirst%3DJ.%2BG.%26aulast%3DShamsie%26aufirst%3DS.%2BG.%26aulast%3DSchectman%26aufirst%3DG.%26atitle%3DDiscontinuation%2520rates%2520of%2520cholesterol-lowering%2520medications%253A%2520implications%2520for%2520primary%2520care%26jtitle%3DAm.%2520J.%2520Managed%2520Care%26date%3D1999%26volume%3D5%26spage%3D437%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Offermanns, S.</span><span> </span><span class="NLM_article-title">The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">384</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=384-390&author=S.+Offermanns&title=The+nicotinic+acid+receptor+GPR109A+%28HM74A+or+PUMA-G%29+as+a+new+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOffermanns%26aufirst%3DS.%26atitle%3DThe%2520nicotinic%2520acid%2520receptor%2520GPR109A%2520%2528HM74A%2520or%2520PUMA-G%2529%2520as%2520a%2520new%2520therapeutic%2520target%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D384%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span> </span><span class="NLM_article-title">Recent progress in the discovery of niacin receptor agonists</span> <span class="citation_source-journal">Curr. Opin. Drug. Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">452</span><span class="NLM_x">–</span> <span class="NLM_lpage">459</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=17659487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFCns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=452-459&author=G.+Sempleauthor=P.+D.+Boatmanauthor=J.+G.+Richman&title=Recent+progress+in+the+discovery+of+niacin+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in the discovery of niacin receptor agonists</span></div><div class="casAuthors">Semple, Graeme; Boatman, P. Douglas; Richman, Jeremy G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">452-459</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Niacin (nicotinic acid) favorably affects multiple serum lipid parameters that are believed to be cardiovascular risk factors, but is also assocd. with a cutaneous flushing adverse effect.  The recent discovery of a G-protein-coupled receptor target for niacin (termed GPR109a) has stimulated interest in the discovery of new compds. with niacin-like effects on lipids, but with fewer adverse effects.  This review discusses the progress made toward the discovery of such mols. and highlights the pharmacol. models used to enable their identification.  The advances made in both these areas may help to det. whether GPR109a is the mol. target responsible for the beneficial anti-atherogenic effects of niacin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuuJctgtqOLVg90H21EOLACvtfcHk0lgbN5Ue64ha1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFCns7k%253D&md5=47c6f2e3bf6a62de9796196d15025617</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3DRecent%2520progress%2520in%2520the%2520discovery%2520of%2520niacin%2520receptor%2520agonists%26jtitle%3DCurr.%2520Opin.%2520Drug.%2520Discovery%2520Dev.%26date%3D2007%26volume%3D10%26spage%3D452%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span> </span><span class="NLM_article-title">Nicotinic acid receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7653</span><span class="NLM_x">–</span> <span class="NLM_lpage">7662</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800896z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7653-7662&author=P.+D.+Boatmanauthor=J.+G.+Richmanauthor=G.+Semple&title=Nicotinic+acid+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Fjm800896z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800896z%26sid%3Dliteratum%253Aachs%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DSemple%26aufirst%3DG.%26atitle%3DNicotinic%2520acid%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7653%26epage%3D7662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Lorenzen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stannek, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrianov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalvinsh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, U.</span><span> </span><span class="NLM_article-title">Characterization of a G Protein-Coupled Receptor for Nicotinic Acid</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2001&pages=349-357&author=A.+Lorenzenauthor=C.+Stannekauthor=H.+Langauthor=V.+Andrianovauthor=I.+Kalvinshauthor=U.+Schwabe&title=Characterization+of+a+G+Protein-Coupled+Receptor+for+Nicotinic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLorenzen%26aufirst%3DA.%26aulast%3DStannek%26aufirst%3DC.%26aulast%3DLang%26aufirst%3DH.%26aulast%3DAndrianov%26aufirst%3DV.%26aulast%3DKalvinsh%26aufirst%3DI.%26aulast%3DSchwabe%26aufirst%3DU.%26atitle%3DCharacterization%2520of%2520a%2520G%2520Protein-Coupled%2520Receptor%2520for%2520Nicotinic%2520Acid%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D59%26spage%3D349%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Maciejewski-Lenoir, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakak, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidarov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span> </span><span class="NLM_article-title">Langerhans Cells Release Prostaglandin D2 in Response to Nicotinic Acid</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">2637</span><span class="NLM_x">–</span> <span class="NLM_lpage">2646</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2006&pages=2637-2646&author=D.+Maciejewski-Lenoirauthor=J.+G.+Richmanauthor=Y.+Hakakauthor=I.+Gaidarovauthor=D.+P.+Behanauthor=D.+T.+Connolly&title=Langerhans+Cells+Release+Prostaglandin+D2+in+Response+to+Nicotinic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaciejewski-Lenoir%26aufirst%3DD.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DHakak%26aufirst%3DY.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26atitle%3DLangerhans%2520Cells%2520Release%2520Prostaglandin%2520D2%2520in%2520Response%2520to%2520Nicotinic%2520Acid%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2006%26volume%3D126%26spage%3D2637%26epage%3D2646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metters, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">6682</span><span class="NLM_x">–</span> <span class="NLM_lpage">6687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cheng%2C+K.%3B+Wu%2C+T.-J.%3B+Wu%2C+K.+K.%3B+Sturino%2C+C.%3B+Metters%2C+K.%3B+Gottesdiener%2C+K.%3B+Wright%2C+S.+D.%3B+Wang%2C+Z.%3B+O%E2%80%99Neill%2C+G.%3B+Lai%2C+E.%3B+Waters%2C+M.+G.Proc.+Natl.+Acad.+Sci+U.S.A.+2006%2C+103%2C+6682%E2%80%936687"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DT.-J.%26aulast%3DWu%26aufirst%3DK.%2BK.%26aulast%3DSturino%26aufirst%3DC.%26aulast%3DMetters%26aufirst%3DK.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DWright%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DE.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D6682%26epage%3D6687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Benyo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gille, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offermanns, S.</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1844</span><span class="NLM_x">–</span> <span class="NLM_lpage">1849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Benyo%2C+Z.%3B+Gille%2C+A.%3B+Bennett%2C+C.+L.%3B+Clausen%2C+B.+E.%3B+Offermanns%2C+S.Mol.+Pharmacol.+2006%2C+70%2C+1844%E2%80%931849"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenyo%26aufirst%3DZ.%26aulast%3DGille%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DC.%2BL.%26aulast%3DClausen%26aufirst%3DB.%2BE.%26aulast%3DOffermanns%26aufirst%3DS.%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D1844%26epage%3D1849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hanson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gille, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwykiel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukasova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunaru, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offermanns, S.</span><span> </span><span class="NLM_article-title">Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2910</span><span class="NLM_x">–</span> <span class="NLM_lpage">2919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1172%2FJCI42273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=20664170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaiur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=2910-2919&author=J.+Hansonauthor=A.+Gilleauthor=S.+Zwykielauthor=M.+Lukasovaauthor=B.+E.+Clausenauthor=K.+Ahmedauthor=S+Tunaruauthor=A.+Wirthauthor=S.+Offermanns&title=Nicotinic+acid-+and+monomethyl+fumarate-induced+flushing+involves+GPR109A+expressed+by+keratinocytes+and+COX-2-dependent+prostanoid+formation+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice</span></div><div class="casAuthors">Hanson, Julien; Gille, Andreas; Zwykiel, Sabrina; Lukasova, Martina; Clausen, Bjoern E.; Ahmed, Kashan; Tunaru, Sorin; Wirth, Angela; Offermanns, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2910-2919</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">The antidyslipidemic drug nicotinic acid and the antipsoriatic drug monomethyl fumarate induce cutaneous flushing through activation of G protein-coupled receptor 109A (GPR109A).  Flushing is a troublesome side effect of nicotinic acid, but may be a direct reflection of the wanted effects of monomethyl fumarate.  Here we analyzed the mechanisms underlying GPR109A-mediated flushing and show that both Langerhans cells and keratinocytes express GPR109A in mice.  Using cell ablation approaches and transgenic cell type-specific GPR109A expression in Gpr109a-/- mice, we have provided evidence that the early phase of flushing depends on GPR109A expressed on Langerhans cells, whereas the late phase is mediated by GPR109A expressed on keratinocytes.  Interestingly, the first phase of flushing was blocked by a selective cyclooxygenase-1 (COX-1) inhibitor, and the late phase was sensitive to a selective COX-2 inhibitor.  Both monomethyl fumarate and nicotinic acid induced PGE2 formation in isolated keratinocytes through activation of GPR109A and COX-2.  Thus, the early and late phases of the GPR109A-mediated cutaneous flushing reaction involve different epidermal cell types and prostanoid-forming enzymes.  These data will help to guide new efficient approaches to mitigate nicotinic acid-induced flushing and may help to exploit the potential antipsoriatic effects of GPR109A agonists in the skin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Q1MnzAkJp7Vg90H21EOLACvtfcHk0lh9Sz4d87cBCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaiur%252FK&md5=8df71b503797827226a21884771e568d</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1172%2FJCI42273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI42273%26sid%3Dliteratum%253Aachs%26aulast%3DHanson%26aufirst%3DJ.%26aulast%3DGille%26aufirst%3DA.%26aulast%3DZwykiel%26aufirst%3DS.%26aulast%3DLukasova%26aufirst%3DM.%26aulast%3DClausen%26aufirst%3DB.%2BE.%26aulast%3DAhmed%26aufirst%3DK.%26aulast%3DTunaru%26aufirst%3DS%26aulast%3DWirth%26aufirst%3DA.%26aulast%3DOffermanns%26aufirst%3DS.%26atitle%3DNicotinic%2520acid-%2520and%2520monomethyl%2520fumarate-induced%2520flushing%2520involves%2520GPR109A%2520expressed%2520by%2520keratinocytes%2520and%2520COX-2-dependent%2520prostanoid%2520formation%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D2910%26epage%3D2919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Paolini, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchel, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kher, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norquist, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meehan, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bays, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantyne, C. M.</span><span> </span><span class="NLM_article-title">Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">625</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2008&pages=625-630&author=J.+F.+Paoliniauthor=Y.+B.+Mitchelauthor=R.+Reyesauthor=U.+Kherauthor=E.+Laiauthor=D.+J.+Watsonauthor=J.+M.+Norquistauthor=A.+G.+Meehanauthor=H.+E.+Baysauthor=M.+Davidsonauthor=C.+M.+Ballantyne&title=Effects+of+Laropiprant+on+Nicotinic+Acid-Induced+Flushing+in+Patients+With+Dyslipidemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DJ.%2BF.%26aulast%3DMitchel%26aufirst%3DY.%2BB.%26aulast%3DReyes%26aufirst%3DR.%26aulast%3DKher%26aufirst%3DU.%26aulast%3DLai%26aufirst%3DE.%26aulast%3DWatson%26aufirst%3DD.%2BJ.%26aulast%3DNorquist%26aufirst%3DJ.%2BM.%26aulast%3DMeehan%26aufirst%3DA.%2BG.%26aulast%3DBays%26aufirst%3DH.%2BE.%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DBallantyne%26aufirst%3DC.%2BM.%26atitle%3DEffects%2520of%2520Laropiprant%2520on%2520Nicotinic%2520Acid-Induced%2520Flushing%2520in%2520Patients%2520With%2520Dyslipidemia%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2008%26volume%3D101%26spage%3D625%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanemitsu-Parks, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidarov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerra, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cham, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornelas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span> </span><span class="NLM_article-title">Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">18028</span><span class="NLM_x">–</span> <span class="NLM_lpage">18036</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=18028-18036&author=J.+G.+Richmanauthor=M.+Kanemitsu-Parksauthor=I.+Gaidarovauthor=J.+S.+Cameronauthor=P.+Griffinauthor=H.+Zhengauthor=N.+C.+Guerraauthor=L.+Chamauthor=D.+P.+Behanauthor=P.+D.+Boatmanauthor=R.+Chenauthor=P.+J.+Skinnerauthor=P.+Ornelasauthor=G.+Sempleauthor=D.+T.+Connolly&title=Nicotinic+Acid+Receptor+Agonists+Differentially+Activate+Downstream+Effectors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DKanemitsu-Parks%26aufirst%3DM.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DCameron%26aufirst%3DJ.%2BS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DGuerra%26aufirst%3DN.%2BC.%26aulast%3DCham%26aufirst%3DL.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DOrnelas%26aufirst%3DP.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26atitle%3DNicotinic%2520Acid%2520Receptor%2520Agonists%2520Differentially%2520Activate%2520Downstream%2520Effectors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D18028%26epage%3D18036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharbaoui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carballo-Jane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span> </span><span class="NLM_article-title">3-(1<i>H</i>-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5101</span><span class="NLM_x">–</span> <span class="NLM_lpage">5108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800258p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5101-5108&author=G.+Sempleauthor=P.+J.+Skinnerauthor=T.+Gharbaouiauthor=Y.-J.+Shinauthor=J.-K.+Jungauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=S.+Y.+Tamuraauthor=P.+D.+Boatmanauthor=C.+R.+Sageauthor=T.+O.+Schraderauthor=R.+Chenauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=M.+G.+Watersauthor=K.+Chengauthor=A.+K.+Taggartauthor=T.-Q.+Caiauthor=E.+Carballo-Janeauthor=D.+P.+Behanauthor=D.+T.+Connollyauthor=J.+G.+Richman&title=3-%281H-Tetrazol-5-yl%29-1%2C4%2C5%2C6-tetrahydro-cyclopentapyrazole+%28MK-0354%29%3A+A+Partial+Agonist+of+the+Nicotinic+Acid+Receptor%2C+G-Protein+Coupled+Receptor+109a%2C+with+Antilipolytic+but+No+Vasodilatory+Activity+in+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm800258p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800258p%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DShin%26aufirst%3DY.-J.%26aulast%3DJung%26aufirst%3DJ.-K.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%2BY.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3D3-%25281H-Tetrazol-5-yl%2529-1%252C4%252C5%252C6-tetrahydro-cyclopentapyrazole%2520%2528MK-0354%2529%253A%2520A%2520Partial%2520Agonist%2520of%2520the%2520Nicotinic%2520Acid%2520Receptor%252C%2520G-Protein%2520Coupled%2520Receptor%2520109a%252C%2520with%2520Antilipolytic%2520but%2520No%2520Vasodilatory%2520Activity%2520in%2520Mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5101%26epage%3D5108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Lai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radziszewski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perevozskaya, I</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenning, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson-Levonas, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchel, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, J. F.</span><span> </span><span class="NLM_article-title">Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans</span> <span class="citation_source-journal">J. Clin. Lipidol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1016%2Fj.jacl.2008.08.445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=21291763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A280%3ADC%252BC3M7mslamug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=375-383&author=E.+Laiauthor=M.+G.+Watersauthor=J.+R.+Tataauthor=W.+Radziszewskiauthor=I+Perevozskayaauthor=W.+Zhengauthor=L.+Wenningauthor=D.+T.+Connollyauthor=G.+Sempleauthor=A.+O.+Johnson-Levonasauthor=J.+A.+Wagnerauthor=Y.+Mitchelauthor=J.+F.+Paolini&title=Effects+of+a+niacin+receptor+partial+agonist%2C+MK-0354%2C+on+plasma+free+fatty+acids%2C+lipids%2C+and+cutaneous+flushing+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans</span></div><div class="casAuthors">Lai Eseng; Waters M Gerard; Tata James R; Radziszewski Waldemar; Perevozskaya Inna; Zheng Wei; Wenning Larissa; Connolly Daniel T; Semple Graeme; Johnson-Levonas Amy O; Wagner John A; Mitchel Yale; Paolini John F</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical lipidology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">375-83</span>
        ISSN:<span class="NLM_cas:issn">1933-2874</span>.
    </div><div class="casAbstract">BACKGROUND:  Development of niacin-like agents that favorably affect lipids with an improved flushing profile would be beneficial.  OBJECTIVE:  To evaluate a niacin receptor partial agonist, MK-0354, in Phase I and II studies.  METHODS:  The pharmacokinetic/pharmacodynamic effects of single and multiple doses (7 days) of MK-0354 (300-4000 mg) were evaluated in two Phase I studies conducted in healthy men.  A Phase II study assessed the effects of MK-0354 2.5 g once daily on lipids during 4 weeks in 66 dyslipidemic patients.  RESULTS:  MK-0354 single doses up to 4000 mg and multiple doses (7 days) up to 3600 mg produced robust dose-related reductions in free fatty acid (FFA) over 5 hours.  Single doses of MK-0354 300 mg and extended release-niacin (Niaspan) 1 g produced comparable reductions in FFA.  Suppression of FFA following 7 daily doses of MK-0354 was similar to that after a single dose.  In the Phase II study, MK-0354 2.5 g produced little flushing but no clinically meaningful effects on lipids (placebo-adjusted percent change: high-density lipoprotein cholesterol, 0.4%, 95% confidence interval -5.2 to 6.0; low-density lipoprotein cholesterol, -9.8%, 95% confidence interval -16.8 to -2.7; triglyceride, -5.8%, 95% confidence interval -22.6 to 11.9).  CONCLUSION:  Treatment with MK-0354 for 7 days resulted in plasma FFA suppression with minimal cutaneous flushing.  However, 4 weeks of treatment with MK-0354 failed to produce changes in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or triglycerides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrxOcLiWbvsF1C8OJBvdfbfW6udTcc2eb-m_Sxo93O-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7mslamug%253D%253D&md5=92e3f9f50bc99e38c0eba0fe5d823294</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jacl.2008.08.445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacl.2008.08.445%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DE.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DRadziszewski%26aufirst%3DW.%26aulast%3DPerevozskaya%26aufirst%3DI%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DWenning%26aufirst%3DL.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DJohnson-Levonas%26aufirst%3DA.%2BO.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26aulast%3DMitchel%26aufirst%3DY.%26aulast%3DPaolini%26aufirst%3DJ.%2BF.%26atitle%3DEffects%2520of%2520a%2520niacin%2520receptor%2520partial%2520agonist%252C%2520MK-0354%252C%2520on%2520plasma%2520free%2520fatty%2520acids%252C%2520lipids%252C%2520and%2520cutaneous%2520flushing%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Lipidol.%26date%3D2008%26volume%3D2%26spage%3D375%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span> </span><span class="NLM_article-title">Potent Tricyclic Pyrazole Tetrazole Agonists of the Nicotinic Acid Receptor (GPR109a)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2797</span><span class="NLM_x">–</span> <span class="NLM_lpage">2800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2797-2800&author=P.+D.+Boatmanauthor=T.+O.+Schraderauthor=M.+Kasemauthor=B.+R.+Johnsonauthor=P.+J.+Skinnerauthor=J.-K.+Jungauthor=J.+Xuauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=G.+Sempleauthor=C.+R.+Sageauthor=J.+Knudsenauthor=R.+Chenauthor=J.+G.+Richman&title=Potent+Tricyclic+Pyrazole+Tetrazole+Agonists+of+the+Nicotinic+Acid+Receptor+%28GPR109a%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BR.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DJung%26aufirst%3DJ.-K.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DKnudsen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3DPotent%2520Tricyclic%2520Pyrazole%2520Tetrazole%2520Agonists%2520of%2520the%2520Nicotinic%2520Acid%2520Receptor%2520%2528GPR109a%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2797%26epage%3D2800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Taber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartnett, J. C.</span><span> </span><span class="NLM_article-title">Synthesis of the Eight Enantiomerically Pure Diastereomers of the 12-F2-Isoprostanes</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">13121</span><span class="NLM_x">–</span> <span class="NLM_lpage">13126</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja020816v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=13121-13126&author=D.+F.+Taberauthor=M.+Xuauthor=J.+C.+Hartnett&title=Synthesis+of+the+Eight+Enantiomerically+Pure+Diastereomers+of+the+12-F2-Isoprostanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fja020816v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja020816v%26sid%3Dliteratum%253Aachs%26aulast%3DTaber%26aufirst%3DD.%2BF.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DHartnett%26aufirst%3DJ.%2BC.%26atitle%3DSynthesis%2520of%2520the%2520Eight%2520Enantiomerically%2520Pure%2520Diastereomers%2520of%2520the%252012-F2-Isoprostanes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D13121%26epage%3D13126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hodgson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuzzo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freixas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulikiewicz, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleator, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paris, J.-M.</span><span> </span><span class="NLM_article-title">Intramolecular Cyclopropanation of Unsaturated Terminal Epoxides and Chlorohydrins</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">4456</span><span class="NLM_x">–</span> <span class="NLM_lpage">4462</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja0672932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtF2nsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=4456-4462&author=D.+M.+Hodgsonauthor=Y.+K.+Chungauthor=I.+Nuzzoauthor=G.+Freixasauthor=K.+K.+Kulikiewiczauthor=E.+Cleatorauthor=J.-M.+Paris&title=Intramolecular+Cyclopropanation+of+Unsaturated+Terminal+Epoxides+and+Chlorohydrins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Intramolecular Cyclopropanation of Unsaturated Terminal Epoxides and Chlorohydrins</span></div><div class="casAuthors">Hodgson, David M.; Chung, Ying Kit; Nuzzo, Irene; Freixas, Gloria; Kulikiewicz, Krystyna K.; Cleator, Ed; Paris, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4456-4462</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lithium 2,2,6,6-tetramethylpiperidide (LTMP)-induced intramol. cyclopropanation of unsatd. terminal epoxides, e.g. I, provides an efficient and completely stereoselective entry to bicyclo[3.1.0]hexan-2-ols, e.g. II, and bicyclo[4.1.0]heptan-2-ols.  Further elaboration of C-5 and C-6 stannyl-substituted bicyclo[3.1.0]hexan-2-ols via Sn-Li exchange/electrophile trapping or Stille coupling generates a range of substituted bicyclic cyclopropanes.  An alternative straightforward cyclopropanation protocol using a catalytic amt. of 2,2,6,6-tetramethylpiperidine (TMP) allows for a convenient (1 g-7.5 kg) synthesis of bicyclo[3.1.0]hexan-2-ol and other bicyclic adducts.  The synthetic utility of this chem. has been demonstrated in a concise asym. synthesis of (+)-β-cuparenone (III).  The related unsatd. chlorohydrins also undergo intramol. cyclopropanation via in situ epoxide formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMk8oGYnbbCrVg90H21EOLACvtfcHk0liH8yus5ib4nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtF2nsL4%253D&md5=fe699d08dd4e9e4b59f3bae28d2668e8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fja0672932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0672932%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DD.%2BM.%26aulast%3DChung%26aufirst%3DY.%2BK.%26aulast%3DNuzzo%26aufirst%3DI.%26aulast%3DFreixas%26aufirst%3DG.%26aulast%3DKulikiewicz%26aufirst%3DK.%2BK.%26aulast%3DCleator%26aufirst%3DE.%26aulast%3DParis%26aufirst%3DJ.-M.%26atitle%3DIntramolecular%2520Cyclopropanation%2520of%2520Unsaturated%2520Terminal%2520Epoxides%2520and%2520Chlorohydrins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2007%26volume%3D129%26spage%3D4456%26epage%3D4462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Nolwenn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">List, B.</span><span> </span><span class="NLM_article-title">Highly Enantioselective Transfer Hydrogenation of α,β-Unsaturated Ketones</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">13368</span><span class="NLM_x">–</span> <span class="NLM_lpage">13369</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=13368-13369&author=J.+A.+Nolwennauthor=B.+List&title=Highly+Enantioselective+Transfer+Hydrogenation+of+%CE%B1%2C%CE%B2-Unsaturated+Ketones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNolwenn%26aufirst%3DJ.%2BA.%26aulast%3DList%26aufirst%3DB.%26atitle%3DHighly%2520Enantioselective%2520Transfer%2520Hydrogenation%2520of%2520%25CE%25B1%252C%25CE%25B2-Unsaturated%2520Ketones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D13368%26epage%3D13369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="note"><p class="first last">Optically pure R-29 was prepared by DIBAL-H reduction of the optically pure lactone (<i>R</i>)-5-(chloromethyl)dihydrofuran-2(3<i>H</i>)-one. For the analogous reduction to prepare S-29 from (<i>S</i>)-5-(chloromethyl)dihydrofuran-2(3<i>H</i>)-one, see:</p></div><div class="NLM_citation" id="cit18a"><span><span class="NLM_contrib-group">Lewis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayless, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libertine, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wels, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wypij, D. M.</span><span> </span><span class="NLM_article-title">5-Lipoxygenase inhibitors with histamine H1 receptor antagonist activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2265</span><span class="NLM_x">–</span> <span class="NLM_lpage">2268</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2265-2268&author=T.+A.+Lewisauthor=L.+Baylessauthor=J.+B.+Eckmanauthor=J.+L.+Ellisauthor=G.+Grewalauthor=L.+Libertineauthor=J.+M.+Nicolasauthor=R.+T.+Scannellauthor=B.+F.+Welsauthor=K.+Wenbergauthor=D.+M.+Wypij&title=5-Lipoxygenase+inhibitors+with+histamine+H1+receptor+antagonist+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DT.%2BA.%26aulast%3DBayless%26aufirst%3DL.%26aulast%3DEckman%26aufirst%3DJ.%2BB.%26aulast%3DEllis%26aufirst%3DJ.%2BL.%26aulast%3DGrewal%26aufirst%3DG.%26aulast%3DLibertine%26aufirst%3DL.%26aulast%3DNicolas%26aufirst%3DJ.%2BM.%26aulast%3DScannell%26aufirst%3DR.%2BT.%26aulast%3DWels%26aufirst%3DB.%2BF.%26aulast%3DWenberg%26aufirst%3DK.%26aulast%3DWypij%26aufirst%3DD.%2BM.%26atitle%3D5-Lipoxygenase%2520inhibitors%2520with%2520histamine%2520H1%2520receptor%2520antagonist%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2265%26epage%3D2268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For the synthesis of (<i>S</i>)-5-(chloromethyl)dihydrofuran-2(3<i>H</i>)-one from (<i>S</i>)-(+)-epichlorohydrin, see:</p></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_contrib-group">Movassaghi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. N.</span><span> </span><span class="NLM_article-title">A Direct Method for the Conversion of Terminal Epoxides into γ-Butanolides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">2456</span><span class="NLM_x">–</span> <span class="NLM_lpage">2457</span><div class="note"><p class="first last">(<i>R</i>)-5-(Chloromethyl)dihydrofuran-2(3<i>H</i>)-one was prepared from (<i>R</i>)-(−)-epichlorohydrin in similar fashion</p></div></span><div class="citationLinks">[<a href="/doi/10.1021/ja025604c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=2456-2457&author=M.+Movassaghiauthor=E.+N.+Jacobsen&title=A+Direct+Method+for+the+Conversion+of+Terminal+Epoxides+into+%CE%B3-Butanolides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fja025604c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja025604c%26sid%3Dliteratum%253Aachs%26aulast%3DMovassaghi%26aufirst%3DM.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DA%2520Direct%2520Method%2520for%2520the%2520Conversion%2520of%2520Terminal%2520Epoxides%2520into%2520%25CE%25B3-Butanolides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D2456%26epage%3D2457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Tokunaga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. N.</span><span> </span><span class="NLM_article-title">Asymmetric catalysis with water: efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">936</span><span class="NLM_x">–</span> <span class="NLM_lpage">938</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1126%2Fscience.277.5328.936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=9252321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADyaK2sXltlCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=936-938&author=M.+Tokunagaauthor=J.+F.+Larrowauthor=F.+Kakiuchiauthor=E.+N.+Jacobsen&title=Asymmetric+catalysis+with+water%3A+efficient+kinetic+resolution+of+terminal+epoxides+by+means+of+catalytic+hydrolysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric catalysis with water: efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis</span></div><div class="casAuthors">Tokunaga, Makoto; Larrow, Jay F.; Kakiuchi, Fumitoshi; Jacobsen, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5328</span>),
    <span class="NLM_cas:pages">936-938</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 16 refs.  Epoxides are versatile building blocks for org. synthesis.  However, terminal epoxides are arguably the most important subclass of these compds., and no general and practical method existss for their prodn. in enantiomerically pure form.  Terminal epoxides are available very inexpensively as racemic mixts., and kinetic resoln. is an attractive strategy for the prodn. of optically active epoxides, given an economical and operationally simple method.  Readily accessible synthetic catalysts (chiral cobalt-based salen complexes) have been used for the efficient asym. hydrolysis of terminal epoxides.  This process uses water as the only reagent, no added solvent, and low loadings of a recyclable catalyst (<0.5 mol percent), and it affords highly valuable terminal epoxides and 1,2-diols in high yield with high enantiomeric enrichment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDq5Z45iFaUbVg90H21EOLACvtfcHk0lh6lmrCN8Pcfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltlCrt70%253D&md5=ad79e0bf023e87fc21c77e858bacc83b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5328.936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5328.936%26sid%3Dliteratum%253Aachs%26aulast%3DTokunaga%26aufirst%3DM.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DKakiuchi%26aufirst%3DF.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DAsymmetric%2520catalysis%2520with%2520water%253A%2520efficient%2520kinetic%2520resolution%2520of%2520terminal%2520epoxides%2520by%2520means%2520of%2520catalytic%2520hydrolysis%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D936%26epage%3D938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharbaoui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carballo-Jane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span> </span><span class="NLM_article-title">3-(1<i>H</i>-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5101</span><span class="NLM_x">–</span> <span class="NLM_lpage">5108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800258p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5101-5108&author=G.+Sempleauthor=P.+J.+Skinnerauthor=T.+Gharbaouiauthor=Y.-J.+Shinauthor=J.-K.+Jungauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=S.+Y.+Tamuraauthor=P.+D.+Boatmanauthor=C.+R.+Sageauthor=T.+O.+Schraderauthor=R.+Chenauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=M.+G.+Watersauthor=K.+Chengauthor=A.+K.+Taggartauthor=T.-Q.+Caiauthor=E.+Carballo-Janeauthor=D.+P.+Behanauthor=D.+T.+Connollyauthor=J.+G.+Richman&title=3-%281H-Tetrazol-5-yl%29-1%2C4%2C5%2C6-tetrahydro-cyclopentapyrazole+%28MK-0354%29%3A+A+Partial+Agonist+of+the+Nicotinic+Acid+Receptor%2C+G-Protein+Coupled+Receptor+109a%2C+with+Antilipolytic+but+No+Vasodilatory+Activity+in+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm800258p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800258p%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DShin%26aufirst%3DY.-J.%26aulast%3DJung%26aufirst%3DJ.-K.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%2BY.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3D3-%25281H-Tetrazol-5-yl%2529-1%252C4%252C5%252C6-tetrahydro-cyclopentapyrazole%2520%2528MK-0354%2529%253A%2520A%2520Partial%2520Agonist%2520of%2520the%2520Nicotinic%2520Acid%2520Receptor%252C%2520G-Protein%2520Coupled%2520Receptor%2520109a%252C%2520with%2520Antilipolytic%2520but%2520No%2520Vasodilatory%2520Activity%2520in%2520Mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5101%26epage%3D5108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Imbriglio, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smenton, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, A. K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carballo-Jane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span> </span><span class="NLM_article-title">GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2121</span><span class="NLM_x">–</span> <span class="NLM_lpage">2124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2121-2124&author=J.+E.+Imbriglioauthor=S.+Changauthor=R.+Liangauthor=S.+Raghavanauthor=D.+Schmidtauthor=A+Smentonauthor=S.+Triaauthor=T.+O.+Schraderauthor=J.-K.+Jungauthor=C.+Esserauthor=A.+K.+P.+Taggartauthor=K.+Chengauthor=E.+Carballo-Janeauthor=M.+G.+Watersauthor=J.+R.+Tataauthor=S.+L.+Colletti&title=GPR109a+agonists.+Part+1%3A+5-Alkyl+and+5-aryl-pyrazole-tetrazoles+as+agonists+of+the+human+orphan+G-protein+coupled+receptor+GPR109a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImbriglio%26aufirst%3DJ.%2BE.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DR.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DD.%26aulast%3DSmenton%26aufirst%3DA%26aulast%3DTria%26aufirst%3DS.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DJung%26aufirst%3DJ.-K.%26aulast%3DEsser%26aufirst%3DC.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%2BP.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26atitle%3DGPR109a%2520agonists.%2520Part%25201%253A%25205-Alkyl%2520and%25205-aryl-pyrazole-tetrazoles%2520as%2520agonists%2520of%2520the%2520human%2520orphan%2520G-protein%2520coupled%2520receptor%2520GPR109a%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2121%26epage%3D2124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Carballo-Jane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerckens, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlapiano, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, A. K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span> </span><span class="NLM_article-title">Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1016%2Fj.vascn.2007.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=17643322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGkt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=308-316&author=E.+Carballo-Janeauthor=L.+S.+Gerckensauthor=S.+Luellauthor=A.+S.+Parlapianoauthor=M.+Wolffauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=A.+K.+P.+Taggartauthor=M.+G.+Watersauthor=J.+G.+Richmanauthor=M.+E.+McCannauthor=M.+J.+Forrest&title=Comparison+of+rat+and+dog+models+of+vasodilatation+and+lipolysis+for+the+calculation+of+a+therapeutic+index+for+GPR109A+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists</span></div><div class="casAuthors">Carballo-Jane, Ester; Gerckens, Lynn S.; Luell, Silvi; Parlapiano, Allison S.; Wolff, Michael; Colletti, Steven L.; Tata, James R.; Taggart, Andrew K. P.; Waters, M. Gerard; Richman, Jeremy G.; McCann, Margaret E.; Forrest, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">308-316</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: GPR109A is the receptor mediating both the antilipolytic and vasodilatory effects of nicotinic acid.  In order to develop agonists for GPR109A with improved therapeutic indexes we have sought to optimize animal models that evaluate both nicotinic acid-mediated inhibition of lipolysis and stimulation of vasodilatation.  The rat and the dog have previously been used to study the antilipolytic effects of nicotinic acid, but no optimal vasodilatation model exits in either species.  Methods: We have developed a vasodilatation model in the rat that measures changes in ear perfusion using laser Doppler flowmetry.  In the dog, we have developed a model of vasodilatation measuring changes in red color values in the ear, using a spectrocolorimeter.  Effects of GPR109A agonists on lipolysis were measured in both species after oral dosing of compds., and measuring plasma levels of free fatty acids.  Results: In both rat and dog, GPR109A agonists induce dose- and time-dependent vasodilatation, similar to that obsd. in humans.  Vasodilatation is inhibited in both species with cyclooxygenase inhibitors or a specific DP1 receptor antagonist, indicating that, as in man, nicotinic acid-induced vasodilatation in rats and dogs is mainly mediated by the release of PGD2.  Discussion: Our results show that both rat and dog are useful models for the characterization of GPR109A agonists.  A therapeutic index for GPR109A agonists can be calcd. in either species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaJsGTtqvjVbVg90H21EOLACvtfcHk0lhGqTOQ1mStDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGkt7zL&md5=a41bfc87540867cdddb43cf32d0413cd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2007.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2007.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DGerckens%26aufirst%3DL.%2BS.%26aulast%3DLuell%26aufirst%3DS.%26aulast%3DParlapiano%26aufirst%3DA.%2BS.%26aulast%3DWolff%26aufirst%3DM.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%2BP.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DMcCann%26aufirst%3DM.%2BE.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26atitle%3DComparison%2520of%2520rat%2520and%2520dog%2520models%2520of%2520vasodilatation%2520and%2520lipolysis%2520for%2520the%2520calculation%2520of%2520a%2520therapeutic%2520index%2520for%2520GPR109A%2520agonists%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2007%26volume%3D56%26spage%3D308%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Boatman, P. D.; Schrader, T. O.; Semple, G; Skinner, P; J.; Jung, J.-K.</span><span> </span><span class="NLM_article-title">Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof</span>. U.S. Patent US 7241792, <span class="NLM_month">July</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+D.+Boatman&author=T.+O.+Schrader&author=G+Semple&author=P%3B+J.+Skinner&author=J.-K.+Jung&title=Fused+pyrazole+derivatives+and+methods+of+treatment+of+metabolic-related+disorders+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26atitle%3DFused%2520pyrazole%2520derivatives%2520and%2520methods%2520of%2520treatment%2520of%2520metabolic-related%2520disorders%2520thereof%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Robbins, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaine, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christman, B. W.</span><span> </span><span class="NLM_article-title">Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">1639</span><span class="NLM_x">–</span> <span class="NLM_lpage">1644</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2001&pages=1639-1644&author=I.+M.+Robbinsauthor=R.+J.+Barstauthor=L.+J.+Rubinauthor=S.+P.+Gaineauthor=P.+V.+Priceauthor=J.+D.+Morrowauthor=B.+W.+Christman&title=Increased+levels+of+prostaglandin+D%282%29+suggest+macrophage+activation+in+patients+with+primary+pulmonary+hypertension"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DGaine%26aufirst%3DS.%2BP.%26aulast%3DPrice%26aufirst%3DP.%2BV.%26aulast%3DMorrow%26aufirst%3DJ.%2BD.%26aulast%3DChristman%26aufirst%3DB.%2BW.%26atitle%3DIncreased%2520levels%2520of%2520prostaglandin%2520D%25282%2529%2520suggest%2520macrophage%2520activation%2520in%2520patients%2520with%2520primary%2520pulmonary%2520hypertension%26jtitle%3DChest%26date%3D2001%26volume%3D120%26spage%3D1639%26epage%3D1644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Awad, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. J.,  II.</span><span> </span><span class="NLM_article-title">Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation</span> <span class="citation_source-journal">J. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1016%2F0091-6749%2894%2990371-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=8182221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADyaK2MXptlyrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1994&pages=817-824&issue=5&author=J.+A.+Awadauthor=J.+D.+Morrowauthor=L.+J.+Roberts&title=Detection+of+the+major+urinary+metabolite+of+prostaglandin+D2+in+the+circulation%3A+demonstration+of+elevated+levels+in+patients+with+disorders+of+systemic+mast+cell+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of the major urinary metabolite of prostaglandin D2 in the circulation: Demonstration of elevated levels in patients with disorders of systemic mast cell activation</span></div><div class="casAuthors">Awad, Joseph A.; Morrow, Jason D.; Roberts, L. Jackson, II</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">817-24</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Mosby-Year Book</span>)
        </div><div class="casAbstract">The symptoms and hemodynamic alterations that accompany episodes of systemic mast cell activation have been largely attributed to excessive prostaglandin(PG)D2 release.  Quantification of the major urinary metabolite of PGD2 has been invaluable in elucidating a role for PGD2 in these clin. entities and in the biochem. evaluation of systemic mastocytosis.  With the use of a modified mass spectrometric assay for the major urinary metabolite of PGD2, this metabolite was detected in plasma from 10 normal volunteers (3.5 ± 1.4 pg/mL).  Ingestion of niacin, which induces endogenous release of PGD2, increased plasma levels of this metabolite 6.3 to 33 times above the upper limit of normal by 2 h.  Thereafter, levels declined gradually but remained elevated for up to 6 to 8 h.  In contrast, circulating levels of 9α, 11β-PGF2, the initial metabolite of PGD2, peaked by 30 min and returned to baseline by 2 h.  The clin. utility of measuring the major urinary metabolite in the circulation was demonstrated by detection of markedly increased levels in plasma and serum from patients with systemic mastocytosis and a patient with a severe type I allergic reaction.  Thus in the biochem. evaluation of episodes of systemic mast cell activation and endeavors to further elucidate the role of PGD2 in human disease, there are kinetic advantages of measuring the major urinary metabolite of PGD2 in the circulation.  One particular advantage is the evaluation of clin. events, which only in retrospect are suspected to be assocd. with excessive release of PGD2, yet plasma or serum was obtained proximate to the event.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRikMSssGV_LVg90H21EOLACvtfcHk0lgFUOcM3HQFyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptlyrur8%253D&md5=2783930937744605f39bb438d27ab07a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2F0091-6749%2894%2990371-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-6749%252894%252990371-9%26sid%3Dliteratum%253Aachs%26aulast%3DAwad%26aufirst%3DJ.%2BA.%26aulast%3DMorrow%26aufirst%3DJ.%2BD.%26aulast%3DRoberts%26aufirst%3DL.%2BJ.%26atitle%3DDetection%2520of%2520the%2520major%2520urinary%2520metabolite%2520of%2520prostaglandin%2520D2%2520in%2520the%2520circulation%253A%2520demonstration%2520of%2520elevated%2520levels%2520in%2520patients%2520with%2520disorders%2520of%2520systemic%2520mast%2520cell%2520activation%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D1994%26volume%3D93%26issue%3D5%26spage%3D817%26epage%3D824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Lauring, B.; Taggart, A.; Tata, J.; Dunbar, R.; Caro, L.; Cheng, K.; Chin, J.; Colletti, S.; Cote, J.; Kalilieh, S.; Liu, J.; Luo, W.-L.; MacLean, A.; Paolini, J.; Peterson, L.; Sirah, W.; Waters, M. G.; Wu, T.-J.; Xuan, F.; Boatman, P. D.; Semple, G.; Behan, D.; Connelly, D.; Lai, E.; Wagner, J.; Wright, S.; Cuffie, C.; Mitchel, Y.; Rader, D.; Plump, A.</span><div class="note"><p class="first last">Unpublished results</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lauring%2C+B.%3B+Taggart%2C+A.%3B+Tata%2C+J.%3B+Dunbar%2C+R.%3B+Caro%2C+L.%3B+Cheng%2C+K.%3B+Chin%2C+J.%3B+Colletti%2C+S.%3B+Cote%2C+J.%3B+Kalilieh%2C+S.%3B+Liu%2C+J.%3B+Luo%2C+W.-L.%3B+MacLean%2C+A.%3B+Paolini%2C+J.%3B+Peterson%2C+L.%3B+Sirah%2C+W.%3B+Waters%2C+M.+G.%3B+Wu%2C+T.-J.%3B+Xuan%2C+F.%3B+Boatman%2C+P.+D.%3B+Semple%2C+G.%3B+Behan%2C+D.%3B+Connelly%2C+D.%3B+Lai%2C+E.%3B+Wagner%2C+J.%3B+Wright%2C+S.%3B+Cuffie%2C+C.%3B+Mitchel%2C+Y.%3B+Rader%2C+D.%3B+Plump%2C+A.Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLauring%26aufirst%3DB." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><div class="note"><p class="first last">Enantiopurity (% ee) was determined at the subsequent intramolecular cyclopropanation step. Alcohol 1<i>R</i>,2<i>R</i>,5<i>S</i>-<b>9c</b> was converted to the corresponding Mosher ester derivative (employing (<i>R</i>)-(−)-Mosher acid chloride) and comparing <sup>1</sup>H NMR spectral data with that of the Mosher ester derivative of the racemic alcohol obtained by intramolecular cyclopropanation of (±)-2-(but-3-enyl)oxirane. See:</p></div><span class="NLM_contrib-group">Mosher, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dale, J. A.</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Enantiopurity+%28%25+ee%29+was+determined+at+the+subsequent+intramolecular+cyclopropanation+step.+Alcohol+1R%2C2R%2C5S-9c+was+converted+to+the+corresponding+Mosher+ester+derivative+%28employing+%28R%29-%28%E2%88%92%29-Mosher+acid+chloride%29+and+comparing+1H+NMR+spectral+data+with+that+of+the+Mosher+ester+derivative+of+the+racemic+alcohol+obtained+by+intramolecular+cyclopropanation+of+%28%C2%B1%29-2-%28but-3-enyl%29oxirane.+See%3AMosher%2C+H.+S.%3B+Dale%2C+J.+A.J.+Am.+Chem.+Soc.+1973%2C+95%2C+512%E2%80%93519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMosher%26aufirst%3DH.%2BS.%26aulast%3DDale%26aufirst%3DJ.%2BA.%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1973%26volume%3D95%26spage%3D512%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Liang Tan, Wenzhong Yan, John D. McCorvy, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 9841-9878. <a href="https://doi.org/10.1021/acs.jmedchem.8b00435" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00435%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBiased%252BLigands%252Bof%252BG%252BProtein-Coupled%252BReceptors%252B%252528GPCRs%252529%25253A%252BStructure%2525E2%252580%252593Functional%252BSelectivity%252BRelationships%252B%252528SFSRs%252529%252Band%252BTherapeutic%252BPotential%26aulast%3DTan%26aufirst%3DLiang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D10072018%26date%3D25062018%26volume%3D61%26issue%3D22%26spage%3D9841%26epage%3D9878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Graeme  Milligan</span>, <span class="hlFld-ContribAuthor ">Bharat  Shimpukade</span>, <span class="hlFld-ContribAuthor ">Trond  Ulven</span>, and <span class="hlFld-ContribAuthor ">Brian D.  Hudson</span>  . </span><span class="cited-content_cbyCitation_article-title">Complex Pharmacology of Free Fatty Acid Receptors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2017,</strong> <em>117 </em>
                                    (1)
                                     , 67-110. <a href="https://doi.org/10.1021/acs.chemrev.6b00056" title="DOI URL">https://doi.org/10.1021/acs.chemrev.6b00056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.6b00056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.6b00056%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DComplex%252BPharmacology%252Bof%252BFree%252BFatty%252BAcid%252BReceptors%26aulast%3DMilligan%26aufirst%3DGraeme%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D21012016%26date%3D14062016%26date%3D11012017%26volume%3D117%26issue%3D1%26spage%3D67%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amruta  Joshi-Pangu</span>, <span class="hlFld-ContribAuthor ">Ryan D.  Cohen</span>, <span class="hlFld-ContribAuthor ">Matthew T.  Tudge</span>, and <span class="hlFld-ContribAuthor ">Yonggang  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Dearomatization of Electron-Deficient Nitrogen Heterocycles via Cobalt-Catalyzed Asymmetric Cyclopropanation. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (8)
                                     , 3070-3075. <a href="https://doi.org/10.1021/acs.joc.6b00322" title="DOI URL">https://doi.org/10.1021/acs.joc.6b00322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b00322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b00322%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDearomatization%252Bof%252BElectron-Deficient%252BNitrogen%252BHeterocycles%252Bvia%252BCobalt-Catalyzed%252BAsymmetric%252BCyclopropanation%26aulast%3DJoshi-Pangu%26aufirst%3DAmruta%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D12022016%26date%3D06042016%26date%3D15042016%26date%3D29032016%26volume%3D81%26issue%3D8%26spage%3D3070%26epage%3D3075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Craig C.  Correll</span> and <span class="hlFld-ContribAuthor ">Brian A.  McKittrick</span>  . </span><span class="cited-content_cbyCitation_article-title">Biased Ligand Modulation of Seven Transmembrane Receptors (7TMRs): Functional Implications for Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (16)
                                     , 6887-6896. <a href="https://doi.org/10.1021/jm401677g" title="DOI URL">https://doi.org/10.1021/jm401677g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401677g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401677g%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBiased%252BLigand%252BModulation%252Bof%252BSeven%252BTransmembrane%252BReceptors%252B%2525287TMRs%252529%25253A%252BFunctional%252BImplications%252Bfor%252BDrug%252BDiscovery%26aulast%3DCorrell%26aufirst%3DCraig%2BC.%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D29102013%26date%3D29042014%26date%3D28082014%26date%3D03042014%26volume%3D57%26issue%3D16%26spage%3D6887%26epage%3D6896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dehua  Yang</span>, <span class="hlFld-ContribAuthor ">Qingtong  Zhou</span>, <span class="hlFld-ContribAuthor ">Viktorija  Labroska</span>, <span class="hlFld-ContribAuthor ">Shanshan  Qin</span>, <span class="hlFld-ContribAuthor ">Sanaz  Darbalaei</span>, <span class="hlFld-ContribAuthor ">Yiran  Wu</span>, <span class="hlFld-ContribAuthor ">Elita  Yuliantie</span>, <span class="hlFld-ContribAuthor ">Linshan  Xie</span>, <span class="hlFld-ContribAuthor ">Houchao  Tao</span>, <span class="hlFld-ContribAuthor ">Jianjun  Cheng</span>, <span class="hlFld-ContribAuthor ">Qing  Liu</span>, <span class="hlFld-ContribAuthor ">Suwen  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenqing  Shui</span>, <span class="hlFld-ContribAuthor ">Yi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ming-Wei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">G protein-coupled receptors: structure- and function-based drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-020-00435-w" title="DOI URL">https://doi.org/10.1038/s41392-020-00435-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-020-00435-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-020-00435-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DG%252Bprotein-coupled%252Breceptors%25253A%252Bstructure-%252Band%252Bfunction-based%252Bdrug%252Bdiscovery%26aulast%3DYang%26aufirst%3DDehua%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid G.  Menchikov</span>, <span class="hlFld-ContribAuthor ">Evgeny V.  Shulishov</span>, <span class="hlFld-ContribAuthor ">Yury V.  Tomilov</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the catalytic cyclopropanation of unsaturated compounds with diazomethane. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Reviews</span><span> <strong>2021,</strong> <em>90 </em>
                                    (2)
                                     , 199-230. <a href="https://doi.org/10.1070/RCR4982" title="DOI URL">https://doi.org/10.1070/RCR4982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1070/RCR4982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1070%2FRCR4982%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bcatalytic%252Bcyclopropanation%252Bof%252Bunsaturated%252Bcompounds%252Bwith%252Bdiazomethane%26aulast%3DMenchikov%26aufirst%3DLeonid%2BG.%26date%3D2021%26volume%3D90%26issue%3D2%26spage%3D199%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">María D.  Carretta</span>, <span class="hlFld-ContribAuthor ">Yonathan  Barría</span>, <span class="hlFld-ContribAuthor ">Katherine  Borquez</span>, <span class="hlFld-ContribAuthor ">Bárbara  Urra</span>, <span class="hlFld-ContribAuthor ">Andrés  Rivera</span>, <span class="hlFld-ContribAuthor ">Pablo  Alarcón</span>, <span class="hlFld-ContribAuthor ">María A.  Hidalgo</span>, <span class="hlFld-ContribAuthor ">Rafael A.  Burgos</span>. </span><span class="cited-content_cbyCitation_article-title">β-hydroxybutyrate and hydroxycarboxylic acid receptor 2 agonists activate the AKT, ERK and AMPK pathways, which are involved in bovine neutrophil chemotaxis. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-69500-2" title="DOI URL">https://doi.org/10.1038/s41598-020-69500-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-69500-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-69500-2%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3D%2525CE%2525B2-hydroxybutyrate%252Band%252Bhydroxycarboxylic%252Bacid%252Breceptor%252B2%252Bagonists%252Bactivate%252Bthe%252BAKT%25252C%252BERK%252Band%252BAMPK%252Bpathways%25252C%252Bwhich%252Bare%252Binvolved%252Bin%252Bbovine%252Bneutrophil%252Bchemotaxis%26aulast%3DCarretta%26aufirst%3DMar%25C3%25ADa%2BD.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuriko  Miyazawa</span>, <span class="hlFld-ContribAuthor ">Takahiro  Yamaguchi</span>, <span class="hlFld-ContribAuthor ">Mitsuhiro  Yamaguchi</span>, <span class="hlFld-ContribAuthor ">Keiko  Tago</span>, <span class="hlFld-ContribAuthor ">Akihiro  Tamura</span>, <span class="hlFld-ContribAuthor ">Daisuke  Sugiyama</span>, <span class="hlFld-ContribAuthor ">Takahide  Aburatani</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Nishizawa</span>, <span class="hlFld-ContribAuthor ">Nobuya  Kurikawa</span>, <span class="hlFld-ContribAuthor ">Keita  Kono</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyrrole derivatives as potent agonists for the niacin receptor GPR109A. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (10)
                                     , 127105. <a href="https://doi.org/10.1016/j.bmcl.2020.127105" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127105%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyrrole%252Bderivatives%252Bas%252Bpotent%252Bagonists%252Bfor%252Bthe%252Bniacin%252Breceptor%252BGPR109A%26aulast%3DMiyazawa%26aufirst%3DYuriko%26date%3D2020%26volume%3D30%26issue%3D10%26spage%3D127105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bastian  Muriel</span>, <span class="hlFld-ContribAuthor ">Alec  Gagnebin</span>, <span class="hlFld-ContribAuthor ">Jerome  Waser</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of bicyclo[3.1.0]hexanes by (3 + 2) annulation of cyclopropenes with aminocyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (46)
                                     , 10716-10722. <a href="https://doi.org/10.1039/C9SC03790J" title="DOI URL">https://doi.org/10.1039/C9SC03790J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC03790J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC03790J%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DSynthesis%252Bof%252Bbicyclo%25255B3.1.0%25255Dhexanes%252Bby%252B%2525283%252B%25252B%252B2%252529%252Bannulation%252Bof%252Bcyclopropenes%252Bwith%252Baminocyclopropanes%26aulast%3DMuriel%26aufirst%3DBastian%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D46%26spage%3D10716%26epage%3D10722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad  Seyedabadi</span>, <span class="hlFld-ContribAuthor ">Mohammad Hossein  Ghahremani</span>, <span class="hlFld-ContribAuthor ">Paul R.  Albert</span>. </span><span class="cited-content_cbyCitation_article-title">Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2019,</strong> <em>200 </em>, 148-178. <a href="https://doi.org/10.1016/j.pharmthera.2019.05.006" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2019.05.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2019.05.006%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DBiased%252Bsignaling%252Bof%252BG%252Bprotein%252Bcoupled%252Breceptors%252B%252528GPCRs%252529%25253A%252BMolecular%252Bdeterminants%252Bof%252BGPCR%25252Ftransducer%252Bselectivity%252Band%252Btherapeutic%252Bpotential%26aulast%3DSeyedabadi%26aufirst%3DMohammad%26date%3D2019%26volume%3D200%26spage%3D148%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Оleksii Yu.  Voskoboynik</span>, <span class="hlFld-ContribAuthor ">Oleksandra S.  Kolomoets</span>, <span class="hlFld-ContribAuthor ">Oleksii M.  Antypenko</span>, <span class="hlFld-ContribAuthor ">Galina О.  Zhernova</span>, <span class="hlFld-ContribAuthor ">Inna S.  Nosulenko</span>, <span class="hlFld-ContribAuthor ">Galyna G.  Berest</span>, <span class="hlFld-ContribAuthor ">Volodymyr M.  Shvets</span>, <span class="hlFld-ContribAuthor ">Sergiy I.  Kovalenko</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Hypolipidemic Activity of New 6,6-Disubstituted 3-R-6,7-Dihydro-2
              H
              -[1,2,4]triazino[2,3-
              c
              ]quinazolin-2-Ones. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2018,</strong> <em>55 </em>
                                    (1)
                                     , 318-325. <a href="https://doi.org/10.1002/jhet.3054" title="DOI URL">https://doi.org/10.1002/jhet.3054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3054%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DSynthesis%252Band%252BHypolipidemic%252BActivity%252Bof%252BNew%252B6%25252C6-Disubstituted%252B3-R-6%25252C7-Dihydro-2%252BH%252B-%25255B1%25252C2%25252C4%25255Dtriazino%25255B2%25252C3-%252Bc%252B%25255Dquinazolin-2-Ones%26aulast%3DVoskoboynik%26aufirst%3D%25D0%259Eleksii%2BYu.%26date%3D2018%26date%3D2017%26volume%3D55%26issue%3D1%26spage%3D318%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew W.  Brown</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments in the Chemistry of Pyrazoles. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 55-107. <a href="https://doi.org/10.1016/bs.aihch.2018.02.001" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.02.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.02.001%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252BDevelopments%252Bin%252Bthe%252BChemistry%252Bof%252BPyrazoles%26aulast%3DBrown%26aufirst%3DAndrew%2BW.%26date%3D2018%26spage%3D55%26epage%3D107%26pub%3DElsevier%26date%3D2018%26volume%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olga  Bobileva</span>, <span class="hlFld-ContribAuthor ">Martins  Ikaunieks</span>, <span class="hlFld-ContribAuthor ">Gunars  Duburs</span>, <span class="hlFld-ContribAuthor ">Ilona  Mandrika</span>, <span class="hlFld-ContribAuthor ">Ramona  Petrovska</span>, <span class="hlFld-ContribAuthor ">Janis  Klovins</span>, <span class="hlFld-ContribAuthor ">Einars  Loza</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of ( E )-2-(5-phenylpent-2-en-4-ynamido)cyclohex-1-ene-1-carboxylate derivatives as HCA2 receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (16)
                                     , 4314-4329. <a href="https://doi.org/10.1016/j.bmc.2017.06.028" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.06.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.06.028%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252B%252528%252BE%252B%252529-2-%2525285-phenylpent-2-en-4-ynamido%252529cyclohex-1-ene-1-carboxylate%252Bderivatives%252Bas%252BHCA2%252Breceptor%252Bagonists%26aulast%3DBobileva%26aufirst%3DOlga%26date%3D2017%26volume%3D25%26issue%3D16%26spage%3D4314%26epage%3D4329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Offermanns</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxy-Carboxylic Acid Receptor Actions in Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Trends in Endocrinology & Metabolism</span><span> <strong>2017,</strong> <em>28 </em>
                                    (3)
                                     , 227-236. <a href="https://doi.org/10.1016/j.tem.2016.11.007" title="DOI URL">https://doi.org/10.1016/j.tem.2016.11.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tem.2016.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tem.2016.11.007%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Endocrinology%2520%2526%2520Metabolism%26atitle%3DHydroxy-Carboxylic%252BAcid%252BReceptor%252BActions%252Bin%252BMetabolism%26aulast%3DOffermanns%26aufirst%3DStefan%26date%3D2017%26volume%3D28%26issue%3D3%26spage%3D227%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Puttur D.  Prasad</span>, <span class="hlFld-ContribAuthor ">Ashish  Gurav</span>, <span class="hlFld-ContribAuthor ">Huabin  Zhu</span>, <span class="hlFld-ContribAuthor ">Pamela M.  Martin</span>, <span class="hlFld-ContribAuthor ">Matam  Vijay-Kumar</span>, <span class="hlFld-ContribAuthor ">Nagendra  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">The Relationship Between Probiotics and Dietary Fiber Consumption and Cardiovascular Health. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 73-90. <a href="https://doi.org/10.1016/B978-0-12-805130-6.00005-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-805130-6.00005-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-805130-6.00005-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-805130-6.00005-7%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRelationship%252BBetween%252BProbiotics%252Band%252BDietary%252BFiber%252BConsumption%252Band%252BCardiovascular%252BHealth%26aulast%3DPrasad%26aufirst%3DPuttur%2BD.%26date%3D2017%26spage%3D73%26epage%3D90%26pub%3DElsevier%26atitle%3DDietary%252BFiber%252Bfor%252Bthe%252BPrevention%252Bof%252BCardiovascular%252BDisease%26date%3D2017%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Garima  Verma</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">The therapeutic voyage of pyrazole and its analogs: A review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>120 </em>, 170-201. <a href="https://doi.org/10.1016/j.ejmech.2016.04.077" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.077%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Btherapeutic%252Bvoyage%252Bof%252Bpyrazole%252Band%252Bits%252Banalogs%25253A%252BA%252Breview%26aulast%3DKhan%26aufirst%3DMohemmed%2BFaraz%26date%3D2016%26volume%3D120%26spage%3D170%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harsh  Goel</span>, <span class="hlFld-ContribAuthor ">Richard L.  Dunbar</span>. </span><span class="cited-content_cbyCitation_article-title">Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics. </span><span class="cited-content_cbyCitation_journal-name">Current Atherosclerosis Reports</span><span> <strong>2016,</strong> <em>18 </em>
                                    (4)
                                     <a href="https://doi.org/10.1007/s11883-016-0570-9" title="DOI URL">https://doi.org/10.1007/s11883-016-0570-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11883-016-0570-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11883-016-0570-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Atherosclerosis%2520Reports%26atitle%3DNiacin%252BAlternatives%252Bfor%252BDyslipidemia%25253A%252BFool%2525E2%252580%252599s%252BGold%252Bor%252BGold%252BMine%25253F%252BPart%252BII%25253A%252BNovel%252BNiacin%252BMimetics%26aulast%3DGoel%26aufirst%3DHarsh%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gong  Xu</span>, <span class="hlFld-ContribAuthor ">Philippe  Renaud</span>. </span><span class="cited-content_cbyCitation_article-title">Intramolecular Cyclopropanation of 1,4-Dienes through Hydroboration-Homologation: Easy Access to Bicyclo[3.1.0]hexanes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2016,</strong> <em>128 </em>
                                    (11)
                                     , 3721-3725. <a href="https://doi.org/10.1002/ange.201511100" title="DOI URL">https://doi.org/10.1002/ange.201511100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201511100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201511100%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DIntramolecular%252BCyclopropanation%252Bof%252B1%25252C4-Dienes%252Bthrough%252BHydroboration-Homologation%25253A%252BEasy%252BAccess%252Bto%252BBicyclo%25255B3.1.0%25255Dhexanes%26aulast%3DXu%26aufirst%3DGong%26date%3D2016%26date%3D2016%26volume%3D128%26issue%3D11%26spage%3D3721%26epage%3D3725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gong  Xu</span>, <span class="hlFld-ContribAuthor ">Philippe  Renaud</span>. </span><span class="cited-content_cbyCitation_article-title">Intramolecular Cyclopropanation of 1,4-Dienes through Hydroboration-Homologation: Easy Access to Bicyclo[3.1.0]hexanes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2016,</strong> <em>55 </em>
                                    (11)
                                     , 3657-3661. <a href="https://doi.org/10.1002/anie.201511100" title="DOI URL">https://doi.org/10.1002/anie.201511100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201511100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201511100%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DIntramolecular%252BCyclopropanation%252Bof%252B1%25252C4-Dienes%252Bthrough%252BHydroboration-Homologation%25253A%252BEasy%252BAccess%252Bto%252BBicyclo%25255B3.1.0%25255Dhexanes%26aulast%3DXu%26aufirst%3DGong%26date%3D2016%26date%3D2016%26volume%3D55%26issue%3D11%26spage%3D3657%26epage%3D3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenji  Suzuki</span>, <span class="hlFld-ContribAuthor ">Takako  Kaneko-Kawano</span>. </span><span class="cited-content_cbyCitation_article-title">Biological roles and therapeutic potential of G protein-coupled receptors for free fatty acids and metabolic intermediates. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Fitness and Sports Medicine</span><span> <strong>2016,</strong> <em>5 </em>
                                    (3)
                                     , 213-227. <a href="https://doi.org/10.7600/jpfsm.5.213" title="DOI URL">https://doi.org/10.7600/jpfsm.5.213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7600/jpfsm.5.213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7600%2Fjpfsm.5.213%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Fitness%2520and%2520Sports%2520Medicine%26atitle%3DBiological%252Broles%252Band%252Btherapeutic%252Bpotential%252Bof%252BG%252Bprotein-coupled%252Breceptors%252Bfor%252Bfree%252Bfatty%252Bacids%252Band%252Bmetabolic%252Bintermediates%26aulast%3DSuzuki%26aufirst%3DKenji%26date%3D2016%26volume%3D5%26issue%3D3%26spage%3D213%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacobus P.D.  van Veldhoven</span>, <span class="hlFld-ContribAuthor ">Rongfang  Liu</span>, <span class="hlFld-ContribAuthor ">Stephanie A.  Thee</span>, <span class="hlFld-ContribAuthor ">Yessica  Wouters</span>, <span class="hlFld-ContribAuthor ">Sanne J.M.  Verhoork</span>, <span class="hlFld-ContribAuthor ">Christiaan  Mooiman</span>, <span class="hlFld-ContribAuthor ">Julien  Louvel</span>, <span class="hlFld-ContribAuthor ">Adriaan P.  IJzerman</span>. </span><span class="cited-content_cbyCitation_article-title">Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (14)
                                     , 4013-4025. <a href="https://doi.org/10.1016/j.bmc.2015.02.018" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.02.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.02.018%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAffinity%252Band%252Bkinetics%252Bstudy%252Bof%252Banthranilic%252Bacids%252Bas%252BHCA2%252Breceptor%252Bagonists%26aulast%3Dvan%2BVeldhoven%26aufirst%3DJacobus%2BP.D.%26date%3D2015%26volume%3D23%26issue%3D14%26spage%3D4013%26epage%3D4025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyeon Young  Kim</span>, <span class="hlFld-ContribAuthor ">Vithal B.  Jadhav</span>, <span class="hlFld-ContribAuthor ">Dae Young  Jeong</span>, <span class="hlFld-ContribAuthor ">Woo Kyu  Park</span>, <span class="hlFld-ContribAuthor ">Jong-Hwan  Song</span>, <span class="hlFld-ContribAuthor ">Sunkyung  Lee</span>, <span class="hlFld-ContribAuthor ">Heeyeong  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2015,</strong> <em>38 </em>
                                    (6)
                                     , 1019-1032. <a href="https://doi.org/10.1007/s12272-015-0560-4" title="DOI URL">https://doi.org/10.1007/s12272-015-0560-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-015-0560-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-015-0560-4%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DDiscovery%252Bof%252B4-%252528phenyl%252529thio-1H-pyrazole%252Bderivatives%252Bas%252Bagonists%252Bof%252BGPR109A%25252C%252Ba%252Bhigh%252Baffinity%252Bniacin%252Breceptor%26aulast%3DKim%26aufirst%3DHyeon%2BYoung%26date%3D2015%26date%3D2015%26volume%3D38%26issue%3D6%26spage%3D1019%26epage%3D1032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Offermanns</span>, <span class="hlFld-ContribAuthor ">Markus  Schwaninger</span>. </span><span class="cited-content_cbyCitation_article-title">Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation. </span><span class="cited-content_cbyCitation_journal-name">Trends in Molecular Medicine</span><span> <strong>2015,</strong> <em>21 </em>
                                    (4)
                                     , 245-255. <a href="https://doi.org/10.1016/j.molmed.2015.02.002" title="DOI URL">https://doi.org/10.1016/j.molmed.2015.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molmed.2015.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molmed.2015.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Molecular%2520Medicine%26atitle%3DNutritional%252Bor%252Bpharmacological%252Bactivation%252Bof%252BHCA2%252Bameliorates%252Bneuroinflammation%26aulast%3DOffermanns%26aufirst%3DStefan%26date%3D2015%26volume%3D21%26issue%3D4%26spage%3D245%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer M.  Hughes-Large</span>, <span class="hlFld-ContribAuthor ">Dominic K.T.  Pang</span>, <span class="hlFld-ContribAuthor ">Debra L.  Robson</span>, <span class="hlFld-ContribAuthor ">Pak  Chan</span>, <span class="hlFld-ContribAuthor ">Jelena  Toma</span>, <span class="hlFld-ContribAuthor ">Nica M.  Borradaile</span>. </span><span class="cited-content_cbyCitation_article-title">Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Atherosclerosis</span><span> <strong>2014,</strong> <em>237 </em>
                                    (2)
                                     , 696-704. <a href="https://doi.org/10.1016/j.atherosclerosis.2014.10.090" title="DOI URL">https://doi.org/10.1016/j.atherosclerosis.2014.10.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.atherosclerosis.2014.10.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.atherosclerosis.2014.10.090%26sid%3Dliteratum%253Aachs%26jtitle%3DAtherosclerosis%26atitle%3DNiacin%252Breceptor%252Bactivation%252Bimproves%252Bhuman%252Bmicrovascular%252Bendothelial%252Bcell%252Bangiogenic%252Bfunction%252Bduring%252Blipotoxicity%26aulast%3DHughes-Large%26aufirst%3DJennifer%2BM.%26date%3D2014%26volume%3D237%26issue%3D2%26spage%3D696%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David A.  Hottman</span>, <span class="hlFld-ContribAuthor ">Dustin  Chernick</span>, <span class="hlFld-ContribAuthor ">Shaowu  Cheng</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Ling  Li</span>. </span><span class="cited-content_cbyCitation_article-title">HDL and cognition in neurodegenerative disorders. </span><span class="cited-content_cbyCitation_journal-name">Neurobiology of Disease</span><span> <strong>2014,</strong> <em>72 </em>, 22-36. <a href="https://doi.org/10.1016/j.nbd.2014.07.015" title="DOI URL">https://doi.org/10.1016/j.nbd.2014.07.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nbd.2014.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nbd.2014.07.015%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurobiology%2520of%2520Disease%26atitle%3DHDL%252Band%252Bcognition%252Bin%252Bneurodegenerative%252Bdisorders%26aulast%3DHottman%26aufirst%3DDavid%2BA.%26date%3D2014%26volume%3D72%26spage%3D22%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Offermanns</span>. </span><span class="cited-content_cbyCitation_article-title">Free Fatty Acid (FFA) and Hydroxy Carboxylic Acid (HCA) Receptors. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Pharmacology and Toxicology</span><span> <strong>2014,</strong> <em>54 </em>
                                    (1)
                                     , 407-434. <a href="https://doi.org/10.1146/annurev-pharmtox-011613-135945" title="DOI URL">https://doi.org/10.1146/annurev-pharmtox-011613-135945</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-pharmtox-011613-135945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-pharmtox-011613-135945%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Pharmacology%2520and%2520Toxicology%26atitle%3DFree%252BFatty%252BAcid%252B%252528FFA%252529%252Band%252BHydroxy%252BCarboxylic%252BAcid%252B%252528HCA%252529%252BReceptors%26aulast%3DOffermanns%26aufirst%3DStefan%26date%3D2014%26volume%3D54%26issue%3D1%26spage%3D407%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beth A.  Connolly</span>, <span class="hlFld-ContribAuthor ">Daniel P.  O’Connell</span>, <span class="hlFld-ContribAuthor ">Stefania  Lamon-Fava</span>, <span class="hlFld-ContribAuthor ">Daniel F.  LeBlanc</span>, <span class="hlFld-ContribAuthor ">Yu-Lin  Kuang</span>, <span class="hlFld-ContribAuthor ">Ernst J.  Schaefer</span>, <span class="hlFld-ContribAuthor ">Andrew L.  Coppage</span>, <span class="hlFld-ContribAuthor ">Claude R.  Benedict</span>, <span class="hlFld-ContribAuthor ">Christopher P.  Kiritsy</span>, <span class="hlFld-ContribAuthor ">William W.  Bachovchin</span>. </span><span class="cited-content_cbyCitation_article-title">The high-fat high-fructose hamster as an animal model for niacin’s biological activities in humans. </span><span class="cited-content_cbyCitation_journal-name">Metabolism</span><span> <strong>2013,</strong> <em>62 </em>
                                    (12)
                                     , 1840-1849. <a href="https://doi.org/10.1016/j.metabol.2013.08.001" title="DOI URL">https://doi.org/10.1016/j.metabol.2013.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.metabol.2013.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.metabol.2013.08.001%26sid%3Dliteratum%253Aachs%26jtitle%3DMetabolism%26atitle%3DThe%252Bhigh-fat%252Bhigh-fructose%252Bhamster%252Bas%252Ban%252Banimal%252Bmodel%252Bfor%252Bniacin%2525E2%252580%252599s%252Bbiological%252Bactivities%252Bin%252Bhumans%26aulast%3DConnolly%26aufirst%3DBeth%2BA.%26date%3D2013%26volume%3D62%26issue%3D12%26spage%3D1840%26epage%3D1849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen P.H.  Alexander</span>, <span class="hlFld-ContribAuthor ">Helen E.  Benson</span>, <span class="hlFld-ContribAuthor ">Elena  Faccenda</span>, <span class="hlFld-ContribAuthor ">Adam J.  Pawson</span>, <span class="hlFld-ContribAuthor ">Joanna L.  Sharman</span>, <span class="hlFld-ContribAuthor ">Michael  Spedding</span>, <span class="hlFld-ContribAuthor ">John A.  Peters</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Harmar</span>, . </span><span class="cited-content_cbyCitation_article-title">The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2013,</strong> <em>170 </em>
                                    (8)
                                     , 1459-1581. <a href="https://doi.org/10.1111/bph.12445" title="DOI URL">https://doi.org/10.1111/bph.12445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.12445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.12445%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DThe%252BConcise%252BGuide%252Bto%252BPHARMACOLOGY%252B2013%25252F14%25253A%252BG%252BProtein-Coupled%252BReceptors%26aulast%3DAlexander%26aufirst%3DStephen%2BP.H.%26date%3D2013%26date%3D2013%26volume%3D170%26issue%3D8%26spage%3D1459%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ibragim  Gaidarov</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Chen</span>, <span class="hlFld-ContribAuthor ">Todd  Anthony</span>, <span class="hlFld-ContribAuthor ">Dominique  Maciejewski-Lenoir</span>, <span class="hlFld-ContribAuthor ">Chen  Liaw</span>, <span class="hlFld-ContribAuthor ">David J.  Unett</span>. </span><span class="cited-content_cbyCitation_article-title">Differential tissue and ligand-dependent signaling of GPR109A receptor: Implications for anti-atherosclerotic therapeutic potential. </span><span class="cited-content_cbyCitation_journal-name">Cellular Signalling</span><span> <strong>2013,</strong> <em>25 </em>
                                    (10)
                                     , 2003-2016. <a href="https://doi.org/10.1016/j.cellsig.2013.06.008" title="DOI URL">https://doi.org/10.1016/j.cellsig.2013.06.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cellsig.2013.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cellsig.2013.06.008%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520Signalling%26atitle%3DDifferential%252Btissue%252Band%252Bligand-dependent%252Bsignaling%252Bof%252BGPR109A%252Breceptor%25253A%252BImplications%252Bfor%252Banti-atherosclerotic%252Btherapeutic%252Bpotential%26aulast%3DGaidarov%26aufirst%3DIbragim%26date%3D2013%26volume%3D25%26issue%3D10%26spage%3D2003%26epage%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen L.  Garland</span>. </span><span class="cited-content_cbyCitation_article-title">Are GPCRs Still a Source of New Targets?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Screening</span><span> <strong>2013,</strong> <em>18 </em>
                                    (9)
                                     , 947-966. <a href="https://doi.org/10.1177/1087057113498418" title="DOI URL">https://doi.org/10.1177/1087057113498418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1087057113498418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1087057113498418%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Screening%26atitle%3DAre%252BGPCRs%252BStill%252Ba%252BSource%252Bof%252BNew%252BTargets%25253F%26aulast%3DGarland%26aufirst%3DStephen%2BL.%26date%3D2013%26date%3D2013%26volume%3D18%26issue%3D9%26spage%3D947%26epage%3D966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah  Tonack</span>, <span class="hlFld-ContribAuthor ">Cong  Tang</span>, <span class="hlFld-ContribAuthor ">Stefan  Offermanns</span>. </span><span class="cited-content_cbyCitation_article-title">Endogenous metabolites as ligands for G protein-coupled receptors modulating risk factors for metabolic and cardiovascular disease. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Physiology-Heart and Circulatory Physiology</span><span> <strong>2013,</strong> <em>304 </em>
                                    (4)
                                     , H501-H513. <a href="https://doi.org/10.1152/ajpheart.00641.2012" title="DOI URL">https://doi.org/10.1152/ajpheart.00641.2012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/ajpheart.00641.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fajpheart.00641.2012%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Heart%2520and%2520Circulatory%2520Physiology%26atitle%3DEndogenous%252Bmetabolites%252Bas%252Bligands%252Bfor%252BG%252Bprotein-coupled%252Breceptors%252Bmodulating%252Brisk%252Bfactors%252Bfor%252Bmetabolic%252Band%252Bcardiovascular%252Bdisease%26aulast%3DTonack%26aufirst%3DSarah%26date%3D2013%26volume%3D304%26issue%3D4%26spage%3DH501%26epage%3DH513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">B.  Lauring</span>, <span class="hlFld-ContribAuthor ">A. K. P.  Taggart</span>, <span class="hlFld-ContribAuthor ">J. R.  Tata</span>, <span class="hlFld-ContribAuthor ">R.  Dunbar</span>, <span class="hlFld-ContribAuthor ">L.  Caro</span>, <span class="hlFld-ContribAuthor ">K.  Cheng</span>, <span class="hlFld-ContribAuthor ">J.  Chin</span>, <span class="hlFld-ContribAuthor ">S. L.  Colletti</span>, <span class="hlFld-ContribAuthor ">J.  Cote</span>, <span class="hlFld-ContribAuthor ">S.  Khalilieh</span>, <span class="hlFld-ContribAuthor ">J.  Liu</span>, <span class="hlFld-ContribAuthor ">W.-L.  Luo</span>, <span class="hlFld-ContribAuthor ">A. A.  MacLean</span>, <span class="hlFld-ContribAuthor ">L. B.  Peterson</span>, <span class="hlFld-ContribAuthor ">A. B.  Polis</span>, <span class="hlFld-ContribAuthor ">W.  Sirah</span>, <span class="hlFld-ContribAuthor ">T.-J.  Wu</span>, <span class="hlFld-ContribAuthor ">X.  Liu</span>, <span class="hlFld-ContribAuthor ">L.  Jin</span>, <span class="hlFld-ContribAuthor ">K.  Wu</span>, <span class="hlFld-ContribAuthor ">P. D.  Boatman</span>, <span class="hlFld-ContribAuthor ">G.  Semple</span>, <span class="hlFld-ContribAuthor ">D. P.  Behan</span>, <span class="hlFld-ContribAuthor ">D. T.  Connolly</span>, <span class="hlFld-ContribAuthor ">E.  Lai</span>, <span class="hlFld-ContribAuthor ">J. A.  Wagner</span>, <span class="hlFld-ContribAuthor ">S. D.  Wright</span>, <span class="hlFld-ContribAuthor ">C.  Cuffie</span>, <span class="hlFld-ContribAuthor ">Y. B.  Mitchel</span>, <span class="hlFld-ContribAuthor ">D. J.  Rader</span>, <span class="hlFld-ContribAuthor ">J. F.  Paolini</span>, <span class="hlFld-ContribAuthor ">M. G.  Waters</span>, <span class="hlFld-ContribAuthor ">A.  Plump</span>. </span><span class="cited-content_cbyCitation_article-title">Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression. </span><span class="cited-content_cbyCitation_journal-name">Science Translational Medicine</span><span> <strong>2012,</strong> <em>4 </em>
                                    (148)
                                     , 148ra115-148ra115. <a href="https://doi.org/10.1126/scitranslmed.3003877" title="DOI URL">https://doi.org/10.1126/scitranslmed.3003877</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scitranslmed.3003877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscitranslmed.3003877%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Translational%2520Medicine%26atitle%3DNiacin%252BLipid%252BEfficacy%252BIs%252BIndependent%252Bof%252BBoth%252Bthe%252BNiacin%252BReceptor%252BGPR109A%252Band%252BFree%252BFatty%252BAcid%252BSuppression%26aulast%3DLauring%26aufirst%3DB.%26date%3D2012%26date%3D2012%26volume%3D4%26issue%3D148%26spage%3D148ra115%26epage%3D148ra115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clara C.  Blad</span>, <span class="hlFld-ContribAuthor ">Cong  Tang</span>, <span class="hlFld-ContribAuthor ">Stefan  Offermanns</span>. </span><span class="cited-content_cbyCitation_article-title">G protein-coupled receptors for energy metabolites as new therapeutic targets. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2012,</strong> <em>11 </em>
                                    (8)
                                     , 603-619. <a href="https://doi.org/10.1038/nrd3777" title="DOI URL">https://doi.org/10.1038/nrd3777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd3777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd3777%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DG%252Bprotein-coupled%252Breceptors%252Bfor%252Benergy%252Bmetabolites%252Bas%252Bnew%252Btherapeutic%252Btargets%26aulast%3DBlad%26aufirst%3DClara%2BC.%26date%3D2012%26date%3D2012%26volume%3D11%26issue%3D8%26spage%3D603%26epage%3D619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Time course of the effect of <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> on plasma FFA in male Sprague–Dawley rats after oral administration. <i>N</i> (animal number) is indicated in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Zhan catalyst or second-generation Grubbs’ catalyst; (b) <i>n</i>-BuLi, CH<sub>2</sub>Br<sub>2</sub>, THF; (c) <i>n</i>-BuLi, DMPU, THF, (CH<sub>2</sub>)<sub>2</sub>CHCH<sub>2</sub>Br; (d) Pd/BaSO<sub>4</sub>, quinoline, H<sub>2</sub>; (e) AcOH, H<sub>2</sub>O; (f) TrisIm, NaH; (g) LiTMP, MTBE; (h) cat. TPAP, NMO, 4 Å MS, DCM.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 50% NaOH, CHCl<sub>3</sub>, DCM, cat. triethylbenzylammonium chloride, 45 °C; (b) (1) <i>t</i>-BuLi, THF, −100 °C, (2) MeI, −100 °C to rt; (c) (1) LiDBB, THF, −78 °C, (2) EtOH; (d) cat. TsOH, acetone, H<sub>2</sub>O, rt; (e) Zn dust, KOH, EtOH, 80 °C; (f) (1) LiDBB, THF, −78 °C, (2) R<sup>2</sup>I, rt.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0012.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) LiDBB, THF, −78 °C, (2) DMF, rt; (b) [(Ph<sub>3</sub>)PCH<sub>3</sub>]<sup>+</sup>Br<sup>–</sup>, <i>n</i>-BuLi, THF, rt; (c) cat. TsOH, acetone, H<sub>2</sub>O, rt; (d) Pd(OAc)<sub>2</sub>, CH<sub>2</sub>N<sub>2</sub>, Et<sub>2</sub>O, rt; (e) NaBH<sub>4</sub>, EtOH, rt; (f) NaH, MeI, THF, 0 °C to rt; (g) MsCl, Et<sub>3</sub>N, DCM, 0 °C to rt; (h) NaSMe, DMF; (i) PhOH, D<i>t</i>-BAD, PyPh<sub>2</sub>P, THF.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0013.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (CH<sub>3</sub>)<sub>3</sub>S(O)I, NaH, THF; (b) <i>t</i>-BuLi, THF.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0014.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) KO<i>t</i>-Bu, EtOH, (EtO<sub>2</sub>C)<sub>2</sub>, 0 °C to rt, (2) hydrazine monohydrochloride, H<sub>2</sub>O, rt; (b) LiOH, dioxane, H<sub>2</sub>O; (c) benzyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF; (d) NaI, MeI, THF; (e) KO<i>t</i>-Bu, DMSO, air; (f) (CH<sub>3</sub>)<sub>3</sub>SOI, NaH.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0015.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) [(Ph<sub>3</sub>)PCH<sub>2</sub>CH<sub>3</sub>]<sup>+</sup>Br<sup>–</sup>, LiHMDS, THF, 0 °C to rt; (b) LiTMP, MTBE; (c) cat. TPAP, NMO, 4 Å MS, DCM; (d) (1) KO<i>t</i>-Bu, EtOH, (EtO<sub>2</sub>C)<sub>2</sub>, 0 °C to rt, (2) hydrazine monohydrochloride, H<sub>2</sub>O, rt, (3) HPLC separation; (e) LiOH, dioxane, H<sub>2</sub>O.</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0016.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-butyne, <i>n</i>-BuLi, THF, DMPU, −78 °C to rt; (b) AcOH, H<sub>2</sub>O; (c) TrisIm, NaH; (d) Pd/BaSO<sub>4</sub>, quinoline, H<sub>2</sub>; (e) Jacobsen HKR; (f) LiTMP, MTBE; (g) cat. TPAP, NMO, 4 Å MS, DCM; (h) (1) KO<i>t</i>-Bu, EtOH, (EtO<sub>2</sub>C)<sub>2</sub>, 0 °C to rt, (2) hydrazine monohydrochloride, H<sub>2</sub>O, rt; (i) LiOH, dioxane, H<sub>2</sub>O, rt.</p></p></figure><figure data-id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Quantification of the flushing response of niacin, <i>R</i>,<i>R</i>-<b>19a</b> and <i>R</i>,<i>S</i>-<i>endo</i>-<b>19b</b> as measured by laser Doppler recordings of cutaneous blood flow in the ear of male C57/bl6 mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Human urinary prostaglandin D metabolite in urine following an oral dose of <i>R</i>,<i>R</i>-<b>19a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma concentrations of <i>R</i>,<i>R</i>-<b>19a</b> in humans after oral administration on days 4 and 11 and trough levels on days 5 through 10.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/medium/jm-2011-010964_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma free fatty acid levels of <i>R</i>,<i>R</i>-<b>19a</b> on days 4 and 11 in humans.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm2010964/production/images/large/jm-2011-010964_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2010964&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i180">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawken, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ounpuu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avezum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budaj, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pais, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varigos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisheng, L.</span><span> </span><span class="NLM_article-title">Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=937-952&author=S.+Yusufauthor=S.+Hawkenauthor=S.+Ounpuuauthor=T.+Dansauthor=A.+Avezumauthor=F.+Lanasauthor=M.+McQueenauthor=A.+Budajauthor=P.+Paisauthor=J.+Varigosauthor=L.+Lisheng&title=Effect+of+potentially+modifiable+risk+factors+associated+with+myocardial+infarction+in+52+countries+%28the+INTERHEART+study%29%3A+case-control+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DHawken%26aufirst%3DS.%26aulast%3DOunpuu%26aufirst%3DS.%26aulast%3DDans%26aufirst%3DT.%26aulast%3DAvezum%26aufirst%3DA.%26aulast%3DLanas%26aufirst%3DF.%26aulast%3DMcQueen%26aufirst%3DM.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DPais%26aufirst%3DP.%26aulast%3DVarigos%26aufirst%3DJ.%26aulast%3DLisheng%26aufirst%3DL.%26atitle%3DEffect%2520of%2520potentially%2520modifiable%2520risk%2520factors%2520associated%2520with%2520myocardial%2520infarction%2520in%252052%2520countries%2520%2528the%2520INTERHEART%2520study%2529%253A%2520case-control%2520study%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D937%26epage%3D952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ford, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajani, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croft, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Critchley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labarthe, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottke, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capewell, S.</span><span> </span><span class="NLM_article-title">Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2398</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1056%2FNEJMsa053935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=17554120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Wnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2388-2398&author=E.+S.+Fordauthor=U.+A.+Ajaniauthor=J.+B.+Croftauthor=J.+A.+Critchleyauthor=D.+R.+Labartheauthor=T.+E.+Kottkeauthor=W.+H.+Gilesauthor=S.+Capewell&title=Explaining+the+Decrease+in+U.S.+Deaths+from+Coronary+Disease%2C+1980%E2%80%932000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Explaining the decrease in U.S. deaths from coronary disease, 1980-2000</span></div><div class="casAuthors">Ford, Earl S.; Ajani, Umed A.; Croft, Janet B.; Critchley, Jula A.; Labarthe, Darwin R.; Kottke, Thomas E.; Giles, Wayne H.; Capewell, Simon</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2388-2398</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Mortality from coronary heart disease in the United States has decreased substantially in recent decades.  We conducted a study to det. how much of this de- crease could be explained by the use of medical and surgical treatments as opposed to changes in cardiovascular risk factors.  METHODS We applied a previously validated statistical model, IMPACT, to data on the use and effectiveness of specific cardiac treatments and on changes in risk factors between 1980 and 2000 among U.S. adults 25 to 84 years old.  The difference between the obsd. and expected no. of deaths from coronary heart disease in 2000 was distributed among the treatments and risk factors included in the analyses.  RESULTS From 1980 through 2000, the age-adjusted death rate for coronary heart disease fell from 542.9 to 266.8 deaths per 100,000 population among men and from 263.3 to 134.4 deaths per 100,000 population among women, resulting in 341,745 fewer deaths from coronary heart disease in 2000.  Approx. 47% of this decrease was attributed to treatments, including secondary preventive therapies after myocardial infarction or revascularization (11%), initial treatments for acute myocardial infarction or unstable angina (10%), treatments for heart failure (9%), revascularization for chronic angina (5%), and other therapies (12%).  Approx. 44% was attributed to changes in risk factors, including redns. in total cholesterol (24%), systolic blood pressure (20%), smoking prevalence (12%), and phys. inactivity (5%), although these redns. were partially offset by increases in the body-mass index and the prevalence of diabetes, which accounted for an increased no. of deaths (8% and 10%, resp.).  CONCLUSIONS Approx. half the decline in U.S. deaths from coronary heart disease from 1980 through 2000 may be attributable to redns. in major risk factors and approx. half to evidence-based medical therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfR8YfvG_1x7Vg90H21EOLACvtfcHk0lhRCDhZJeW11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Wnsbs%253D&md5=7e9da2fecd73213796adac2ea6b6c10e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMsa053935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMsa053935%26sid%3Dliteratum%253Aachs%26aulast%3DFord%26aufirst%3DE.%2BS.%26aulast%3DAjani%26aufirst%3DU.%2BA.%26aulast%3DCroft%26aufirst%3DJ.%2BB.%26aulast%3DCritchley%26aufirst%3DJ.%2BA.%26aulast%3DLabarthe%26aufirst%3DD.%2BR.%26aulast%3DKottke%26aufirst%3DT.%2BE.%26aulast%3DGiles%26aufirst%3DW.%2BH.%26aulast%3DCapewell%26aufirst%3DS.%26atitle%3DExplaining%2520the%2520Decrease%2520in%2520U.S.%2520Deaths%2520from%2520Coronary%2520Disease%252C%25201980%25E2%2580%25932000%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2388%26epage%3D2398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Bruckert, E</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labreuche, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amarenco, P.</span><span> </span><span class="NLM_article-title">Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis</span> <span class="citation_source-journal">Atherosclerosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">210</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2010&pages=353-361&author=E+Bruckertauthor=J.+Labreucheauthor=P.+Amarenco&title=Meta-analysis+of+the+effect+of+nicotinic+acid+alone+or+in+combination+on+cardiovascular+events+and+atherosclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruckert%26aufirst%3DE%26aulast%3DLabreuche%26aufirst%3DJ.%26aulast%3DAmarenco%26aufirst%3DP.%26atitle%3DMeta-analysis%2520of%2520the%2520effect%2520of%2520nicotinic%2520acid%2520alone%2520or%2520in%2520combination%2520on%2520cardiovascular%2520events%2520and%2520atherosclerosis%26jtitle%3DAtherosclerosis%26date%3D2010%26volume%3D210%26spage%3D353%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hiatt, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shamsie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schectman, G.</span><span> </span><span class="NLM_article-title">Discontinuation rates of cholesterol-lowering medications: implications for primary care</span> <span class="citation_source-journal">Am. J. Managed Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=10387383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A280%3ADyaK1M3ntlylsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=437-444&author=J.+G.+Hiattauthor=S.+G.+Shamsieauthor=G.+Schectman&title=Discontinuation+rates+of+cholesterol-lowering+medications%3A+implications+for+primary+care"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discontinuation rates of cholesterol-lowering medications: implications for primary care</span></div><div class="casAuthors">Hiatt J G; Shamsie S G; Schectman G</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of managed care</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-44</span>
        ISSN:<span class="NLM_cas:issn">1088-0224</span>.
    </div><div class="casAbstract">OBJECTIVE:  To evaluate long-term continuation rates for cholesterol-lowering therapy (niacin, sequestrants, statins) in a multidisciplinary lipid clinic and to evaluate the effectiveness of 2 different dosing strategies designed to improve long-term continuation of therapy.  STUDY DESIGN:  An observational study was done at the Milwaukee Department of Veterans Affairs Medical Center Lipid Clinic, where healthcare personnel were trained to improve patient tolerance to cholesterol-lowering medications.  Primary outcomes were recorded prospectively.  PATIENTS AND METHODS:  Patients were 970 consecutive veterans who began therapy with niacin, sequestrants, or statins between March 1988 and December 1995.  In 1992, two different dosing strategies were initiated to reduce the discontinuation rates for niacin and sequestrants: (1) the niacin titration schedule was lengthened from 3 to 6 weeks and (2) the initial sequestrant dose was reduced from four to two scoops daily.  RESULTS:  Discontinuation rates for niacin and sequestrants were both very high.  For niacin, 48% and 71% of all patients who began therapy discontinued the drug by 1 and 4 years, respectively.  For sequestrants, drug discontinuation rates were 59% and 83% at 1 and 4 years, respectively.  On the other hand, statin discontinuation rates at 1 and 4 years were only 10% and 28%, respectively.  Neither the longer niacin titration schedule nor the lower sequestrant initiation dose reduced these high discontinuation rates.  CONCLUSIONS:  Despite initiation of niacin and sequestrant therapy in the setting of a multidisciplinary lipid clinic, drug discontinuation rates were high and were similar to rates observed in primary-care settings.  Neither the specialized resources available in a lipid clinic nor protocols designed to improve tolerance to therapy reduced the high drug discontinuation rate.  Unless more tolerable niacin and sequestrant formulations become available, reliance on statins as the preferred cholesterol-lowering agents will continue because they have fewer side effects and lower discontinuation rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRX_kW4SNRgIWhHGZei4OW9fW6udTcc2ebGzHcF908bNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3ntlylsA%253D%253D&md5=cc9feb4ea6ce733c5b3e5581b66da762</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHiatt%26aufirst%3DJ.%2BG.%26aulast%3DShamsie%26aufirst%3DS.%2BG.%26aulast%3DSchectman%26aufirst%3DG.%26atitle%3DDiscontinuation%2520rates%2520of%2520cholesterol-lowering%2520medications%253A%2520implications%2520for%2520primary%2520care%26jtitle%3DAm.%2520J.%2520Managed%2520Care%26date%3D1999%26volume%3D5%26spage%3D437%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Offermanns, S.</span><span> </span><span class="NLM_article-title">The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">384</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=384-390&author=S.+Offermanns&title=The+nicotinic+acid+receptor+GPR109A+%28HM74A+or+PUMA-G%29+as+a+new+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOffermanns%26aufirst%3DS.%26atitle%3DThe%2520nicotinic%2520acid%2520receptor%2520GPR109A%2520%2528HM74A%2520or%2520PUMA-G%2529%2520as%2520a%2520new%2520therapeutic%2520target%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D384%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span> </span><span class="NLM_article-title">Recent progress in the discovery of niacin receptor agonists</span> <span class="citation_source-journal">Curr. Opin. Drug. Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">452</span><span class="NLM_x">–</span> <span class="NLM_lpage">459</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=17659487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFCns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=452-459&author=G.+Sempleauthor=P.+D.+Boatmanauthor=J.+G.+Richman&title=Recent+progress+in+the+discovery+of+niacin+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in the discovery of niacin receptor agonists</span></div><div class="casAuthors">Semple, Graeme; Boatman, P. Douglas; Richman, Jeremy G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">452-459</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Niacin (nicotinic acid) favorably affects multiple serum lipid parameters that are believed to be cardiovascular risk factors, but is also assocd. with a cutaneous flushing adverse effect.  The recent discovery of a G-protein-coupled receptor target for niacin (termed GPR109a) has stimulated interest in the discovery of new compds. with niacin-like effects on lipids, but with fewer adverse effects.  This review discusses the progress made toward the discovery of such mols. and highlights the pharmacol. models used to enable their identification.  The advances made in both these areas may help to det. whether GPR109a is the mol. target responsible for the beneficial anti-atherogenic effects of niacin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuuJctgtqOLVg90H21EOLACvtfcHk0ljNKlzKHIx6gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFCns7k%253D&md5=47c6f2e3bf6a62de9796196d15025617</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3DRecent%2520progress%2520in%2520the%2520discovery%2520of%2520niacin%2520receptor%2520agonists%26jtitle%3DCurr.%2520Opin.%2520Drug.%2520Discovery%2520Dev.%26date%3D2007%26volume%3D10%26spage%3D452%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span> </span><span class="NLM_article-title">Nicotinic acid receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7653</span><span class="NLM_x">–</span> <span class="NLM_lpage">7662</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800896z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7653-7662&author=P.+D.+Boatmanauthor=J.+G.+Richmanauthor=G.+Semple&title=Nicotinic+acid+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Fjm800896z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800896z%26sid%3Dliteratum%253Aachs%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DSemple%26aufirst%3DG.%26atitle%3DNicotinic%2520acid%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7653%26epage%3D7662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Lorenzen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stannek, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrianov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalvinsh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, U.</span><span> </span><span class="NLM_article-title">Characterization of a G Protein-Coupled Receptor for Nicotinic Acid</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2001&pages=349-357&author=A.+Lorenzenauthor=C.+Stannekauthor=H.+Langauthor=V.+Andrianovauthor=I.+Kalvinshauthor=U.+Schwabe&title=Characterization+of+a+G+Protein-Coupled+Receptor+for+Nicotinic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLorenzen%26aufirst%3DA.%26aulast%3DStannek%26aufirst%3DC.%26aulast%3DLang%26aufirst%3DH.%26aulast%3DAndrianov%26aufirst%3DV.%26aulast%3DKalvinsh%26aufirst%3DI.%26aulast%3DSchwabe%26aufirst%3DU.%26atitle%3DCharacterization%2520of%2520a%2520G%2520Protein-Coupled%2520Receptor%2520for%2520Nicotinic%2520Acid%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D59%26spage%3D349%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Maciejewski-Lenoir, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakak, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidarov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span> </span><span class="NLM_article-title">Langerhans Cells Release Prostaglandin D2 in Response to Nicotinic Acid</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">2637</span><span class="NLM_x">–</span> <span class="NLM_lpage">2646</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2006&pages=2637-2646&author=D.+Maciejewski-Lenoirauthor=J.+G.+Richmanauthor=Y.+Hakakauthor=I.+Gaidarovauthor=D.+P.+Behanauthor=D.+T.+Connolly&title=Langerhans+Cells+Release+Prostaglandin+D2+in+Response+to+Nicotinic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaciejewski-Lenoir%26aufirst%3DD.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DHakak%26aufirst%3DY.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26atitle%3DLangerhans%2520Cells%2520Release%2520Prostaglandin%2520D2%2520in%2520Response%2520to%2520Nicotinic%2520Acid%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2006%26volume%3D126%26spage%3D2637%26epage%3D2646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metters, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">6682</span><span class="NLM_x">–</span> <span class="NLM_lpage">6687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cheng%2C+K.%3B+Wu%2C+T.-J.%3B+Wu%2C+K.+K.%3B+Sturino%2C+C.%3B+Metters%2C+K.%3B+Gottesdiener%2C+K.%3B+Wright%2C+S.+D.%3B+Wang%2C+Z.%3B+O%E2%80%99Neill%2C+G.%3B+Lai%2C+E.%3B+Waters%2C+M.+G.Proc.+Natl.+Acad.+Sci+U.S.A.+2006%2C+103%2C+6682%E2%80%936687"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DT.-J.%26aulast%3DWu%26aufirst%3DK.%2BK.%26aulast%3DSturino%26aufirst%3DC.%26aulast%3DMetters%26aufirst%3DK.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DWright%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DE.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D6682%26epage%3D6687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Benyo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gille, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offermanns, S.</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1844</span><span class="NLM_x">–</span> <span class="NLM_lpage">1849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Benyo%2C+Z.%3B+Gille%2C+A.%3B+Bennett%2C+C.+L.%3B+Clausen%2C+B.+E.%3B+Offermanns%2C+S.Mol.+Pharmacol.+2006%2C+70%2C+1844%E2%80%931849"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenyo%26aufirst%3DZ.%26aulast%3DGille%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DC.%2BL.%26aulast%3DClausen%26aufirst%3DB.%2BE.%26aulast%3DOffermanns%26aufirst%3DS.%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D1844%26epage%3D1849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hanson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gille, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwykiel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukasova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunaru, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offermanns, S.</span><span> </span><span class="NLM_article-title">Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2910</span><span class="NLM_x">–</span> <span class="NLM_lpage">2919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1172%2FJCI42273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=20664170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaiur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=2910-2919&author=J.+Hansonauthor=A.+Gilleauthor=S.+Zwykielauthor=M.+Lukasovaauthor=B.+E.+Clausenauthor=K.+Ahmedauthor=S+Tunaruauthor=A.+Wirthauthor=S.+Offermanns&title=Nicotinic+acid-+and+monomethyl+fumarate-induced+flushing+involves+GPR109A+expressed+by+keratinocytes+and+COX-2-dependent+prostanoid+formation+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice</span></div><div class="casAuthors">Hanson, Julien; Gille, Andreas; Zwykiel, Sabrina; Lukasova, Martina; Clausen, Bjoern E.; Ahmed, Kashan; Tunaru, Sorin; Wirth, Angela; Offermanns, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2910-2919</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">The antidyslipidemic drug nicotinic acid and the antipsoriatic drug monomethyl fumarate induce cutaneous flushing through activation of G protein-coupled receptor 109A (GPR109A).  Flushing is a troublesome side effect of nicotinic acid, but may be a direct reflection of the wanted effects of monomethyl fumarate.  Here we analyzed the mechanisms underlying GPR109A-mediated flushing and show that both Langerhans cells and keratinocytes express GPR109A in mice.  Using cell ablation approaches and transgenic cell type-specific GPR109A expression in Gpr109a-/- mice, we have provided evidence that the early phase of flushing depends on GPR109A expressed on Langerhans cells, whereas the late phase is mediated by GPR109A expressed on keratinocytes.  Interestingly, the first phase of flushing was blocked by a selective cyclooxygenase-1 (COX-1) inhibitor, and the late phase was sensitive to a selective COX-2 inhibitor.  Both monomethyl fumarate and nicotinic acid induced PGE2 formation in isolated keratinocytes through activation of GPR109A and COX-2.  Thus, the early and late phases of the GPR109A-mediated cutaneous flushing reaction involve different epidermal cell types and prostanoid-forming enzymes.  These data will help to guide new efficient approaches to mitigate nicotinic acid-induced flushing and may help to exploit the potential antipsoriatic effects of GPR109A agonists in the skin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Q1MnzAkJp7Vg90H21EOLACvtfcHk0lhib3LaZc8LmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaiur%252FK&md5=8df71b503797827226a21884771e568d</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1172%2FJCI42273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI42273%26sid%3Dliteratum%253Aachs%26aulast%3DHanson%26aufirst%3DJ.%26aulast%3DGille%26aufirst%3DA.%26aulast%3DZwykiel%26aufirst%3DS.%26aulast%3DLukasova%26aufirst%3DM.%26aulast%3DClausen%26aufirst%3DB.%2BE.%26aulast%3DAhmed%26aufirst%3DK.%26aulast%3DTunaru%26aufirst%3DS%26aulast%3DWirth%26aufirst%3DA.%26aulast%3DOffermanns%26aufirst%3DS.%26atitle%3DNicotinic%2520acid-%2520and%2520monomethyl%2520fumarate-induced%2520flushing%2520involves%2520GPR109A%2520expressed%2520by%2520keratinocytes%2520and%2520COX-2-dependent%2520prostanoid%2520formation%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D2910%26epage%3D2919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Paolini, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchel, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kher, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norquist, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meehan, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bays, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantyne, C. M.</span><span> </span><span class="NLM_article-title">Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">625</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2008&pages=625-630&author=J.+F.+Paoliniauthor=Y.+B.+Mitchelauthor=R.+Reyesauthor=U.+Kherauthor=E.+Laiauthor=D.+J.+Watsonauthor=J.+M.+Norquistauthor=A.+G.+Meehanauthor=H.+E.+Baysauthor=M.+Davidsonauthor=C.+M.+Ballantyne&title=Effects+of+Laropiprant+on+Nicotinic+Acid-Induced+Flushing+in+Patients+With+Dyslipidemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DJ.%2BF.%26aulast%3DMitchel%26aufirst%3DY.%2BB.%26aulast%3DReyes%26aufirst%3DR.%26aulast%3DKher%26aufirst%3DU.%26aulast%3DLai%26aufirst%3DE.%26aulast%3DWatson%26aufirst%3DD.%2BJ.%26aulast%3DNorquist%26aufirst%3DJ.%2BM.%26aulast%3DMeehan%26aufirst%3DA.%2BG.%26aulast%3DBays%26aufirst%3DH.%2BE.%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DBallantyne%26aufirst%3DC.%2BM.%26atitle%3DEffects%2520of%2520Laropiprant%2520on%2520Nicotinic%2520Acid-Induced%2520Flushing%2520in%2520Patients%2520With%2520Dyslipidemia%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2008%26volume%3D101%26spage%3D625%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanemitsu-Parks, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidarov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerra, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cham, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornelas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span> </span><span class="NLM_article-title">Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">18028</span><span class="NLM_x">–</span> <span class="NLM_lpage">18036</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=18028-18036&author=J.+G.+Richmanauthor=M.+Kanemitsu-Parksauthor=I.+Gaidarovauthor=J.+S.+Cameronauthor=P.+Griffinauthor=H.+Zhengauthor=N.+C.+Guerraauthor=L.+Chamauthor=D.+P.+Behanauthor=P.+D.+Boatmanauthor=R.+Chenauthor=P.+J.+Skinnerauthor=P.+Ornelasauthor=G.+Sempleauthor=D.+T.+Connolly&title=Nicotinic+Acid+Receptor+Agonists+Differentially+Activate+Downstream+Effectors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DKanemitsu-Parks%26aufirst%3DM.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DCameron%26aufirst%3DJ.%2BS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DGuerra%26aufirst%3DN.%2BC.%26aulast%3DCham%26aufirst%3DL.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DOrnelas%26aufirst%3DP.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26atitle%3DNicotinic%2520Acid%2520Receptor%2520Agonists%2520Differentially%2520Activate%2520Downstream%2520Effectors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D18028%26epage%3D18036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharbaoui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carballo-Jane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span> </span><span class="NLM_article-title">3-(1<i>H</i>-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5101</span><span class="NLM_x">–</span> <span class="NLM_lpage">5108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800258p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5101-5108&author=G.+Sempleauthor=P.+J.+Skinnerauthor=T.+Gharbaouiauthor=Y.-J.+Shinauthor=J.-K.+Jungauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=S.+Y.+Tamuraauthor=P.+D.+Boatmanauthor=C.+R.+Sageauthor=T.+O.+Schraderauthor=R.+Chenauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=M.+G.+Watersauthor=K.+Chengauthor=A.+K.+Taggartauthor=T.-Q.+Caiauthor=E.+Carballo-Janeauthor=D.+P.+Behanauthor=D.+T.+Connollyauthor=J.+G.+Richman&title=3-%281H-Tetrazol-5-yl%29-1%2C4%2C5%2C6-tetrahydro-cyclopentapyrazole+%28MK-0354%29%3A+A+Partial+Agonist+of+the+Nicotinic+Acid+Receptor%2C+G-Protein+Coupled+Receptor+109a%2C+with+Antilipolytic+but+No+Vasodilatory+Activity+in+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm800258p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800258p%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DShin%26aufirst%3DY.-J.%26aulast%3DJung%26aufirst%3DJ.-K.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%2BY.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3D3-%25281H-Tetrazol-5-yl%2529-1%252C4%252C5%252C6-tetrahydro-cyclopentapyrazole%2520%2528MK-0354%2529%253A%2520A%2520Partial%2520Agonist%2520of%2520the%2520Nicotinic%2520Acid%2520Receptor%252C%2520G-Protein%2520Coupled%2520Receptor%2520109a%252C%2520with%2520Antilipolytic%2520but%2520No%2520Vasodilatory%2520Activity%2520in%2520Mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5101%26epage%3D5108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Lai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radziszewski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perevozskaya, I</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenning, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson-Levonas, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchel, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, J. F.</span><span> </span><span class="NLM_article-title">Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans</span> <span class="citation_source-journal">J. Clin. Lipidol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1016%2Fj.jacl.2008.08.445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=21291763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A280%3ADC%252BC3M7mslamug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=375-383&author=E.+Laiauthor=M.+G.+Watersauthor=J.+R.+Tataauthor=W.+Radziszewskiauthor=I+Perevozskayaauthor=W.+Zhengauthor=L.+Wenningauthor=D.+T.+Connollyauthor=G.+Sempleauthor=A.+O.+Johnson-Levonasauthor=J.+A.+Wagnerauthor=Y.+Mitchelauthor=J.+F.+Paolini&title=Effects+of+a+niacin+receptor+partial+agonist%2C+MK-0354%2C+on+plasma+free+fatty+acids%2C+lipids%2C+and+cutaneous+flushing+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans</span></div><div class="casAuthors">Lai Eseng; Waters M Gerard; Tata James R; Radziszewski Waldemar; Perevozskaya Inna; Zheng Wei; Wenning Larissa; Connolly Daniel T; Semple Graeme; Johnson-Levonas Amy O; Wagner John A; Mitchel Yale; Paolini John F</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical lipidology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">375-83</span>
        ISSN:<span class="NLM_cas:issn">1933-2874</span>.
    </div><div class="casAbstract">BACKGROUND:  Development of niacin-like agents that favorably affect lipids with an improved flushing profile would be beneficial.  OBJECTIVE:  To evaluate a niacin receptor partial agonist, MK-0354, in Phase I and II studies.  METHODS:  The pharmacokinetic/pharmacodynamic effects of single and multiple doses (7 days) of MK-0354 (300-4000 mg) were evaluated in two Phase I studies conducted in healthy men.  A Phase II study assessed the effects of MK-0354 2.5 g once daily on lipids during 4 weeks in 66 dyslipidemic patients.  RESULTS:  MK-0354 single doses up to 4000 mg and multiple doses (7 days) up to 3600 mg produced robust dose-related reductions in free fatty acid (FFA) over 5 hours.  Single doses of MK-0354 300 mg and extended release-niacin (Niaspan) 1 g produced comparable reductions in FFA.  Suppression of FFA following 7 daily doses of MK-0354 was similar to that after a single dose.  In the Phase II study, MK-0354 2.5 g produced little flushing but no clinically meaningful effects on lipids (placebo-adjusted percent change: high-density lipoprotein cholesterol, 0.4%, 95% confidence interval -5.2 to 6.0; low-density lipoprotein cholesterol, -9.8%, 95% confidence interval -16.8 to -2.7; triglyceride, -5.8%, 95% confidence interval -22.6 to 11.9).  CONCLUSION:  Treatment with MK-0354 for 7 days resulted in plasma FFA suppression with minimal cutaneous flushing.  However, 4 weeks of treatment with MK-0354 failed to produce changes in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or triglycerides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrxOcLiWbvsF1C8OJBvdfbfW6udTcc2eZQyRe8dvu2Obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7mslamug%253D%253D&md5=92e3f9f50bc99e38c0eba0fe5d823294</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jacl.2008.08.445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacl.2008.08.445%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DE.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DRadziszewski%26aufirst%3DW.%26aulast%3DPerevozskaya%26aufirst%3DI%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DWenning%26aufirst%3DL.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DJohnson-Levonas%26aufirst%3DA.%2BO.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26aulast%3DMitchel%26aufirst%3DY.%26aulast%3DPaolini%26aufirst%3DJ.%2BF.%26atitle%3DEffects%2520of%2520a%2520niacin%2520receptor%2520partial%2520agonist%252C%2520MK-0354%252C%2520on%2520plasma%2520free%2520fatty%2520acids%252C%2520lipids%252C%2520and%2520cutaneous%2520flushing%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Lipidol.%26date%3D2008%26volume%3D2%26spage%3D375%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span> </span><span class="NLM_article-title">Potent Tricyclic Pyrazole Tetrazole Agonists of the Nicotinic Acid Receptor (GPR109a)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2797</span><span class="NLM_x">–</span> <span class="NLM_lpage">2800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2797-2800&author=P.+D.+Boatmanauthor=T.+O.+Schraderauthor=M.+Kasemauthor=B.+R.+Johnsonauthor=P.+J.+Skinnerauthor=J.-K.+Jungauthor=J.+Xuauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=G.+Sempleauthor=C.+R.+Sageauthor=J.+Knudsenauthor=R.+Chenauthor=J.+G.+Richman&title=Potent+Tricyclic+Pyrazole+Tetrazole+Agonists+of+the+Nicotinic+Acid+Receptor+%28GPR109a%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BR.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DJung%26aufirst%3DJ.-K.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DKnudsen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3DPotent%2520Tricyclic%2520Pyrazole%2520Tetrazole%2520Agonists%2520of%2520the%2520Nicotinic%2520Acid%2520Receptor%2520%2528GPR109a%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2797%26epage%3D2800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Taber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartnett, J. C.</span><span> </span><span class="NLM_article-title">Synthesis of the Eight Enantiomerically Pure Diastereomers of the 12-F2-Isoprostanes</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">13121</span><span class="NLM_x">–</span> <span class="NLM_lpage">13126</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja020816v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=13121-13126&author=D.+F.+Taberauthor=M.+Xuauthor=J.+C.+Hartnett&title=Synthesis+of+the+Eight+Enantiomerically+Pure+Diastereomers+of+the+12-F2-Isoprostanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fja020816v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja020816v%26sid%3Dliteratum%253Aachs%26aulast%3DTaber%26aufirst%3DD.%2BF.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DHartnett%26aufirst%3DJ.%2BC.%26atitle%3DSynthesis%2520of%2520the%2520Eight%2520Enantiomerically%2520Pure%2520Diastereomers%2520of%2520the%252012-F2-Isoprostanes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D13121%26epage%3D13126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hodgson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuzzo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freixas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulikiewicz, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleator, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paris, J.-M.</span><span> </span><span class="NLM_article-title">Intramolecular Cyclopropanation of Unsaturated Terminal Epoxides and Chlorohydrins</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">4456</span><span class="NLM_x">–</span> <span class="NLM_lpage">4462</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja0672932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtF2nsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=4456-4462&author=D.+M.+Hodgsonauthor=Y.+K.+Chungauthor=I.+Nuzzoauthor=G.+Freixasauthor=K.+K.+Kulikiewiczauthor=E.+Cleatorauthor=J.-M.+Paris&title=Intramolecular+Cyclopropanation+of+Unsaturated+Terminal+Epoxides+and+Chlorohydrins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Intramolecular Cyclopropanation of Unsaturated Terminal Epoxides and Chlorohydrins</span></div><div class="casAuthors">Hodgson, David M.; Chung, Ying Kit; Nuzzo, Irene; Freixas, Gloria; Kulikiewicz, Krystyna K.; Cleator, Ed; Paris, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4456-4462</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lithium 2,2,6,6-tetramethylpiperidide (LTMP)-induced intramol. cyclopropanation of unsatd. terminal epoxides, e.g. I, provides an efficient and completely stereoselective entry to bicyclo[3.1.0]hexan-2-ols, e.g. II, and bicyclo[4.1.0]heptan-2-ols.  Further elaboration of C-5 and C-6 stannyl-substituted bicyclo[3.1.0]hexan-2-ols via Sn-Li exchange/electrophile trapping or Stille coupling generates a range of substituted bicyclic cyclopropanes.  An alternative straightforward cyclopropanation protocol using a catalytic amt. of 2,2,6,6-tetramethylpiperidine (TMP) allows for a convenient (1 g-7.5 kg) synthesis of bicyclo[3.1.0]hexan-2-ol and other bicyclic adducts.  The synthetic utility of this chem. has been demonstrated in a concise asym. synthesis of (+)-β-cuparenone (III).  The related unsatd. chlorohydrins also undergo intramol. cyclopropanation via in situ epoxide formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMk8oGYnbbCrVg90H21EOLACvtfcHk0li-mNBBGeljhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtF2nsL4%253D&md5=fe699d08dd4e9e4b59f3bae28d2668e8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fja0672932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0672932%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DD.%2BM.%26aulast%3DChung%26aufirst%3DY.%2BK.%26aulast%3DNuzzo%26aufirst%3DI.%26aulast%3DFreixas%26aufirst%3DG.%26aulast%3DKulikiewicz%26aufirst%3DK.%2BK.%26aulast%3DCleator%26aufirst%3DE.%26aulast%3DParis%26aufirst%3DJ.-M.%26atitle%3DIntramolecular%2520Cyclopropanation%2520of%2520Unsaturated%2520Terminal%2520Epoxides%2520and%2520Chlorohydrins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2007%26volume%3D129%26spage%3D4456%26epage%3D4462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Nolwenn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">List, B.</span><span> </span><span class="NLM_article-title">Highly Enantioselective Transfer Hydrogenation of α,β-Unsaturated Ketones</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">13368</span><span class="NLM_x">–</span> <span class="NLM_lpage">13369</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=13368-13369&author=J.+A.+Nolwennauthor=B.+List&title=Highly+Enantioselective+Transfer+Hydrogenation+of+%CE%B1%2C%CE%B2-Unsaturated+Ketones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNolwenn%26aufirst%3DJ.%2BA.%26aulast%3DList%26aufirst%3DB.%26atitle%3DHighly%2520Enantioselective%2520Transfer%2520Hydrogenation%2520of%2520%25CE%25B1%252C%25CE%25B2-Unsaturated%2520Ketones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D13368%26epage%3D13369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="note"><p class="first last">Optically pure R-29 was prepared by DIBAL-H reduction of the optically pure lactone (<i>R</i>)-5-(chloromethyl)dihydrofuran-2(3<i>H</i>)-one. For the analogous reduction to prepare S-29 from (<i>S</i>)-5-(chloromethyl)dihydrofuran-2(3<i>H</i>)-one, see:</p></div><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_contrib-group">Lewis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayless, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libertine, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wels, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wypij, D. M.</span><span> </span><span class="NLM_article-title">5-Lipoxygenase inhibitors with histamine H1 receptor antagonist activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2265</span><span class="NLM_x">–</span> <span class="NLM_lpage">2268</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2265-2268&author=T.+A.+Lewisauthor=L.+Baylessauthor=J.+B.+Eckmanauthor=J.+L.+Ellisauthor=G.+Grewalauthor=L.+Libertineauthor=J.+M.+Nicolasauthor=R.+T.+Scannellauthor=B.+F.+Welsauthor=K.+Wenbergauthor=D.+M.+Wypij&title=5-Lipoxygenase+inhibitors+with+histamine+H1+receptor+antagonist+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DT.%2BA.%26aulast%3DBayless%26aufirst%3DL.%26aulast%3DEckman%26aufirst%3DJ.%2BB.%26aulast%3DEllis%26aufirst%3DJ.%2BL.%26aulast%3DGrewal%26aufirst%3DG.%26aulast%3DLibertine%26aufirst%3DL.%26aulast%3DNicolas%26aufirst%3DJ.%2BM.%26aulast%3DScannell%26aufirst%3DR.%2BT.%26aulast%3DWels%26aufirst%3DB.%2BF.%26aulast%3DWenberg%26aufirst%3DK.%26aulast%3DWypij%26aufirst%3DD.%2BM.%26atitle%3D5-Lipoxygenase%2520inhibitors%2520with%2520histamine%2520H1%2520receptor%2520antagonist%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2265%26epage%3D2268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For the synthesis of (<i>S</i>)-5-(chloromethyl)dihydrofuran-2(3<i>H</i>)-one from (<i>S</i>)-(+)-epichlorohydrin, see:</p></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_contrib-group">Movassaghi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. N.</span><span> </span><span class="NLM_article-title">A Direct Method for the Conversion of Terminal Epoxides into γ-Butanolides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">2456</span><span class="NLM_x">–</span> <span class="NLM_lpage">2457</span><div class="note"><p class="first last">(<i>R</i>)-5-(Chloromethyl)dihydrofuran-2(3<i>H</i>)-one was prepared from (<i>R</i>)-(−)-epichlorohydrin in similar fashion</p></div></span><div class="citationLinks">[<a href="/doi/10.1021/ja025604c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=2456-2457&author=M.+Movassaghiauthor=E.+N.+Jacobsen&title=A+Direct+Method+for+the+Conversion+of+Terminal+Epoxides+into+%CE%B3-Butanolides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fja025604c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja025604c%26sid%3Dliteratum%253Aachs%26aulast%3DMovassaghi%26aufirst%3DM.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DA%2520Direct%2520Method%2520for%2520the%2520Conversion%2520of%2520Terminal%2520Epoxides%2520into%2520%25CE%25B3-Butanolides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D2456%26epage%3D2457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Tokunaga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. N.</span><span> </span><span class="NLM_article-title">Asymmetric catalysis with water: efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">936</span><span class="NLM_x">–</span> <span class="NLM_lpage">938</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1126%2Fscience.277.5328.936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=9252321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADyaK2sXltlCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=936-938&author=M.+Tokunagaauthor=J.+F.+Larrowauthor=F.+Kakiuchiauthor=E.+N.+Jacobsen&title=Asymmetric+catalysis+with+water%3A+efficient+kinetic+resolution+of+terminal+epoxides+by+means+of+catalytic+hydrolysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric catalysis with water: efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis</span></div><div class="casAuthors">Tokunaga, Makoto; Larrow, Jay F.; Kakiuchi, Fumitoshi; Jacobsen, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5328</span>),
    <span class="NLM_cas:pages">936-938</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 16 refs.  Epoxides are versatile building blocks for org. synthesis.  However, terminal epoxides are arguably the most important subclass of these compds., and no general and practical method existss for their prodn. in enantiomerically pure form.  Terminal epoxides are available very inexpensively as racemic mixts., and kinetic resoln. is an attractive strategy for the prodn. of optically active epoxides, given an economical and operationally simple method.  Readily accessible synthetic catalysts (chiral cobalt-based salen complexes) have been used for the efficient asym. hydrolysis of terminal epoxides.  This process uses water as the only reagent, no added solvent, and low loadings of a recyclable catalyst (<0.5 mol percent), and it affords highly valuable terminal epoxides and 1,2-diols in high yield with high enantiomeric enrichment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDq5Z45iFaUbVg90H21EOLACvtfcHk0lgUlzfIPWJxAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltlCrt70%253D&md5=ad79e0bf023e87fc21c77e858bacc83b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5328.936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5328.936%26sid%3Dliteratum%253Aachs%26aulast%3DTokunaga%26aufirst%3DM.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DKakiuchi%26aufirst%3DF.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DAsymmetric%2520catalysis%2520with%2520water%253A%2520efficient%2520kinetic%2520resolution%2520of%2520terminal%2520epoxides%2520by%2520means%2520of%2520catalytic%2520hydrolysis%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D936%26epage%3D938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharbaoui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boatman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carballo-Jane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span> </span><span class="NLM_article-title">3-(1<i>H</i>-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5101</span><span class="NLM_x">–</span> <span class="NLM_lpage">5108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800258p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5101-5108&author=G.+Sempleauthor=P.+J.+Skinnerauthor=T.+Gharbaouiauthor=Y.-J.+Shinauthor=J.-K.+Jungauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=S.+Y.+Tamuraauthor=P.+D.+Boatmanauthor=C.+R.+Sageauthor=T.+O.+Schraderauthor=R.+Chenauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=M.+G.+Watersauthor=K.+Chengauthor=A.+K.+Taggartauthor=T.-Q.+Caiauthor=E.+Carballo-Janeauthor=D.+P.+Behanauthor=D.+T.+Connollyauthor=J.+G.+Richman&title=3-%281H-Tetrazol-5-yl%29-1%2C4%2C5%2C6-tetrahydro-cyclopentapyrazole+%28MK-0354%29%3A+A+Partial+Agonist+of+the+Nicotinic+Acid+Receptor%2C+G-Protein+Coupled+Receptor+109a%2C+with+Antilipolytic+but+No+Vasodilatory+Activity+in+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm800258p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800258p%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DShin%26aufirst%3DY.-J.%26aulast%3DJung%26aufirst%3DJ.-K.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%2BY.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%26aulast%3DCai%26aufirst%3DT.-Q.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3D3-%25281H-Tetrazol-5-yl%2529-1%252C4%252C5%252C6-tetrahydro-cyclopentapyrazole%2520%2528MK-0354%2529%253A%2520A%2520Partial%2520Agonist%2520of%2520the%2520Nicotinic%2520Acid%2520Receptor%252C%2520G-Protein%2520Coupled%2520Receptor%2520109a%252C%2520with%2520Antilipolytic%2520but%2520No%2520Vasodilatory%2520Activity%2520in%2520Mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5101%26epage%3D5108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Imbriglio, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smenton, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, A. K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carballo-Jane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span> </span><span class="NLM_article-title">GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2121</span><span class="NLM_x">–</span> <span class="NLM_lpage">2124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2121-2124&author=J.+E.+Imbriglioauthor=S.+Changauthor=R.+Liangauthor=S.+Raghavanauthor=D.+Schmidtauthor=A+Smentonauthor=S.+Triaauthor=T.+O.+Schraderauthor=J.-K.+Jungauthor=C.+Esserauthor=A.+K.+P.+Taggartauthor=K.+Chengauthor=E.+Carballo-Janeauthor=M.+G.+Watersauthor=J.+R.+Tataauthor=S.+L.+Colletti&title=GPR109a+agonists.+Part+1%3A+5-Alkyl+and+5-aryl-pyrazole-tetrazoles+as+agonists+of+the+human+orphan+G-protein+coupled+receptor+GPR109a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImbriglio%26aufirst%3DJ.%2BE.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DR.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DD.%26aulast%3DSmenton%26aufirst%3DA%26aulast%3DTria%26aufirst%3DS.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DJung%26aufirst%3DJ.-K.%26aulast%3DEsser%26aufirst%3DC.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%2BP.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26atitle%3DGPR109a%2520agonists.%2520Part%25201%253A%25205-Alkyl%2520and%25205-aryl-pyrazole-tetrazoles%2520as%2520agonists%2520of%2520the%2520human%2520orphan%2520G-protein%2520coupled%2520receptor%2520GPR109a%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2121%26epage%3D2124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Carballo-Jane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerckens, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlapiano, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taggart, A. K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span> </span><span class="NLM_article-title">Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1016%2Fj.vascn.2007.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=17643322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGkt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=308-316&author=E.+Carballo-Janeauthor=L.+S.+Gerckensauthor=S.+Luellauthor=A.+S.+Parlapianoauthor=M.+Wolffauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=A.+K.+P.+Taggartauthor=M.+G.+Watersauthor=J.+G.+Richmanauthor=M.+E.+McCannauthor=M.+J.+Forrest&title=Comparison+of+rat+and+dog+models+of+vasodilatation+and+lipolysis+for+the+calculation+of+a+therapeutic+index+for+GPR109A+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists</span></div><div class="casAuthors">Carballo-Jane, Ester; Gerckens, Lynn S.; Luell, Silvi; Parlapiano, Allison S.; Wolff, Michael; Colletti, Steven L.; Tata, James R.; Taggart, Andrew K. P.; Waters, M. Gerard; Richman, Jeremy G.; McCann, Margaret E.; Forrest, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">308-316</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: GPR109A is the receptor mediating both the antilipolytic and vasodilatory effects of nicotinic acid.  In order to develop agonists for GPR109A with improved therapeutic indexes we have sought to optimize animal models that evaluate both nicotinic acid-mediated inhibition of lipolysis and stimulation of vasodilatation.  The rat and the dog have previously been used to study the antilipolytic effects of nicotinic acid, but no optimal vasodilatation model exits in either species.  Methods: We have developed a vasodilatation model in the rat that measures changes in ear perfusion using laser Doppler flowmetry.  In the dog, we have developed a model of vasodilatation measuring changes in red color values in the ear, using a spectrocolorimeter.  Effects of GPR109A agonists on lipolysis were measured in both species after oral dosing of compds., and measuring plasma levels of free fatty acids.  Results: In both rat and dog, GPR109A agonists induce dose- and time-dependent vasodilatation, similar to that obsd. in humans.  Vasodilatation is inhibited in both species with cyclooxygenase inhibitors or a specific DP1 receptor antagonist, indicating that, as in man, nicotinic acid-induced vasodilatation in rats and dogs is mainly mediated by the release of PGD2.  Discussion: Our results show that both rat and dog are useful models for the characterization of GPR109A agonists.  A therapeutic index for GPR109A agonists can be calcd. in either species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaJsGTtqvjVbVg90H21EOLACvtfcHk0lhjdRqCsTqH_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGkt7zL&md5=a41bfc87540867cdddb43cf32d0413cd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2007.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2007.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DGerckens%26aufirst%3DL.%2BS.%26aulast%3DLuell%26aufirst%3DS.%26aulast%3DParlapiano%26aufirst%3DA.%2BS.%26aulast%3DWolff%26aufirst%3DM.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%2BP.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26aulast%3DMcCann%26aufirst%3DM.%2BE.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26atitle%3DComparison%2520of%2520rat%2520and%2520dog%2520models%2520of%2520vasodilatation%2520and%2520lipolysis%2520for%2520the%2520calculation%2520of%2520a%2520therapeutic%2520index%2520for%2520GPR109A%2520agonists%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2007%26volume%3D56%26spage%3D308%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Boatman, P. D.; Schrader, T. O.; Semple, G; Skinner, P; J.; Jung, J.-K.</span><span> </span><span class="NLM_article-title">Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof</span>. U.S. Patent US 7241792, <span class="NLM_month">July</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+D.+Boatman&author=T.+O.+Schrader&author=G+Semple&author=P%3B+J.+Skinner&author=J.-K.+Jung&title=Fused+pyrazole+derivatives+and+methods+of+treatment+of+metabolic-related+disorders+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26atitle%3DFused%2520pyrazole%2520derivatives%2520and%2520methods%2520of%2520treatment%2520of%2520metabolic-related%2520disorders%2520thereof%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Robbins, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaine, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christman, B. W.</span><span> </span><span class="NLM_article-title">Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">1639</span><span class="NLM_x">–</span> <span class="NLM_lpage">1644</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2001&pages=1639-1644&author=I.+M.+Robbinsauthor=R.+J.+Barstauthor=L.+J.+Rubinauthor=S.+P.+Gaineauthor=P.+V.+Priceauthor=J.+D.+Morrowauthor=B.+W.+Christman&title=Increased+levels+of+prostaglandin+D%282%29+suggest+macrophage+activation+in+patients+with+primary+pulmonary+hypertension"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DGaine%26aufirst%3DS.%2BP.%26aulast%3DPrice%26aufirst%3DP.%2BV.%26aulast%3DMorrow%26aufirst%3DJ.%2BD.%26aulast%3DChristman%26aufirst%3DB.%2BW.%26atitle%3DIncreased%2520levels%2520of%2520prostaglandin%2520D%25282%2529%2520suggest%2520macrophage%2520activation%2520in%2520patients%2520with%2520primary%2520pulmonary%2520hypertension%26jtitle%3DChest%26date%3D2001%26volume%3D120%26spage%3D1639%26epage%3D1644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Awad, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. J.,  II.</span><span> </span><span class="NLM_article-title">Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation</span> <span class="citation_source-journal">J. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm2010964&amp;key=10.1016%2F0091-6749%2894%2990371-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm2010964&amp;key=8182221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm2010964&amp;key=1%3ACAS%3A528%3ADyaK2MXptlyrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1994&pages=817-824&issue=5&author=J.+A.+Awadauthor=J.+D.+Morrowauthor=L.+J.+Roberts&title=Detection+of+the+major+urinary+metabolite+of+prostaglandin+D2+in+the+circulation%3A+demonstration+of+elevated+levels+in+patients+with+disorders+of+systemic+mast+cell+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of the major urinary metabolite of prostaglandin D2 in the circulation: Demonstration of elevated levels in patients with disorders of systemic mast cell activation</span></div><div class="casAuthors">Awad, Joseph A.; Morrow, Jason D.; Roberts, L. Jackson, II</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">817-24</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Mosby-Year Book</span>)
        </div><div class="casAbstract">The symptoms and hemodynamic alterations that accompany episodes of systemic mast cell activation have been largely attributed to excessive prostaglandin(PG)D2 release.  Quantification of the major urinary metabolite of PGD2 has been invaluable in elucidating a role for PGD2 in these clin. entities and in the biochem. evaluation of systemic mastocytosis.  With the use of a modified mass spectrometric assay for the major urinary metabolite of PGD2, this metabolite was detected in plasma from 10 normal volunteers (3.5 ± 1.4 pg/mL).  Ingestion of niacin, which induces endogenous release of PGD2, increased plasma levels of this metabolite 6.3 to 33 times above the upper limit of normal by 2 h.  Thereafter, levels declined gradually but remained elevated for up to 6 to 8 h.  In contrast, circulating levels of 9α, 11β-PGF2, the initial metabolite of PGD2, peaked by 30 min and returned to baseline by 2 h.  The clin. utility of measuring the major urinary metabolite in the circulation was demonstrated by detection of markedly increased levels in plasma and serum from patients with systemic mastocytosis and a patient with a severe type I allergic reaction.  Thus in the biochem. evaluation of episodes of systemic mast cell activation and endeavors to further elucidate the role of PGD2 in human disease, there are kinetic advantages of measuring the major urinary metabolite of PGD2 in the circulation.  One particular advantage is the evaluation of clin. events, which only in retrospect are suspected to be assocd. with excessive release of PGD2, yet plasma or serum was obtained proximate to the event.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRikMSssGV_LVg90H21EOLACvtfcHk0lguPoOGEaLpKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptlyrur8%253D&md5=2783930937744605f39bb438d27ab07a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2F0091-6749%2894%2990371-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-6749%252894%252990371-9%26sid%3Dliteratum%253Aachs%26aulast%3DAwad%26aufirst%3DJ.%2BA.%26aulast%3DMorrow%26aufirst%3DJ.%2BD.%26aulast%3DRoberts%26aufirst%3DL.%2BJ.%26atitle%3DDetection%2520of%2520the%2520major%2520urinary%2520metabolite%2520of%2520prostaglandin%2520D2%2520in%2520the%2520circulation%253A%2520demonstration%2520of%2520elevated%2520levels%2520in%2520patients%2520with%2520disorders%2520of%2520systemic%2520mast%2520cell%2520activation%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D1994%26volume%3D93%26issue%3D5%26spage%3D817%26epage%3D824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Lauring, B.; Taggart, A.; Tata, J.; Dunbar, R.; Caro, L.; Cheng, K.; Chin, J.; Colletti, S.; Cote, J.; Kalilieh, S.; Liu, J.; Luo, W.-L.; MacLean, A.; Paolini, J.; Peterson, L.; Sirah, W.; Waters, M. G.; Wu, T.-J.; Xuan, F.; Boatman, P. D.; Semple, G.; Behan, D.; Connelly, D.; Lai, E.; Wagner, J.; Wright, S.; Cuffie, C.; Mitchel, Y.; Rader, D.; Plump, A.</span><div class="note"><p class="first last">Unpublished results</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lauring%2C+B.%3B+Taggart%2C+A.%3B+Tata%2C+J.%3B+Dunbar%2C+R.%3B+Caro%2C+L.%3B+Cheng%2C+K.%3B+Chin%2C+J.%3B+Colletti%2C+S.%3B+Cote%2C+J.%3B+Kalilieh%2C+S.%3B+Liu%2C+J.%3B+Luo%2C+W.-L.%3B+MacLean%2C+A.%3B+Paolini%2C+J.%3B+Peterson%2C+L.%3B+Sirah%2C+W.%3B+Waters%2C+M.+G.%3B+Wu%2C+T.-J.%3B+Xuan%2C+F.%3B+Boatman%2C+P.+D.%3B+Semple%2C+G.%3B+Behan%2C+D.%3B+Connelly%2C+D.%3B+Lai%2C+E.%3B+Wagner%2C+J.%3B+Wright%2C+S.%3B+Cuffie%2C+C.%3B+Mitchel%2C+Y.%3B+Rader%2C+D.%3B+Plump%2C+A.Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLauring%26aufirst%3DB." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><div class="note"><p class="first last">Enantiopurity (% ee) was determined at the subsequent intramolecular cyclopropanation step. Alcohol 1<i>R</i>,2<i>R</i>,5<i>S</i>-<b>9c</b> was converted to the corresponding Mosher ester derivative (employing (<i>R</i>)-(−)-Mosher acid chloride) and comparing <sup>1</sup>H NMR spectral data with that of the Mosher ester derivative of the racemic alcohol obtained by intramolecular cyclopropanation of (±)-2-(but-3-enyl)oxirane. See:</p></div><span class="NLM_contrib-group">Mosher, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dale, J. A.</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Enantiopurity+%28%25+ee%29+was+determined+at+the+subsequent+intramolecular+cyclopropanation+step.+Alcohol+1R%2C2R%2C5S-9c+was+converted+to+the+corresponding+Mosher+ester+derivative+%28employing+%28R%29-%28%E2%88%92%29-Mosher+acid+chloride%29+and+comparing+1H+NMR+spectral+data+with+that+of+the+Mosher+ester+derivative+of+the+racemic+alcohol+obtained+by+intramolecular+cyclopropanation+of+%28%C2%B1%29-2-%28but-3-enyl%29oxirane.+See%3AMosher%2C+H.+S.%3B+Dale%2C+J.+A.J.+Am.+Chem.+Soc.+1973%2C+95%2C+512%E2%80%93519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMosher%26aufirst%3DH.%2BS.%26aulast%3DDale%26aufirst%3DJ.%2BA.%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1973%26volume%3D95%26spage%3D512%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm2010964&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-8%3Barticle%3Aarticle%3A10.1021%2Fjm2010964%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm2010964" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799ce161f943cdc","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
